WorldWideScience

Sample records for actinium d

  1. Production of Actinium-225 via High Energy Proton Induced Spallation of Thorium-232

    International Nuclear Information System (INIS)

    The science of cancer research is currently expanding its use of alpha particle emitting radioisotopes. Coupled with the discovery and proliferation of molecular species that seek out and attach to tumors, new therapy and diagnostics are being developed to enhance the treatment of cancer and other diseases. This latest technology is commonly referred to as Alpha Immunotherapy (AIT). Actinium-225/Bismuth-213 is a parent/daughter alpha-emitting radioisotope pair that is highly sought after because of the potential for treating numerous diseases and its ability to be chemically compatible with many known and widely used carrier molecules (such as monoclonal antibodies and proteins/peptides). Unfortunately, the worldwide supply of actinium-225 is limited to about 1,000mCi annually and most of that is currently spoken for, thus limiting the ability of this radioisotope pair to enter into research and subsequently clinical trials. The route proposed herein utilizes high energy protons to produce actinium-225 via spallation of a thorium-232 target. As part of previous R and D efforts carried out at Argonne National Laboratory recently in support of the proposed US FRIB facility, it was shown that a very effective production mechanism for actinium-225 is spallation of thorium-232 by high energy proton beams. The base-line simulation for the production rate of actinium-225 by this reaction mechanism is 8E12 atoms per second at 200 MeV proton beam energy with 50 g/cm2 thorium target and 100 kW beam power. An irradiation of one actinium-225 half-life (10 days) produces ∼100 Ci of actinium-225. For a given beam current the reaction cross section increases slightly with energy to about 400 MeV and then decreases slightly for beam energies in the several GeV regime. The object of this effort is to refine the simulations at proton beam energies of 400 MeV and above up to about 8 GeV. Once completed, the simulations will be experimentally verified using 400 MeV and 8 GeV protons

  2. Production of Actinium-225 via High Energy Proton Induced Spallation of Thorium-232

    Energy Technology Data Exchange (ETDEWEB)

    Harvey, James T.; Nolen, Jerry; Vandergrift, George; Gomes, Itacil; Kroc, Tom; Horwitz, Phil; McAlister, Dan; Bowers, Del; Sullivan, Vivian; Greene, John

    2011-12-30

    The science of cancer research is currently expanding its use of alpha particle emitting radioisotopes. Coupled with the discovery and proliferation of molecular species that seek out and attach to tumors, new therapy and diagnostics are being developed to enhance the treatment of cancer and other diseases. This latest technology is commonly referred to as Alpha Immunotherapy (AIT). Actinium-225/Bismuth-213 is a parent/daughter alpha-emitting radioisotope pair that is highly sought after because of the potential for treating numerous diseases and its ability to be chemically compatible with many known and widely used carrier molecules (such as monoclonal antibodies and proteins/peptides). Unfortunately, the worldwide supply of actinium-225 is limited to about 1,000mCi annually and most of that is currently spoken for, thus limiting the ability of this radioisotope pair to enter into research and subsequently clinical trials. The route proposed herein utilizes high energy protons to produce actinium-225 via spallation of a thorium-232 target. As part of previous R and D efforts carried out at Argonne National Laboratory recently in support of the proposed US FRIB facility, it was shown that a very effective production mechanism for actinium-225 is spallation of thorium-232 by high energy proton beams. The base-line simulation for the production rate of actinium-225 by this reaction mechanism is 8E12 atoms per second at 200 MeV proton beam energy with 50 g/cm2 thorium target and 100 kW beam power. An irradiation of one actinium-225 half-life (10 days) produces {approx}100 Ci of actinium-225. For a given beam current the reaction cross section increases slightly with energy to about 400 MeV and then decreases slightly for beam energies in the several GeV regime. The object of this effort is to refine the simulations at proton beam energies of 400 MeV and above up to about 8 GeV. Once completed, the simulations will be experimentally verified using 400 MeV and 8 Ge

  3. Spectroscopic and computational investigation of actinium coordination chemistry

    Science.gov (United States)

    Ferrier, Maryline G.; Batista, Enrique R.; Berg, John M.; Birnbaum, Eva R.; Cross, Justin N.; Engle, Jonathan W.; La Pierre, Henry S.; Kozimor, Stosh A.; Lezama Pacheco, Juan S.; Stein, Benjamin W.; Stieber, S. Chantal E.; Wilson, Justin J.

    2016-08-01

    Actinium-225 is a promising isotope for targeted-α therapy. Unfortunately, progress in developing chelators for medicinal applications has been hindered by a limited understanding of actinium chemistry. This knowledge gap is primarily associated with handling actinium, as it is highly radioactive and in short supply. Hence, AcIII reactivity is often inferred from the lanthanides and minor actinides (that is, Am, Cm), with limited success. Here we overcome these challenges and characterize actinium in HCl solutions using X-ray absorption spectroscopy and molecular dynamics density functional theory. The Ac-Cl and Ac-OH2O distances are measured to be 2.95(3) and 2.59(3) Å, respectively. The X-ray absorption spectroscopy comparisons between AcIII and AmIII in HCl solutions indicate AcIII coordinates more inner-sphere Cl1- ligands (3.2+/-1.1) than AmIII (0.8+/-0.3). These results imply diverse reactivity for the +3 actinides and highlight the unexpected and unique AcIII chemical behaviour.

  4. Separation of Actinium 227 from the uranium minerals

    International Nuclear Information System (INIS)

    The purpose of this work was to separate Actinium 227, whose content is 18%, from the mineral carnotite found in Gomez Chihuahua mountain range in Mexico. The mineral before processing is is pre-concentrated and passed, first through anionic exchange resins, later the eluate obtained is passed through cationic resins. The resins were 20-50 MESH QOWEX and 100-200 MESH 50 X 8-20 in some cased 200-400 MESH AG 50W-X8, 1X8 in other cases. The eluates from the ionic exchange were electrodeposited on stainless steel polished disc cathode and platinum electrode as anode; under a current ODF 10mA for 2.5 to 5 hours and of 100mA for .5 of an hour. it was possible to identify the Actinium 227 by means of its descendents, TH-227 and RA-223, through alpha spectroscopy. Due to the radiochemical purity which the electro deposits were obtained the Actinium 227 was low and was not quantitatively determined. A large majority of the members of the natural radioactive series 3 were identified and even alpha energies reported in the literature with very low percentages of non-identified emissions were observed. We conclude that a more precise study is needed concerning ionic exchange and electrodeposit to obtain an Actinium 227 of radiochemical purity. (Author)

  5. Spectroscopic and computational investigation of actinium coordination chemistry

    Science.gov (United States)

    Ferrier, Maryline G.; Batista, Enrique R.; Berg, John M.; Birnbaum, Eva R.; Cross, Justin N.; Engle, Jonathan W.; La Pierre, Henry S.; Kozimor, Stosh A.; Lezama Pacheco, Juan S.; Stein, Benjamin W.; Stieber, S. Chantal E.; Wilson, Justin J.

    2016-01-01

    Actinium-225 is a promising isotope for targeted-α therapy. Unfortunately, progress in developing chelators for medicinal applications has been hindered by a limited understanding of actinium chemistry. This knowledge gap is primarily associated with handling actinium, as it is highly radioactive and in short supply. Hence, AcIII reactivity is often inferred from the lanthanides and minor actinides (that is, Am, Cm), with limited success. Here we overcome these challenges and characterize actinium in HCl solutions using X-ray absorption spectroscopy and molecular dynamics density functional theory. The Ac–Cl and Ac–OH2O distances are measured to be 2.95(3) and 2.59(3) Å, respectively. The X-ray absorption spectroscopy comparisons between AcIII and AmIII in HCl solutions indicate AcIII coordinates more inner-sphere Cl1– ligands (3.2±1.1) than AmIII (0.8±0.3). These results imply diverse reactivity for the +3 actinides and highlight the unexpected and unique AcIII chemical behaviour. PMID:27531582

  6. Discovery of the actinium, thorium, protactinium, and uranium isotopes

    CERN Document Server

    Fry, C

    2012-01-01

    Currently, 31 actinium, 31 thorium, 28 protactinium, and 23 uranium isotopes have so far been observed; the discovery of these isotopes is discussed. For each isotope a brief summary of the first refereed publication, including the production and identification method, is presented.

  7. Spectroscopic and computational investigation of actinium coordination chemistry.

    Science.gov (United States)

    Ferrier, Maryline G; Batista, Enrique R; Berg, John M; Birnbaum, Eva R; Cross, Justin N; Engle, Jonathan W; La Pierre, Henry S; Kozimor, Stosh A; Lezama Pacheco, Juan S; Stein, Benjamin W; Stieber, S Chantal E; Wilson, Justin J

    2016-01-01

    Actinium-225 is a promising isotope for targeted-α therapy. Unfortunately, progress in developing chelators for medicinal applications has been hindered by a limited understanding of actinium chemistry. This knowledge gap is primarily associated with handling actinium, as it is highly radioactive and in short supply. Hence, Ac(III) reactivity is often inferred from the lanthanides and minor actinides (that is, Am, Cm), with limited success. Here we overcome these challenges and characterize actinium in HCl solutions using X-ray absorption spectroscopy and molecular dynamics density functional theory. The Ac-Cl and Ac-OH2O distances are measured to be 2.95(3) and 2.59(3) Å, respectively. The X-ray absorption spectroscopy comparisons between Ac(III) and Am(III) in HCl solutions indicate Ac(III) coordinates more inner-sphere Cl(1-) ligands (3.2±1.1) than Am(III) (0.8±0.3). These results imply diverse reactivity for the +3 actinides and highlight the unexpected and unique Ac(III) chemical behaviour. PMID:27531582

  8. Analysis of the gamma spectra of the uranium, actinium, and thorium decay series

    International Nuclear Information System (INIS)

    This report describes the identification of radionuclides in the uranium, actinium, and thorium series by analysis of gamma spectra in the energy range of 40 to 1400 keV. Energies and absolute efficiencies for each gamma line were measured by means of a high-resolution germanium detector and compared with those in the literature. A gamma spectroscopy method, which utilizes an on-line computer for deconvolution of spectra, search and identification of each line, and estimation of activity for each radionuclide, was used to analyze soil and uranium tailings, and ore

  9. Thorium and actinium polyphosphonate compounds as bone-seeking alpha particle-emitting agents.

    Science.gov (United States)

    Henriksen, Gjermund; Bruland, Oyvind S; Larsen, Roy H

    2004-01-01

    The present study explores the use of alpha-particle-emitting, bone-seeking agents as candidates for targeted radiotherapy. Actinium and thorium 1,4,7,10 tetraazacyclododecane N,N',N'',N''' 1,4,7,10-tetra(methylene) phosphonic acid (DOTMP) and thorium-diethylene triamine N,N',N'' penta(methylene) phosphonic acid (DTMP) were prepared and their biodistribution evaluated in conventional Balb/C mice at four hours after injection. All three bone-seeking agents showed a high uptake in bone and a low uptake in soft tissues. Among the soft tissue organs, only kidney had a relatively high uptake. The femur/kidney ratios for 227Th-DTMP, 228-Ac-DOTMP and 227Th-DOTMP were 14.2, 7.6 and 6.0, respectively. A higher liver uptake of 228Ac-DOTMP was seen than for 227Th-DTMP and 227Th-DOTMP. This suggests that some demetallation of the 228Ac-DOTMP complex had occurred. The results indicate that 225Ac-DOTMP, 227Th-DOTMP and 227Th-DTMP have promising properties as potential therapeutic bone-seeking agents.

  10. Developments towards in-gas-jet laser spectroscopy studies of actinium isotopes at LISOL

    Science.gov (United States)

    Raeder, S.; Bastin, B.; Block, M.; Creemers, P.; Delahaye, P.; Ferrer, R.; Fléchard, X.; Franchoo, S.; Ghys, L.; Gaffney, L. P.; Granados, C.; Heinke, R.; Hijazi, L.; Huyse, M.; Kron, T.; Kudryavtsev, Yu.; Laatiaoui, M.; Lecesne, N.; Luton, F.; Moore, I. D.; Martinez, Y.; Mogilevskiy, E.; Naubereit, P.; Piot, J.; Rothe, S.; Savajols, H.; Sels, S.; Sonnenschein, V.; Traykov, E.; Van Beveren, C.; Van den Bergh, P.; Van Duppen, P.; Wendt, K.; Zadvornaya, A.

    2016-06-01

    To study exotic nuclides at the borders of stability with laser ionization and spectroscopy techniques, highest efficiencies in combination with a high spectral resolution are required. These usually opposing requirements are reconciled by applying the in-gas-laser ionization and spectroscopy (IGLIS) technique in the supersonic gas jet produced by a de Laval nozzle installed at the exit of the stopping gas cell. Carrying out laser ionization in the low-temperature and low density supersonic gas jet eliminates pressure broadening, which will significantly improve the spectral resolution. This article presents the required modifications at the Leuven Isotope Separator On-Line (LISOL) facility that are needed for the first on-line studies of in-gas-jet laser spectroscopy. Different geometries for the gas outlet and extraction ion guides have been tested for their performance regarding the acceptance of laser ionized species as well as for their differential pumping capacities. The specifications and performance of the temporarily installed high repetition rate laser system, including a narrow bandwidth injection-locked Ti:sapphire laser, are discussed and first preliminary results on neutron-deficient actinium isotopes are presented indicating the high capability of this novel technique.

  11. Groundwater seepage from the Ranger uranium mine tailings dam: radioisotopes of radium, thorium and actinium. Supervising Scientist report 106

    International Nuclear Information System (INIS)

    Monitoring of bores near the Ranger uranium mine tailings dam has revealed deterioration in water quality in several bores since 1983. In a group of bores to the north of the dam, increases have been observed of up to 500 times for sulphate concentrations and of up to 5 times for 226Ra concentrations. Results are presented here of measurements of members of the uranium, thorium and actinium decay series in borewater samples collected between 1985 and 1993. In particular, measurements of all four naturally-occurring radium isotopes have been used in an investigation of the mechanism of radium concentration changes. For the most seepage-affected bores the major findings of the study include: 228Ra/226Ra 223Ra /226Ra and 224Ra/228Ra ratios all increased over the course of the study; barium concentrations show high seasonal variability, being lower in November than May, but strontium concentrations show a steady increase with time. Calculations show that the groundwater is probably saturated with respect to barite but not with respect to celestite or anglesite; sulphide concentrations are low in comparison with sulphate, and are higher in November than in May; and 227Ac concentrations have increased with time, but do not account for the high 223Ra/226Ra ratios. It is concluded on the basis of these observations that increases in Ra isotope concentrations observed in a number of seepage-affected bores arise from increases in salinity leading to desorption of radium from adsorption sites in the vicinity of the bore rather by direct transport of radium from the tailings. Increased salinity is also causing the observed increases in 227Ac and strontium concentrations, while formation of a barite solid phase in the groundwater is causing the removal of some radium from solution. This is the cause of the increasing radium isotope ratios noted above

  12. Production of actinium, thorium and radium isotopes from natural thorium irradiated with protons up to 141 MeV

    Energy Technology Data Exchange (ETDEWEB)

    Ermolaev, S.V.; Zhuikov, B.L.; Kokhanyuk, V.M.; Matushko, V.L. [Russian Academy of Sciences, Moscow (Russian Federation). Inst. of Nuclear Research; Kalmykov, S.N. [Lomonosov Moscow State Univ., Moscow (Russian Federation). Chemistry Dept.; Aliev, R.A. [Lomonosov Moscow State Univ., Moscow (Russian Federation). Skobeltsyn Inst. of Nuclear Physics; Tananaev, I.G.; Myasoedov, B.F. [Russian Academy of Sciences, Moscow (Russian Federation). A.N. Frumkin Inst. of Physical Chemistry and Electrochemistry

    2012-07-01

    Cross sections of {sup 225}Ac, {sup 227}Ac, {sup 227}Th and {sup 228}Th in thorium-232 targets irradiated with protons in the energy range 21-141 MeV have been measured. Based on these data, production yields of {sup 225}Ac and {sup 223}Ra in thick thorium targets have been calculated. It is possible to produce in proton energy range 60-140 MeV about 96 GBq (2.6 Ci) {sup 225}Ac per 10-d irradiation with 100 {mu}A proton beam current and 10-d decay, and much higher amount of {sup 223}Ra. The impurities of {sup 227}Ac and {sup 224}Ra are important and need to be assessed for further medical applications. (orig.)

  13. origin of elements of the Uranium-235 family observed in the Ellez river near the EL-4 experimental nuclear reactor in dismantling (Monts d'Arree- Finistere department)

    International Nuclear Information System (INIS)

    In a previous study which concerned the catchment basin of the harbour of Brest, the A.C.R.O. put in evidence a marking by artificial radioelements around the power plant of Brennilis which can be imputed without ambiguities to the nuclear installation. It also put in evidence abnormalities concerning the natural radioactivity which justifies this new study. In the area of the Monts d'Arree, actinium 227 (227Ac), non born by its ascendents which are 235U and 231Pa is observed. This phenomenon is characterized by mass activities superior to these ones of 235U and able to reach these ones of 238U. Its presence corresponds with the drainage of the Ellez river since the former channel of radioactive effluents releases from the nuclear power plant EL-4 up to the reservoir Saint-Herblot situated 6 km downstream. The strongest values of radioactivity are registered near the disused power plant, at this place a relationship exists between the level of actinium 227 and this one of the artificial radioactivity as it exists a relationship with the decay products of radon exhaled from the subsoil (210Pb). But its presence is not limited to a part of the Ellez river, it is equally observed in terrestrial medium, in places in priori not influenced by the direct liquid effluents of the power plant. This place is situated at more than 4 km and without any connection with the Ellez waters. At this stage of the study, it is not possible to answer with certainty the question of the origin of this phenomenon. A new reorientation is considered indispensable to clarify definitively the origin of this unknown phenomenon in the scientific publications and the environmental monitoring. (N.C.)

  14. Origin of elements of the Uranium-235 family observed in the Ellez river near the EL-4 experimental nuclear reactor in dismantling (Monts d'Arree- Finistere department); Origine des elements de la famille de l'uranium-235 observes dans la riviere Ellez a proximite du reacteur nucleaire experimental EL4 en cours de demantelement (Mont d'Arree - departement du Finistere). Resultats et premiers constats annee 2006

    Energy Technology Data Exchange (ETDEWEB)

    NONE

    2006-07-01

    In a previous study which concerned the catchment basin of the harbour of Brest, the A.C.R.O. put in evidence a marking by artificial radioelements around the power plant of Brennilis which can be imputed without ambiguities to the nuclear installation. It also put in evidence abnormalities concerning the natural radioactivity which justifies this new study. In the area of the Monts d'Arree, actinium 227 ({sup 227}Ac), non born by its ascendents which are {sup 235}U and {sup 231}Pa is observed. This phenomenon is characterized by mass activities superior to these ones of {sup 235}U and able to reach these ones of {sup 238}U. Its presence corresponds with the drainage of the Ellez river since the former channel of radioactive effluents releases from the nuclear power plant EL-4 up to the reservoir Saint-Herblot situated 6 km downstream. The strongest values of radioactivity are registered near the disused power plant, at this place a relationship exists between the level of actinium 227 and this one of the artificial radioactivity as it exists a relationship with the decay products of radon exhaled from the subsoil ({sup 210}Pb). But its presence is not limited to a part of the Ellez river, it is equally observed in terrestrial medium, in places in priori not influenced by the direct liquid effluents of the power plant. This place is situated at more than 4 km and without any connection with the Ellez waters. At this stage of the study, it is not possible to answer with certainty the question of the origin of this phenomenon. A new reorientation is considered indispensable to clarify definitively the origin of this unknown phenomenon in the scientific publications and the environmental monitoring. (N.C.)

  15. D and D projects trends

    International Nuclear Information System (INIS)

    This series of slides presents: 1 - the Various types of needs and types of operations in any D and D project, 2 - the strong variety of nuclear units to dismantle, 3 - the D and D dependence on nuclear operators' strategy (Immediate/Deferred dismantling), 4 - the demand for D and D services with respect to the ageing of the nuclear fleet, 5 - the impacts to come on the D and D environment due to the Fukushima accident, 6 - the geographical dependence of D and D demands, 7 - the different D and D choices from nuclear operators in the supply chain management, 8 - the key levers in a D and D project performance, 9 - Some key competencies in D and D, 10 - Risk management for both clients and suppliers in a D and D project, 11 - AREVA involvement in Fukushima project as a key demonstration of a critical D and D project management

  16. Production of actinium-225 for alpha particle mediated radioimmunotherapy.

    Science.gov (United States)

    Boll, Rose A; Malkemus, Dairin; Mirzadeh, Saed

    2005-05-01

    The initial clinical trials for treatment of acute myeloid leukemia have demonstrated the effectiveness of the alpha emitter (213)Bi in killing cancer cells. Bismuth-213 is obtained from a radionuclide generator system from decay of 10-days (225)Ac parent. Recent pre-clinical studies have also shown the potential application of both (213)Bi, and the (225)Ac parent radionuclide in a variety of cancer systems and targeted radiotherapy. This paper describes our five years of experience in production of (225)Ac in partial support of the on-going clinical trials. A four-step chemical process, consisting of both anion and cation exchange chromatography, is utilized for routine separation of carrier-free (225)Ac from a mixture of (228)Th, (229)Th and (232)Th. The separation of Ra and Ac from Th is achieved using the marcoporous anion exchange resin MP1 in 8M HNO(3) media. Two sequential MP1/NO(3) columns provide a separation factor of approximately 10(6) for Ra and Ac from Th. The separation of Ac from Ra is accomplished on a low cross-linking cation exchange resin AG50-X4 using 1.2M HNO(3) as eluant. Two sequential AG50/NO(3) columns provide a separation factor of approximately 10(2) for Ac from Ra. A 60-day processing schedule has been adopted in order to reduce the processing cost and to provide the highest levels of (225)Ac possible. Over an 8-week campaign, a total of approximately 100 mCi of (225)Ac (approximately 80% of the theoretical yield) is shipped in 5-6 batches, with the first batch typically consisting of approximately 50 mCi. After the initial separation and purification of Ac, the Ra pool is re-processed on a bi-weekly schedule or as needed to provide smaller batches of (225)Ac. The averaged radioisotopic purity of the (225)Ac was 99.6 +/- 0.7% with a (225)Ra content of < or =0.6%, and an average (229)Th content of (4(-4)(+5)) x 10(-5)%.

  17. Vitamin D

    Science.gov (United States)

    Vitamins are substances that your body needs to grow and develop normally. Vitamin D helps your body absorb calcium. Calcium is ... main building blocks of bone. A lack of vitamin D can lead to bone diseases such as ...

  18. Vitamin D

    Science.gov (United States)

    ... thin, and brittle bones, a condition known as rickets in children and osteomalacia in adults. Vitamin D ... the body. In children, vitamin D deficiency causes rickets, where the bones become soft and bend. It's ...

  19. Vitamin D

    Science.gov (United States)

    ... your body needs to grow and develop normally. Vitamin D helps your body absorb calcium. Calcium is one ... main building blocks of bone. A lack of vitamin D can lead to bone diseases such as osteoporosis ...

  20. Hadronic production of $D(2550)$, $D^*(2600)$, $D(2750)$, $D^*_1(2760)$ and $D^*_3(2760)$

    CERN Document Server

    Zhao, Ze; Zhang, Ailin

    2016-01-01

    Hadronic decays of radially excited $2D$ $D(2^3D_1)$, $D(2^3D_3)$, $D(2D_2)$ and $D(2D^\\prime_2)$ have been studied in a $^3P_0$ model. All OZI-allowed decay channels of these $2D$ $D$ resonances have been given, and relevant decay widths have been calculated. $D(2550)$, $D^*(2600)$, $D(2750)$, $D^*_1(2760)$ and $D^*_3(2760)$ can be produced in hadronic decays of $D(2^3D_1)$, $D(2^3D_3)$, $D(2D_2)$ and $D(2D^\\prime_2)$. In different assignments, hadronic decay widths and some relevant ratios from the $2D$ $D$ resonances to $D(2550)$, $D^*(2600)$, $D(2750)$, $D^*_1(2760)$ or $D^*_3(2760)$ final states have been predicted, which may provide some more information to identify these resonances in forthcoming experiments.

  1. Vitamin D

    OpenAIRE

    Grant, William B; Tangpricha, Vin

    2012-01-01

    Evidence that vitamin D reduces the risk of many types of disease is increasing exponentially. In 2011, 3,100 publications with “vitamin D” in the title or abstract were published, up from 2,606 in 2010, 1,303 in 2005, and 796 in 2000. A committee operating under the auspices of the Institute of Medicine (IOM) of the US National Academies reviewed the evidence for beneficial effects of vitamin D. Their report, issued at the end of 2010, 1 found what they considered to be strong evidence for o...

  2. Economic evaluation of D-T, D-3He, and catalyzed D-D fusion reactors

    International Nuclear Information System (INIS)

    Because the D-3He reaction generates no neutrons and the D-D reaction can use abundant fuel resources, these reactions are expected to be used in advanced fuel fusion reactors. Economic considerations and engineering problems are important for realizing such reactors as commercial plants. Therefore, we estimate and compare the cost of electricity (COE) from D-T, D-3He, and catalyzed D-D (cat D-D) fusion reactors. D-3He and cat D-D reactors have a low neutron wall load. Therefore, the D-3He reactor has no wall replacement cost. In addition, no tritium breeding system is needed for the D-3He reactor, but 3He gas is rare. Because the reaction rates of the D-3He and D-D reactions are less, D-3He and D-D reactors require highly efficient confinement properties and operation at high ion temperatures. Furthermore, the power densities of D-3He and D-D reactors are smaller than that of the D-T reactor; thus, D-3He and D-D reactors require a large plasma volume. Assuming a high ion temperature (= 60 keV) and high normalized beta (= 7-8), the COE of a D-3He reactor is expected to be similar to that of a D-T reactor. In terms of cost, cat D-D is disadvantageous in comparison with D-3He and D-T reactors. (author)

  3. D3+D6 solution and D4+D6 solution

    Energy Technology Data Exchange (ETDEWEB)

    Shin Heiyoung E-mail: hyshin@physics.utexas.edu

    2001-04-16

    We make the supergravity solutions describing the branes (D3 branes and D4 branes) localized within the D6 branes in the near core region of D6 brane. From the D=11 solutions (M3 branes and M4 branes with the Z{sub N} identifications in the transverse space) we obtain the D=10 supergravity solutions of D3 branes localized within D6 branes and D4 branes localized within D6 branes by reducing the dimension down to D=10 along a circular direction of S{sup 3} part of the transverse space. M3 brane solution leads to D=10 background representing D3 branes localized on D6 branes in the region close to the D6 branes core. M4 branes lead to the D4 branes localized on D6 branes in the region close to the D6 brane core.

  4. Color suppressed contributions to the decay modes B_{d,s} -> D_{s,d} D_{s,d}, B_{d,s} -> D_{s,d} D^*_{s,d}, and B_{d,s} -> D^*_{s,d} D^*_{s,d}

    OpenAIRE

    Eeg, Jan O.; Fajfer, Svjetlana; Prapotnik, Anita

    2005-01-01

    The amplitudes for decays of the type $B_{d,s} \\to D_{s,d} D_{s,d}$, have no factorizable contributions, while $B_{d,s} \\to D_{s,d} D^*_{s,d}$, and $B_{d,s} \\to D^*_{s,d} D^*_{s,d}$ have relatively small factorizable contributions through the annihilation mechanism. The dominant contributions to the decay amplitudes arise from chiral loop contributions and tree level amplitudes which can be obtained in terms of soft gluon emissions forming a gluon condensate. We predict that the branching rat...

  5. Facts about Vitamin D

    Science.gov (United States)

    ... D? We get vitamin D from three sources—food, supplements, and sunlight. Sunlight When exposed to sunlight, the ... dark skin get extra vitamin D from fortified foods or supplements. How much is too much? Vitamin D toxicity ...

  6. D-D tokamak reactor studies

    International Nuclear Information System (INIS)

    A tokamak D-D reactor design, utilizing the advantages of a deuterium-fueled reactor but with parameters not unnecessarily extended from existing D-T designs, is presented. Studies leading to the choice of a design and initial studies of the design are described. The studies are in the areas of plasma engineering, first-wall/blanket/shield design, magnet design, and tritium/fuel/vacuum requirements. Conclusions concerning D-D tokamak reactors are stated

  7. Unsuccessful vitamin D treatment

    DEFF Research Database (Denmark)

    Schmedes, Anne; Hey, Henrik; Larsson, Iben;

    2012-01-01

    Vitamin D3 (25-OHD3) analyses have increased exponentially and vitamin D deficiency (vitamin D2). Lack of effect of treatment can be due to: 1......) too low dose, 2) incorrect analytical methods when injection treatment (vitamin D2) is used, 3) obesity, 4) seasonal variations, and 5) poor compliance. Treatment is mandatory in order to prevent osteopenia and osteoporosis. Vitamin D3 is more potent than vitamin D2. Injections with vitamin D2 should...... be replaced by vitamin D3....

  8. Vitamin D and diabetes

    DEFF Research Database (Denmark)

    Wolden-Kirk, Heidi; Overbergh, Lut; Christesen, Henrik Thybo;

    2011-01-01

    Experimental evidence indicates that vitamin D may play a role in the defense against type 1 diabetes (T1D) as well as type 2 diabetes (T2D). Epidemiological data have established a link between vitamin D deficiency and an increased incidence of both T1D and T2D, whereas early and long-term vitamin...... D supplementation may decrease the risk of these disorders. The protective effects of vitamin D are mediated through the regulation of several components such as the immune system and calcium homeostasis. However, an increasing amount of evidence suggests that vitamin D also affects beta cells...... directly thereby rendering them more resistant to the types of cellular stress encountered during T1D and T2D. This review evaluates the role of vitamin D signaling in the pathogenesis of T1D and T2D with a special emphasis on the direct effects of vitamin D on pancreatic beta cells....

  9. 6D Interpretation of 3D Gravity

    CERN Document Server

    Herfray, Yannick; Scarinci, Carlos

    2016-01-01

    We show that 3D gravity, in its pure connection formulation, admits a natural 6D interpretation. The 3D field equations for the connection are equivalent to 6D Hitchin equations for the Chern-Simons 3-form in the total space of the principal bundle over the 3-dimensional base. Turning this construction around one gets an explanation of why the pure connection formulation of 3D gravity exists. More generally, we interpret 3D gravity as the dimensional reduction of the 6D Hitchin theory. To this end, we show that any SU(2) invariant closed 3-form in the total space of the principal SU(2) bundle can be parametrised by a connection together with a 2-form field on the base. The dimensional reduction of the 6D Hitchin theory then gives rise to 3D gravity coupled to a topological 2-form field.

  10. Calcium and Vitamin D

    Science.gov (United States)

    ... Home › Patients › Treatment › Calcium/Vitamin D Calcium/Vitamin D Getting enough calcium and vitamin D is essential ... counter medications and calcium supplements. What is Vitamin D and What Does it Do? Vitamin D plays ...

  11. A note on the B*(B),B*(B)*,D*(D),D*(D)* molecular states

    Institute of Scientific and Technical Information of China (English)

    SUN Zhi-Feng; LUO Zhi-Gang; HE Jun; LIU Xiang; ZHU Shi-Lin

    2012-01-01

    In the framework of the one-boson-exchange model,we have performed an extensive study of the possible B*(B),B*(B)*,D*(D),D*(D)* molecular states with various quantum numbers after considering the S-wave and D-wave mixing.We also discuss the possible experimental research of these interesting states.

  12. Drug: D03813 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available DERMATOLOGICALS D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AC Corticosteroids... (USAN) D07X CORTICOSTEROIDS, OTHER COMBINATIONS D07XC Corticosteroids, potent, other combinations D07XC04 D

  13. Delta agent (Hepatitis D)

    Science.gov (United States)

    Hepatitis D virus ... Hepatitis D virus (HDV) is found only in people who carry the hepatitis B virus. HDV may make liver ... B virus but who never had symptoms. Hepatitis D infects about 15 million people worldwide. It occurs ...

  14. Vitamin D Test

    Science.gov (United States)

    ... limited. Home Visit Global Sites Search Help? Vitamin D Tests Share this page: Was this page helpful? Also known as: Ergocalciferol (Vitamin D 2 ); Cholecalciferol (Vitamin D 3 ); Calcidiol (25-hydroxyvitamin ...

  15. 3D Animation Essentials

    CERN Document Server

    Beane, Andy

    2012-01-01

    The essential fundamentals of 3D animation for aspiring 3D artists 3D is everywhere--video games, movie and television special effects, mobile devices, etc. Many aspiring artists and animators have grown up with 3D and computers, and naturally gravitate to this field as their area of interest. Bringing a blend of studio and classroom experience to offer you thorough coverage of the 3D animation industry, this must-have book shows you what it takes to create compelling and realistic 3D imagery. Serves as the first step to understanding the language of 3D and computer graphics (CG)Covers 3D anim

  16. 3D video

    CERN Document Server

    Lucas, Laurent; Loscos, Céline

    2013-01-01

    While 3D vision has existed for many years, the use of 3D cameras and video-based modeling by the film industry has induced an explosion of interest for 3D acquisition technology, 3D content and 3D displays. As such, 3D video has become one of the new technology trends of this century.The chapters in this book cover a large spectrum of areas connected to 3D video, which are presented both theoretically and technologically, while taking into account both physiological and perceptual aspects. Stepping away from traditional 3D vision, the authors, all currently involved in these areas, provide th

  17. Vitamin D and Aging

    OpenAIRE

    Gallagher, J. Christopher

    2013-01-01

    Aging affects the formation of 1,25-dihydroxyvitamin D (1,25[OH]2D; calcitriol), the active form of vitamin D. Production of 1,25(OH)2D is reduced by 50% as a result of an age-related decline in renal function, although serum 1,25(OH)2D levels are maintained in part by secondary hyperparathyroidism. Aging also causes a decrease in calcium absorption that precedes the decrease in 1,25(OH)2D by 10 to 15 years. Because 1,25(OH)2D is dependent on an adequate supply of the substrate vitamin D, the...

  18. Observation of D0-D0 oscillations.

    Science.gov (United States)

    Aaij, R; Abellan Beteta, C; Adametz, A; Adeva, B; Adinolfi, M; Adrover, C; Affolder, A; Ajaltouni, Z; Albrecht, J; Alessio, F; Alexander, M; Ali, S; Alkhazov, G; Alvarez Cartelle, P; Alves, A A; Amato, S; Amhis, Y; Anderlini, L; Anderson, J; Andreassen, R; Appleby, R B; Aquines Gutierrez, O; Archilli, F; Artamonov, A; Artuso, M; Aslanides, E; Auriemma, G; Bachmann, S; Back, J J; Baesso, C; Baldini, W; Barlow, R J; Barschel, C; Barsuk, S; Barter, W; Bates, A; Bauer, Th; Bay, A; Beddow, J; Bediaga, I; Belogurov, S; Belous, K; Belyaev, I; Ben-Haim, E; Benayoun, M; Bencivenni, G; Benson, S; Benton, J; Berezhnoy, A; Bernet, R; Bettler, M-O; van Beuzekom, M; Bien, A; Bifani, S; Bird, T; Bizzeti, A; Bjørnstad, P M; Blake, T; Blanc, F; Blanks, C; Blouw, J; Blusk, S; Bobrov, A; Bocci, V; Bondar, A; Bondar, N; Bonivento, W; Borghi, S; Borgia, A; Bowcock, T J V; Bowen, E; Bozzi, C; Brambach, T; van den Brand, J; Bressieux, J; Brett, D; Britsch, M; Britton, T; Brook, N H; Brown, H; Büchler-Germann, A; Burducea, I; Bursche, A; Buytaert, J; Cadeddu, S; Callot, O; Calvi, M; Calvo Gomez, M; Camboni, A; Campana, P; Carbone, A; Carboni, G; Cardinale, R; Cardini, A; Carranza-Mejia, H; Carson, L; Carvalho Akiba, K; Casse, G; Cattaneo, M; Cauet, Ch; Charles, M; Charpentier, Ph; Chen, P; Chiapolini, N; Chrzaszcz, M; Ciba, K; Cid Vidal, X; Ciezarek, G; Clarke, P E L; Clemencic, M; Cliff, H V; Closier, J; Coca, C; Coco, V; Cogan, J; Cogneras, E; Collins, P; Comerma-Montells, A; Contu, A; Cook, A; Coombes, M; Corti, G; Couturier, B; Cowan, G A; Craik, D; Cunliffe, S; Currie, R; D'Ambrosio, C; David, P; David, P N Y; De Bonis, I; De Bruyn, K; De Capua, S; De Cian, M; De Miranda, J M; De Paula, L; De Simone, P; Decamp, D; Deckenhoff, M; Degaudenzi, H; Del Buono, L; Deplano, C; Derkach, D; Deschamps, O; Dettori, F; Di Canto, A; Dickens, J; Dijkstra, H; Diniz Batista, P; Dogaru, M; Domingo Bonal, F; Donleavy, S; Dordei, F; Dosil Suárez, A; Dossett, D; Dovbnya, A; Dupertuis, F; Dzhelyadin, R; Dziurda, A; Dzyuba, A; Easo, S; Egede, U; Egorychev, V; Eidelman, S; van Eijk, D; Eisenhardt, S; Ekelhof, R; Eklund, L; El Rifai, I; Elsasser, Ch; Elsby, D; Falabella, A; Färber, C; Fardell, G; Farinelli, C; Farry, S; Fave, V; Fernandez Albor, V; Ferreira Rodrigues, F; Ferro-Luzzi, M; Filippov, S; Fitzpatrick, C; Fontana, M; Fontanelli, F; Forty, R; Francisco, O; Frank, M; Frei, C; Frosini, M; Furcas, S; Gallas Torreira, A; Galli, D; Gandelman, M; Gandini, P; Gao, Y; Garofoli, J; Garosi, P; Garra Tico, J; Garrido, L; Gaspar, C; Gauld, R; Gersabeck, E; Gersabeck, M; Gershon, T; Ghez, Ph; Gibson, V; Gligorov, V V; Göbel, C; Golubkov, D; Golutvin, A; Gomes, A; Gordon, H; Grabalosa Gándara, M; Graciani Diaz, R; Granado Cardoso, L A; Graugés, E; Graziani, G; Grecu, A; Greening, E; Gregson, S; Grünberg, O; Gui, B; Gushchin, E; Guz, Yu; Gys, T; Hadjivasiliou, C; Haefeli, G; Haen, C; Haines, S C; Hall, S; Hampson, T; Hansmann-Menzemer, S; Harnew, N; Harnew, S T; Harrison, J; Harrison, P F; Hartmann, T; He, J; Heijne, V; Hennessy, K; Henrard, P; Hernando Morata, J A; van Herwijnen, E; Hicks, E; Hill, D; Hoballah, M; Hombach, C; Hopchev, P; Hulsbergen, W; Hunt, P; Huse, T; Hussain, N; Hutchcroft, D; Hynds, D; Iakovenko, V; Ilten, P; Imong, J; Jacobsson, R; Jaeger, A; Jans, E; Jansen, F; Jaton, P; Jing, F; John, M; Johnson, D; Jones, C R; Jost, B; Kaballo, M; Kandybei, S; Karacson, M; Karbach, T M; Kenyon, I R; Kerzel, U; Ketel, T; Keune, A; Khanji, B; Kochebina, O; Komarov, V; Koopman, R F; Koppenburg, P; Korolev, M; Kozlinskiy, A; Kravchuk, L; Kreplin, K; Kreps, M; Krocker, G; Krokovny, P; Kruse, F; Kucharczyk, M; Kudryavtsev, V; Kvaratskheliya, T; La Thi, V N; Lacarrere, D; Lafferty, G; Lai, A; Lambert, D; Lambert, R W; Lanciotti, E; Lanfranchi, G; Langenbruch, C; Latham, T; Lazzeroni, C; Le Gac, R; van Leerdam, J; Lees, J-P; Lefèvre, R; Leflat, A; Lefrançois, J; Leroy, O; Lesiak, T; Li, Y; Li Gioi, L; Liles, M; Lindner, R; Linn, C; Liu, B; Liu, G; von Loeben, J; Lopes, J H; Lopez Asamar, E; Lopez-March, N; Lu, H; Luisier, J; Luo, H; Mac Raighne, A; Machefert, F; Machikhiliyan, I V; Maciuc, F; Maev, O; Maino, M; Malde, S; Manca, G; Mancinelli, G; Mangiafave, N; Marconi, U; Märki, R; Marks, J; Martellotti, G; Martens, A; Martin, L; Martí Sánchez, A; Martinelli, M; Martinez Santos, D; Martins Tostes, D; Massafferri, A; Matev, R; Mathe, Z; Matteuzzi, C; Matveev, M; Maurice, E; Mazurov, A; McCarthy, J; McNulty, R; Meadows, B; Meissner, M; Merk, M; Milanes, D A; Minard, M-N; Molina Rodriguez, J; Monteil, S; Moran, D; Morawski, P; Mountain, R; Mous, I; Muheim, F; Müller, K; Muresan, R; Muryn, B; Muster, B; Naik, P; Nakada, T; Nandakumar, R; Nasteva, I; Needham, M; Neufeld, N; Nguyen, A D; Nguyen, T D; Nguyen-Mau, C; Nicol, M; Niess, V; Nikitin, N; Nikodem, T; Nisar, S; Nomerotski, A; Novoselov, A; Oblakowska-Mucha, A; Obraztsov, V; Oggero, S; Ogilvy, S; Okhrimenko, O; Oldeman, R; Orlandea, M; Otalora Goicochea, J M; Owen, P; Pal, B K; Palano, A; Palutan, M; Panman, J; Papanestis, A; Pappagallo, M; Parkes, C; Parkinson, C J; Passaleva, G; Patel, G D; Patel, M; Patrick, G N; Patrignani, C; Pavel-Nicorescu, C; Pazos Alvarez, A; Pellegrino, A; Penso, G; Pepe Altarelli, M; Perazzini, S; Perego, D L; Perez Trigo, E; Pérez-Calero Yzquierdo, A; Perret, P; Perrin-Terrin, M; Pessina, G; Petridis, K; Petrolini, A; Phan, A; Picatoste Olloqui, E; Pietrzyk, B; Pilař, T; Pinci, D; Playfer, S; Plo Casasus, M; Polci, F; Polok, G; Poluektov, A; Polycarpo, E; Popov, D; Popovici, B; Potterat, C; Powell, A; Prisciandaro, J; Pugatch, V; Puig Navarro, A; Qian, W; Rademacker, J H; Rakotomiaramanana, B; Rangel, M S; Raniuk, I; Rauschmayr, N; Raven, G; Redford, S; Reid, M M; Dos Reis, A C; Ricciardi, S; Richards, A; Rinnert, K; Rives Molina, V; Roa Romero, D A; Robbe, P; Rodrigues, E; Rodriguez Perez, P; Rogers, G J; Roiser, S; Romanovsky, V; Romero Vidal, A; Rouvinet, J; Ruf, T; Ruiz, H; Sabatino, G; Saborido Silva, J J; Sagidova, N; Sail, P; Saitta, B; Salzmann, C; Sanmartin Sedes, B; Sannino, M; Santacesaria, R; Santamarina Rios, C; Santovetti, E; Sapunov, M; Sarti, A; Satriano, C; Satta, A; Savrie, M; Schaack, P; Schiller, M; Schindler, H; Schleich, S; Schlupp, M; Schmelling, M; Schmidt, B; Schneider, O; Schopper, A; Schune, M-H; Schwemmer, R; Sciascia, B; Sciubba, A; Seco, M; Semennikov, A; Senderowska, K; Sepp, I; Serra, N; Serrano, J; Seyfert, P; Shapkin, M; Shapoval, I; Shatalov, P; Shcheglov, Y; Shears, T; Shekhtman, L; Shevchenko, O; Shevchenko, V; Shires, A; Silva Coutinho, R; Skwarnicki, T; Smith, N A; Smith, E; Smith, M; Sobczak, K; Sokoloff, M D; Soler, F J P; Soomro, F; Souza, D; Souza De Paula, B; Spaan, B; Sparkes, A; Spradlin, P; Stagni, F; Stahl, S; Steinkamp, O; Stoica, S; Stone, S; Storaci, B; Straticiuc, M; Straumann, U; Subbiah, V K; Swientek, S; Szczekowski, M; Szczypka, P; Szumlak, T; T'jampens, S; Teklishyn, M; Teodorescu, E; Teubert, F; Thomas, C; Thomas, E; van Tilburg, J; Tisserand, V; Tobin, M; Tolk, S; Tonelli, D; Topp-Joergensen, S; Torr, N; Tournefier, E; Tourneur, S; Tran, M T; Tresch, M; Tsaregorodtsev, A; Tsopelas, P; Tuning, N; Ubeda Garcia, M; Ukleja, A; Urner, D; Uwer, U; Vagnoni, V; Valenti, G; Vazquez Gomez, R; Vazquez Regueiro, P; Vecchi, S; Velthuis, J J; Veltri, M; Veneziano, G; Vesterinen, M; Viaud, B; Vieira, D; Vilasis-Cardona, X; Vollhardt, A; Volyanskyy, D; Voong, D; Vorobyev, A; Vorobyev, V; Voß, C; Voss, H; Waldi, R; Wallace, R; Wandernoth, S; Wang, J; Ward, D R; Watson, N K; Webber, A D; Websdale, D; Whitehead, M; Wicht, J; Wiedner, D; Wiggers, L; Wilkinson, G; Williams, M P; Williams, M; Wilson, F F; Wishahi, J; Witek, M; Witzeling, W; Wotton, S A; Wright, S; Wu, S; Wyllie, K; Xie, Y; Xing, F; Xing, Z; Yang, Z; Young, R; Yuan, X; Yushchenko, O; Zangoli, M; Zavertyaev, M; Zhang, F; Zhang, L; Zhang, W C; Zhang, Y; Zhelezov, A; Zhong, L; Zvyagin, A

    2013-03-01

    We report a measurement of the time-dependent ratio of D(0) → K(+) π- to D(0) → K(-) π(+) decay rates in D(*+)-tagged events using 1.0 fb(-1) of integrated luminosity recorded by the LHCb experiment. We measure the mixing parameters x('2) = (-0.9 ± 1.3) × 10(-4), y' = (7.2 ± 2.4) × 10(-3), and the ratio of doubly-Cabibbo-suppressed to Cabibbo-favored decay rates R(D) = (3.52 ± 0.15) × 10^{-3}, where the uncertainties include statistical and systematic sources. The result excludes the no-mixing hypothesis with a probability corresponding to 9.1 standard deviations and represents the first observation of D0-D0 oscillations from a single measurement. PMID:23521252

  19. The dS/dS Correspondence

    CERN Document Server

    Alishahiha, M; Silverstein, E; Tong, D; Alishahiha, Mohsen; Karch, Andreas; Silverstein, Eva; Tong, David

    2004-01-01

    We present a holographic duality for the de Sitter static patch which consolidates basic features of its geometry and the behavior of gravity and brane probes, valid on timescales short compared to the decay or Poincare recurrence times. Namely de Sitter spacetime $dS_d(R)$ in $d$ dimensions with curvature radius $R$ is holographically dual to two conformal field theories on $dS_{d-1}(R)$, cut off at an energy scale 1/R where they couple to each other and to $d-1$ dimensional gravity. As part of our analysis, we study brane probes in de Sitter and thermal Anti de Sitter spaces, and interpret the terms in the corresponding DBI action via strongly coupled thermal field theory. This provides a dual field theoretic interpretation of the fact that probes take forever to reach a horizon in general relativity.

  20. Fission multipliers for D-D/D-T neutron generators

    International Nuclear Information System (INIS)

    A compact D-D/D-T fusion based neutron generator is being designed at the Lawrence Berkeley National Laboratory to have a potential yield of 1012 D-D n/s and 1014 D-T n/s. Because of its high neutron yield and compact size (∼20 cm in diameter by 4 cm long), this neutron generator design will be suitable for many applications. However, some applications required higher flux available from nuclear reactors and spallation neutron sources operated with GeV proton beams. In this study, a subcritical fission multiplier with keff of 0.98 is coupled with the compact neutron generators in order to increase the neutron flux output. We have chosen two applications to show the gain in flux due to the use of fission multipliers--in-core irradiation and out-of-core irradiation. For the in-core irradiation, we have shown that a gain of ∼25 can be achieved in a positron production system using D-T generator. For the out-of-core irradiation, a gain of ∼17 times is obtained in Boron Neutron Capture Therapy (BNCT) using a D-D neutron generator. The total number of fission neutrons generated by a source neutron in a fission multiplier with keff is ∼50. For the out-of-core irradiation, the theoretical maximum net multiplication is ∼30 due to the absorption of neutrons in the fuel. A discussion of the achievable multiplication and the theoretical multiplication will be presented in this paper

  1. Solid works 3D

    Energy Technology Data Exchange (ETDEWEB)

    Choi, Cheol Yeong

    2004-02-15

    This book explains modeling of solid works 3D and application of 3D CAD/CAM. The contents of this book are outline of modeling such as CAD and 2D and 3D, solid works composition, method of sketch, writing measurement fixing, selecting projection, choosing condition of restriction, practice of sketch, making parts, reforming parts, modeling 3D, revising 3D modeling, using pattern function, modeling necessaries, assembling, floor plan, 3D modeling method, practice floor plans for industrial engineer data aided manufacturing, processing of CAD/CAM interface.

  2. Solid works 3D

    International Nuclear Information System (INIS)

    This book explains modeling of solid works 3D and application of 3D CAD/CAM. The contents of this book are outline of modeling such as CAD and 2D and 3D, solid works composition, method of sketch, writing measurement fixing, selecting projection, choosing condition of restriction, practice of sketch, making parts, reforming parts, modeling 3D, revising 3D modeling, using pattern function, modeling necessaries, assembling, floor plan, 3D modeling method, practice floor plans for industrial engineer data aided manufacturing, processing of CAD/CAM interface.

  3. [Vitamin D and pregnancy].

    Science.gov (United States)

    Benachi, Alexandra; Cordier, Anne-Gael; Courbebaisse, Marie; Souberbielle, Jean-Claude

    2013-10-01

    Vitamin D insufficiency is characterized, since 2005, by 25(OH)D concentration less than 75 nmol/L (or 30 ng/mL). Vitamin D could interfere with many mechanisms involved in preeclampsia's pathogenesis including trophoblastic invasion and immunomodulation as well as blood pressure control and proteinuria. Occurrence of preeclampsia and gestational diabetes seems to be linked to vitamin D deficiency but recent data in the literature are contradictory. Vitamin D supplementation during pregnancy is controversial. Some societies consider it unnecessary and others recommend up to 2000 UI/d. There is no reported case of teratogenicity linked with vitamin D intake. PMID:24054765

  4. Drug: D01711 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available iseptics and disinfectants D08AX07 Sodium hypochlorite D...C) classification [BR:br08303] D DERMATOLOGICALS D08 ANTISEPTICS AND DISINFECTANTS D08A ANTISEPTICS AND DISINFECTANTS D08AX Other ant

  5. Drug: D08245 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available hemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D01 ANTIFUNGALS FOR D...ERMATOLOGICAL USE D01A ANTIFUNGALS FOR TOPICAL USE D01AE Other antifungals for topical use D01AE22 Naftifine

  6. Drug: D06222 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D06222 Mixture, Drug Tricitrates (USP) Sodium citrate [DR:D01781 D05855], Potassium citrate [DR:D05578], Cit...ric acid [DR:D00037 D01222] Alkalizer [systemic]; Alkalizer [urinary]; Anti-urolith

  7. Drug: D08714 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D08714 Mixture, Drug d-Camphor - mentha oil mixt d-Camphor [DR:D06392], Mentha oil ... Peppermint rubber and camphor peppermint D08714 d-Camphor - mentha oil mixt PubChem: 96025397 ...

  8. Drug: D03812 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available OGICALS D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AC Corticosteroids, ...COSTEROIDS, OTHER COMBINATIONS D07XC Corticosteroids, potent, other combinations D07XC04 Diflucortolone D038

  9. Vitamin D Insufficiency

    OpenAIRE

    THACHER, Tom D; Clarke, Bart L.

    2011-01-01

    Vitamin D deficiency, which classically manifests as bone disease (either rickets or osteomalacia), is characterized by impaired bone mineralization. More recently, the term vitamin D insufficiency has been used to describe low levels of serum 25-hydroxyvitamin D that may be associated with other disease outcomes. Reliance on a single cutoff value to define vitamin D deficiency or insufficiency is problematic because of the wide individual variability of the functional effects of vitamin D an...

  10. EUROPEANA AND 3D

    Directory of Open Access Journals (Sweden)

    D. Pletinckx

    2012-09-01

    Full Text Available The current 3D hype creates a lot of interest in 3D. People go to 3D movies, but are we ready to use 3D in our homes, in our offices, in our communication? Are we ready to deliver real 3D to a general public and use interactive 3D in a meaningful way to enjoy, learn, communicate? The CARARE project is realising this for the moment in the domain of monuments and archaeology, so that real 3D of archaeological sites and European monuments will be available to the general public by 2012. There are several aspects to this endeavour. First of all is the technical aspect of flawlessly delivering 3D content over all platforms and operating systems, without installing software. We have currently a working solution in PDF, but HTML5 will probably be the future. Secondly, there is still little knowledge on how to create 3D learning objects, 3D tourist information or 3D scholarly communication. We are still in a prototype phase when it comes to integrate 3D objects in physical or virtual museums. Nevertheless, Europeana has a tremendous potential as a multi-facetted virtual museum. Finally, 3D has a large potential to act as a hub of information, linking to related 2D imagery, texts, video, sound. We describe how to create such rich, explorable 3D objects that can be used intuitively by the generic Europeana user and what metadata is needed to support the semantic linking.

  11. Drug: D09058 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09058 Formula, Drug Kamigedokuto Coptis rhizome [DR:D00092], Scutellaria root [DR:...D06688], Phellodendron bark [DR:D06689], Gardenia fruit [DR:D06731], Bupleurum root [DR:D06727], Artemisia c...:D06895], Cimicifuga rhizome [DR:D06745], Glycyrrhiza [DR:D04365], Rush [ED:E0029

  12. Phototherapy and vitamin D.

    Science.gov (United States)

    Juzeniene, Asta; Grigalavicius, Mantas; Juraleviciute, Marina; Grant, William B

    2016-01-01

    The skin is the site for the photosynthesis of vitamin D and is a target tissue for the active metabolite of vitamin D. An increasing body of evidence indicates that vitamin D produced during phototherapy may be responsible for the positive effects observed during treatment of some skin diseases. Topical or oral application of vitamin D derivatives are used alone or with phototherapy. This paper reviews what is known about the use of phototherapy to enhance vitamin D levels, the use of vitamin D analogues with phototherapy, the efficacy of combination therapies, and controversies regarding some of the outcomes. Vitamin D can play a beneficial role in treating psoriasis, even though the exact role of vitamin D in the pathogenesis and severity of psoriasis remains unclear. The role of vitamin D in vitiligo, atopic dermatitis, polymorphic light eruption, and mycosis fungoides must be further investigated. PMID:27638432

  13. The D0-D8 system revisited

    CERN Document Server

    Lu, J X

    2009-01-01

    We address a few subtle issues regarding the interacting D0-D8 system. There are two existing interpretations for the counter-intuitive non-vanishing attractive cylinder-diagram R-R potential. We improve them each by properly dealing with the divergence of potential in the R-R as well as the NS-NS sector, which has been ignored so far. We further test them by considering the D8 to carry a flux, electric or magnetic. We find that the improved interpretations continue to hold. We resolve a subtle issue regarding the regularization of fermionic zero-modes in the R-R sector when the D8 carries an electric flux so that a meaningful result for the potential can be calculated. The persistence of divergence for the potential in either sector in the presence of a flux on the D8 brane indicates that adding a flux/fluxes on the D8 brane doesn't help to improve its nature of existence as an independent object, therefore reenforcing the previous assertion on D8 branes.

  14. First observations of $\\bar{B}_s^0\\to D^+D^-$, $D_s^+D^-$ and $D^0\\bar{D}^0$ decays

    CERN Document Server

    Aaij, R; Adeva, B; Adinolfi, M; Adrover, C; Affolder, A; Ajaltouni, Z; Albrecht, J; Alessio, F; Alexander, M; Ali, S; Alkhazov, G; Alvarez Cartelle, P; Alves Jr, A A; Amato, S; Amerio, S; Amhis, Y; Anderlini, L; Anderson, J; Andreassen, R; Appleby, R B; Aquines Gutierrez, O; Archilli, F; Artamonov, A; Artuso, M; Aslanides, E; Auriemma, G; Bachmann, S; Back, J J; Baesso, C; Balagura, V; Baldini, W; Barlow, R J; Barschel, C; Barsuk, S; Barter, W; Bauer, Th; Bay, A; Beddow, J; Bedeschi, F; Bediaga, I; Belogurov, S; Belous, K; Belyaev, I; Ben-Haim, E; Benayoun, M; Bencivenni, G; Benson, S; Benton, J; Berezhnoy, A; Bernet, R; Bettler, M -O; van Beuzekom, M; Bien, A; Bifani, S; Bird, T; Bizzeti, A; Bjørnstad, P M; Blake, T; Blanc, F; Blouw, J; Blusk, S; Bocci, V; Bondar, A; Bondar, N; Bonivento, W; Borghi, S; Borgia, A; Bowcock, T J V; Bowen, E; Bozzi, C; Brambach, T; van den Brand, J; Bressieux, J; Brett, D; Britsch, M; Britton, T; Brook, N H; Brown, H; Burducea, I; Bursche, A; Busetto, G; Buytaert, J; Cadeddu, S; Callot, O; Calvi, M; Calvo Gomez, M; Camboni, A; Campana, P; Carbone, A; Carboni, G; Cardinale, R; Cardini, A; Carranza-Mejia, H; Carson, L; Carvalho Akiba, K; Casse, G; Cattaneo, M; Cauet, Ch; Charles, M; Charpentier, Ph; Chen, P; Chiapolini, N; Chrzaszcz, M; Ciba, K; Cid Vidal, X; Ciezarek, G; Clarke, P E L; Clemencic, M; Cliff, H V; Closier, J; Coca, C; Coco, V; Cogan, J; Cogneras, E; Collins, P; Comerma-Montells, A; Contu, A; Cook, A; Coombes, M; Coquereau, S; Corti, G; Couturier, B; Cowan, G A; Craik, D; Cunliffe, S; Currie, R; D'Ambrosio, C; David, P; David, P N Y; De Bonis, I; De Bruyn, K; De Capua, S; De Cian, M; De Miranda, J M; De Oyanguren Campos, M; De Paula, L; De Silva, W; De Simone, P; Decamp, D; Deckenhoff, M; Del Buono, L; Derkach, D; Deschamps, O; Dettori, F; Di Canto, A; Dijkstra, H; Dogaru, M; Donleavy, S; Dordei, F; Dosil Suárez, A; Dossett, D; Dovbnya, A; Dupertuis, F; Dzhelyadin, R; Dziurda, A; Dzyuba, A; Easo, S; Egede, U; Egorychev, V; Eidelman, S; van Eijk, D; Eisenhardt, S; Eitschberger, U; Ekelhof, R; Eklund, L; El Rifai, I; Elsasser, Ch; Elsby, D; Falabella, A; Färber, C; Fardell, G; Farinelli, C; Farry, S; Fave, V; Ferguson, D; Fernandez Albor, V; Ferreira Rodrigues, F; Ferro-Luzzi, M; Filippov, S; Fitzpatrick, C; Fontana, M; Fontanelli, F; Forty, R; Francisco, O; Frank, M; Frei, C; Frosini, M; Furcas, S; Furfaro, E; Gallas Torreira, A; Galli, D; Gandelman, M; Gandini, P; Gao, Y; Garofoli, J; Garosi, P; Garra Tico, J; Garrido, L; Gaspar, C; Gauld, R; Gersabeck, E; Gersabeck, M; Gershon, T; Ghez, Ph; Gibson, V; Gligorov, V V; Göbel, C; Golubkov, D; Golutvin, A; Gomes, A; Gordon, H; Grabalosa Gándara, M; Graciani Diaz, R; Granado Cardoso, L A; Graugés, E; Graziani, G; Grecu, A; Greening, E; Gregson, S; Grünberg, O; Gui, B; Gushchin, E; Guz, Yu; Gys, T; Hadjivasiliou, C; Haefeli, G; Haen, C; Haines, S C; Hall, S; Hampson, T; Hansmann-Menzemer, S; Harnew, N; Harnew, S T; Harrison, J; Hartmann, T; He, J; Heijne, V; Hennessy, K; Henrard, P; Hernando Morata, J A; van Herwijnen, E; Hicks, E; Hill, D; Hoballah, M; Hombach, C; Hopchev, P; Hulsbergen, W; Hunt, P; Huse, T; Hussain, N; Hutchcroft, D; Hynds, D; Iakovenko, V; Idzik, M; Ilten, P; Jacobsson, R; Jaeger, A; Jans, E; Jaton, P; Jing, F; John, M; Johnson, D; Jones, C R; Jost, B; Kaballo, M; Kandybei, S; Karacson, M; Karbach, T M; Kenyon, I R; Kerzel, U; Ketel, T; Keune, A; Khanji, B; Kochebina, O; Komarov, I; Koopman, R F; Koppenburg, P; Korolev, M; Kozlinskiy, A; Kravchuk, L; Kreplin, K; Kreps, M; Krocker, G; Krokovny, P; Kruse, F; Kucharczyk, M; Kudryavtsev, V; Kvaratskheliya, T; La Thi, V N; Lacarrere, D; Lafferty, G; Lai, A; Lambert, D; Lambert, R W; Lanciotti, E; Lanfranchi, G; Langenbruch, C; Latham, T; Lazzeroni, C; Le Gac, R; van Leerdam, J; Lees, J -P; Lefèvre, R; Leflat, A; Lefrançois, J; Leo, S; Leroy, O; Leverington, B; Li, Y; Li Gioi, L; Liles, M; Lindner, R; Linn, C; Liu, B; Liu, G; von Loeben, J; Lohn, S; Lopes, J H; Lopez Asamar, E; Lopez-March, N; Lu, H; Lucchesi, D; Luisier, J; Luo, H; Machefert, F; Machikhiliyan, I V; Maciuc, F; Maev, O; Malde, S; Manca, G; Mancinelli, G; Marconi, U; Märki, R; Marks, J; Martellotti, G; Martens, A; Martin, L; Martín Sánchez, A; Martinelli, M; Martinez Santos, D; Martins Tostes, D; Massafferri, A; Matev, R; Mathe, Z; Matteuzzi, C; Maurice, E; Mazurov, A; McCarthy, J; McNulty, R; Mcnab, A; Meadows, B; Meier, F; Meissner, M; Merk, M; Milanes, D A; Minard, M -N; Molina Rodriguez, J; Monteil, S; Moran, D; Morawski, P; Morello, M J; Mountain, R; Mous, I; Muheim, F; Müller, K; Muresan, R; Muryn, B; Muster, B; Naik, P; Nakada, T; Nandakumar, R; Nasteva, I; Needham, M; Neufeld, N; Nguyen, A D; Nguyen, T D; Nguyen-Mau, C; Nicol, M; Niess, V; Niet, R; Nikitin, N; Nikodem, T; Nomerotski, A; Novoselov, A; Oblakowska-Mucha, A; Obraztsov, V; Oggero, S; Ogilvy, S; Okhrimenko, O; Oldeman, R; Orlandea, M; Otalora Goicochea, J M; Owen, P; Pal, B K; Palano, A; Palutan, M; Panman, J; Papanestis, A; Pappagallo, M; Parkes, C; Parkinson, C J; Passaleva, G; Patel, G D; Patel, M; Patrick, G N; Patrignani, C; Pavel-Nicorescu, C; Pazos Alvarez, A; Pellegrino, A; Penso, G; Pepe Altarelli, M; Perazzini, S; Perego, D L; Perez Trigo, E; Pérez-Calero Yzquierdo, A; Perret, P; Perrin-Terrin, M; Pessina, G; Petridis, K; Petrolini, A; Phan, A; Picatoste Olloqui, E; Pietrzyk, B; Pilař, T; Pinci, D; Playfer, S; Plo Casasus, M; Polci, F; Polok, G; Poluektov, A; Polycarpo, E; Popov, D; Popovici, B; Potterat, C; Powell, A; Prisciandaro, J; Pugatch, V; Puig Navarro, A; Punzi, G; Qian, W; Rademacker, J H; Rakotomiaramanana, B; Rangel, M S; Raniuk, I; Rauschmayr, N; Raven, G; Redford, S; Reid, M M; dos Reis, A C; Ricciardi, S; Richards, A; Rinnert, K; Rives Molina, V; Roa Romero, D A; Robbe, P; Rodrigues, E; Rodriguez Perez, P; Roiser, S; Romanovsky, V; Romero Vidal, A; Rouvinet, J; Ruf, T; Ruffini, F; Ruiz, H; Ruiz Valls, P; Sabatino, G; Saborido Silva, J J; Sagidova, N; Sail, P; Saitta, B; Salzmann, C; Sanmartin Sedes, B; Sannino, M; Santacesaria, R; Santamarina Rios, C; Santovetti, E; Sapunov, M; Sarti, A; Satriano, C; Satta, A; Savrie, M; Savrina, D; Schaack, P; Schiller, M; Schindler, H; Schlupp, M; Schmelling, M; Schmidt, B; Schneider, O; Schopper, A; Schune, M -H; Schwemmer, R; Sciascia, B; Sciubba, A; Seco, M; Semennikov, A; Senderowska, K; Sepp, I; Serra, N; Serrano, J; Seyfert, P; Shapkin, M; Shapoval, I; Shatalov, P; Shcheglov, Y; Shears, T; Shekhtman, L; Shevchenko, O; Shevchenko, V; Shires, A; Silva Coutinho, R; Skwarnicki, T; Smith, N A; Smith, E; Smith, M; Sokoloff, M D; Soler, F J P; Soomro, F; Souza, D; Souza De Paula, B; Spaan, B; Sparkes, A; Spradlin, P; Stagni, F; Stahl, S; Steinkamp, O; Stoica, S; Stone, S; Storaci, B; Straticiuc, M; Straumann, U; Subbiah, V K; Swientek, S; Syropoulos, V; Szczekowski, M; Szczypka, P; Szumlak, T; T'Jampens, S; Teklishyn, M; Teodorescu, E; Teubert, F; Thomas, C; Thomas, E; van Tilburg, J; Tisserand, V; Tobin, M; Tolk, S; Tonelli, D; Topp-Joergensen, S; Torr, N; Tournefier, E; Tourneur, S; Tran, M T; Tresch, M; Tsaregorodtsev, A; Tsopelas, P; Tuning, N; Ubeda Garcia, M; Ukleja, A; Urner, D; Uwer, U; Vagnoni, V; Valenti, G; Vazquez Gomez, R; Vazquez Regueiro, P; Vecchi, S; Velthuis, J J; Veltri, M; Veneziano, G; Vesterinen, M; Viaud, B; Vieira, D; Vilasis-Cardona, X; Vollhardt, A; Volyanskyy, D; Voong, D; Vorobyev, A; Vorobyev, V; Voß, C; Voss, H; Waldi, R; Wallace, R; Wandernoth, S; Wang, J; Ward, D R; Watson, N K; Webber, A D; Websdale, D; Whitehead, M; Wicht, J; Wiechczynski, J; Wiedner, D; Wiggers, L; Wilkinson, G; Williams, M P; Williams, M; Wilson, F F; Wishahi, J; Witek, M; Wotton, S A; Wright, S; Wu, S; Wyllie, K; Xie, Y; Xing, F; Xing, Z; Yang, Z; Young, R; Yuan, X; Yushchenko, O; Zangoli, M; Zavertyaev, M; Zhang, F; Zhang, L; Zhang, W C; Zhang, Y; Zhelezov, A; Zhokhov, A; Zhong, L; Zvyagin, A

    2013-01-01

    First observations and measurements of the branching fractions of the $\\bar{B}_s^0\\to D^+D^-$, $\\bar{B}_s^0\\to D_s^+D^-$ and $\\bar{B}_s^0\\to D^0\\bar{D}^0$ decays are presented using $1.0$~fb$^{-1}$ of data collected by the LHCb experiment. These branching fractions are normalized to those of $\\bar{B}^0\\to D^+D^-$, $B^0\\to D_s^+D^-$ and $B^-\\to D^0D_s^-$, respectively. An excess of events consistent with the decay $\\bar{B}^0\\to D^0\\bar{D}^0$ is also seen, and its branching fraction is measured relative to that of $B^-\\to D^0D_s^-$. Improved measurements of the branching fractions ${\\cal{B}}(\\bar{B}_s^0\\to D_s^+D_s^-)$ and ${\\cal{B}}(B^-\\to D^0D_s^-)$ are reported, each relative to ${\\cal{B}}(B^0\\to D_s^+D^-)$. The ratios of branching fractions are \\begin{align*} {{\\cal{B}}(\\bar{B}_s^0\\to D^+D^-)\\over {\\cal{B}}(\\bar{B}^0\\to D^+D^-)} &= 1.08\\pm 0.20\\pm0.10, \

  15. Purification of selenium from thorium, uranium, radium, actinium and potassium impurities for low background measurements

    International Nuclear Information System (INIS)

    A technique of selenium purification from 232Th, 238U, 226,228Ra, 227Ac and 40K was developed. This technique is simple to perform and employs a minimum number of highly pure reagents (bidistilled water, nitric acid). Operations carried out during purification (elution, evaporation) practically exclude losses of the target product (chemical yields of Se > 99%). A test purification of 100 g of selenium was carried out using this technique. The efficiency of this technique was confirmed by low background gamma spectrometry of the purified selenium sample. Distribution coefficients of Th, U, Ra and Ac on DOWEX 50W- x 8 cation-exchange resin at different concentrations of selenium and nitric acid were experimentally determinated. Instrumental neutron activation analysis of bidistilled water, deionized water and nitric acid was performed. (orig.)

  16. Radium-228 analysis of natural waters by Cherenkov counting of Actinium-228

    Energy Technology Data Exchange (ETDEWEB)

    Aleissa, Khalid A.; Almasoud, Fahad I.; Islam, Mohammed S. [Atomic Energy Research Institute, King Abdul Aziz City for Science and Technology, P.O. Box 6086, Riyadh 11442 (Saudi Arabia); L' Annunziata, Michael F. [IAEA Expert, Montague Group, P.O. Box 5033, Oceanside, CA 92052-5033 (United States)], E-mail: mlannunziata@cox.net

    2008-12-15

    The activities of {sup 228}Ra in natural waters were determined by the Cherenkov counting of the daughter nuclide {sup 228}Ac. The radium was pre-concentrated on MnO{sub 2} and the radium purified via ion exchange and, after a 2-day period of incubation to allow for secular equilibrium between the parent-daughter {sup 228}Ra({sup 228}Ac), the daughter nuclide {sup 228}Ac was isolated by ion exchange according to the method of Nour et al. [2004. Radium-228 determination of natural waters via concentration on manganese dioxide and separation using Diphonix ion exchange resin. Appl. Radiat. Isot. 61, 1173-1178]. The Cherenkov photons produced by {sup 228}Ac were counted directly without the addition of any scintillation reagents. The optimum Cherenkov counting window, sample volume, and vial type were determined experimentally to achieve optimum Cherenkov photon detection efficiency and lowest background count rates. An optimum detection efficiency of 10.9{+-}0.1% was measured for {sup 228}Ac by Cherenkov counting with a very low Cherenkov photon background of 0.317{+-}0.013 cpm. The addition of sodium salicylate into the sample counting vial at a concentration of 0.1 g/mL yielded a more than 3-fold increase in the Cherenkov detection efficiency of {sup 228}Ac to 38%. Tests of the Cherenkov counting technique were conducted with several water standards of known activity and the results obtained compared closely with a conventional liquid scintillation counting technique. The advantages and disadvantages of Cherenkov counting compared to liquid scintillation counting methods are discussed. Advantages include much lower Cherenkov background count rates and consequently lower minimal detectable activities for {sup 228}Ra and no need for expensive environmentally unfriendly liquid scintillation cocktails. The disadvantages of the Cherenkov counting method include the need to measure {sup 228}Ac Cherenkov photon detection efficiency and optimum Cherenkov counting volume, which are not at all required when liquid scintillation analysis is used.

  17. Radium-228 analysis of natural waters by Cherenkov counting of Actinium-228.

    Science.gov (United States)

    Aleissa, Khalid A; Almasoud, Fahad I; Islam, Mohammed S; L'Annunziata, Michael F

    2008-12-01

    The activities of (228)Ra in natural waters were determined by the Cherenkov counting of the daughter nuclide (228)Ac. The radium was pre-concentrated on MnO(2) and the radium purified via ion exchange and, after a 2-day period of incubation to allow for secular equilibrium between the parent-daughter (228)Ra((228)Ac), the daughter nuclide (228)Ac was isolated by ion exchange according to the method of Nour et al. [2004. Radium-228 determination of natural waters via concentration on manganese dioxide and separation using Diphonix ion exchange resin. Appl. Radiat. Isot. 61, 1173-1178]. The Cherenkov photons produced by (228)Ac were counted directly without the addition of any scintillation reagents. The optimum Cherenkov counting window, sample volume, and vial type were determined experimentally to achieve optimum Cherenkov photon detection efficiency and lowest background count rates. An optimum detection efficiency of 10.9+/-0.1% was measured for (228)Ac by Cherenkov counting with a very low Cherenkov photon background of 0.317+/-0.013cpm. The addition of sodium salicylate into the sample counting vial at a concentration of 0.1g/mL yielded a more than 3-fold increase in the Cherenkov detection efficiency of (228)Ac to 38%. Tests of the Cherenkov counting technique were conducted with several water standards of known activity and the results obtained compared closely with a conventional liquid scintillation counting technique. The advantages and disadvantages of Cherenkov counting compared to liquid scintillation counting methods are discussed. Advantages include much lower Cherenkov background count rates and consequently lower minimal detectable activities for (228)Ra and no need for expensive environmentally unfriendly liquid scintillation cocktails. The disadvantages of the Cherenkov counting method include the need to measure (228)Ac Cherenkov photon detection efficiency and optimum Cherenkov counting volume, which are not at all required when liquid scintillation analysis is used.

  18. Purification of selenium from thorium, uranium, radium, actinium and potassium impurities for low background measurements

    Energy Technology Data Exchange (ETDEWEB)

    Rakhimov, A.V. [Joint Institute for Nuclear Research (JINR), Dubna (Russian Federation); Uzbek Academy of Sciences, Tashkent (Uzbekistan). Inst. of Nuclear Physics (INP AS RUz); Warot, G. [CEA-CNRS, Modane (France). Laboratoire Souterrain de Modane (LSM); Karaivanov, D.V. [Joint Institute for Nuclear Research (JINR), Dubna (Russian Federation); Institute for Nuclear Research and Nuclear Energy (INRNE), Sofia (Bulgaria); Kochetov, O.I.; Lebedev, N.A.; Filosofov, D.V. [Joint Institute for Nuclear Research (JINR), Dubna (Russian Federation); Mukhamedshina, N.M.; Sadikov, I.I. [Uzbek Academy of Sciences, Tashkent (Uzbekistan). Inst. of Nuclear Physics (INP AS RUz)

    2013-07-01

    A technique of selenium purification from {sup 232}Th, {sup 238}U, {sup 226,228}Ra, {sup 227}Ac and {sup 40}K was developed. This technique is simple to perform and employs a minimum number of highly pure reagents (bidistilled water, nitric acid). Operations carried out during purification (elution, evaporation) practically exclude losses of the target product (chemical yields of Se > 99%). A test purification of 100 g of selenium was carried out using this technique. The efficiency of this technique was confirmed by low background gamma spectrometry of the purified selenium sample. Distribution coefficients of Th, U, Ra and Ac on DOWEX 50W- x 8 cation-exchange resin at different concentrations of selenium and nitric acid were experimentally determinated. Instrumental neutron activation analysis of bidistilled water, deionized water and nitric acid was performed. (orig.)

  19. Linear free energy relationship applied to trivalent cations with lanthanum and actinium oxide and hydroxide structure

    International Nuclear Information System (INIS)

    Linear free energy relationships for trivalent cations with crystalline M2O3 and, M(OH)3 phases of lanthanides and actinides were developed from known thermodynamic properties of the aqueous trivalent cations, modifying the Sverjensky and Molling equation. The linear free energy relationship for trivalent cations is as ΔGf,MvX0=aMvXΔGn,M3+0+bMvX+βMvXrM3+, where the coefficients aMvX, bMvX, and βMvX characterize a particular structural family of MvX, rM3+ is the ionic radius of M3+ cation, ΔGf,MvX0 is the standard Gibbs free energy of formation of MvX and ΔGn,M3+0 is the standard non-solvation free energy of the cation. The coefficients for the oxide family are: aMvX=0.2705, bMvX=-1984.75 (kJ/mol), and βMvX=197.24 (kJ/molnm). The coefficients for the hydroxide family are: aMvX=0.1587, bMvX=-1474.09 (kJ/mol), and βMvX=791.70 (kJ/molnm).

  20. Actinium: A RESTful Runtime Container for Scriptable Internet of Things Applications

    OpenAIRE

    Kovatsch, Matthias; Lanter, Martin; Duquennoy, Simon

    2012-01-01

    Programming Internet of Things (IoT) applications is challenging because developers have to be knowledgeable in various technical domains, from low-power networking, over embedded operating systems, to distributed algorithms. Hence, it will be challenging to find enough experts to provide software for the vast number of expected devices, which must also be scalable and particularly safe due to the connection to the physical world. To remedy this situation, we propose an architecture that pr...

  1. Reflection asymmetry in odd-A and odd-odd actinium nuclei

    International Nuclear Information System (INIS)

    Theoretical calculations and measurements indicate that octupole correlations are at a maximum in the ground states of the odd-proton nuclei Ac and Pa. It has been expected that odd-odd nuclei should have even larger amount of octupole-octupole correlations. We have recently made measurements on the structure of 224Ac. Although spin and parity assignments could not be made, two bands starting at 354.1 and 360.0 keV have properties characteristic of reflection asymmetric shape. These two bands have very similar rotational constants and also similar alpha decay rates, which suggest similarity between the wavefunctions of these bands. These signatures provide evidence for octupole correlations in these nuclides

  2. Bestimmung der Ionisationsenergie von Actinium und Ultraspurenanalyse von Plutonium mit resonanter Ionisationsmassenspektrometrie (RIMS)

    OpenAIRE

    Waldek, Achim Marcus

    2001-01-01

    ZusammenfassungDie Resonanzionisationsmassenspektrometrie (RIMS) verbindet hohe Elementselektivität mit guter Nachweiseffizienz. Aufgrund dieser Eigenschaften ist die Methode für Ultraspurenanalyse und Untersuchungen an seltenen oder schwer handhabbaren Elementen gut geeignet. Für RIMS werden neutrale Atome mit monochromatischem Laserlicht ein- oder mehrfach resonant auf energetisch hoch liegende Niveaus angeregt und anschließend durch einen weiteren Laserstrahl oder durch ein elektrisches Fe...

  3. New method for large scale production of medically applicable Actinium-225 and Radium-223

    International Nuclear Information System (INIS)

    Alpha-emitters (211At, 212Bi, 213Bi, 223Ra, 225Ac) are promising for targeted radiotherapy of cancer. Only two alpha decays near a cell membrane result in 50% death of cancer cell and only a single decay inside the cell is required for this. 225Ac may be used either directly or as a mother radionuclide in 213Bi isotope generator. Production of 225Ac is provided by three main suppliers - Institute for Transuranium Elements in Germany, Oak Ridge National Laboratory in USA and Institute of Physics and Power Engineering in Obninsk, Russia. The current worldwide production of 225Ac is approximately 1.7 Ci per year that corresponds to only 100-200 patients that could be treated annually. The common approach for 225Ac production is separation from mother 229Th or irradiation of 226Ra with protons in a cyclotron. Both the methods have some practical limitations to be applied routinely. 225Ac can be also produced by irradiation of natural thorium with medium energy protons . Cumulative cross sections of 225Ac, 227Ac, 227Th, 228Th formations have been obtained recently. Thorium targets (1-9 g) were irradiated by 114-91 MeV proton beam (1-50 μA) at INR linear accelerator. After dissolution in 8 M HNO3 + 0.004 M HF thorium was removed by double LLX by HDEHP in toluene (1:1). Ac and REE were pre-concentrated and separated from Ra and most fission products by DGA-Resin (Triskem). After washing out by 0.01 M HNO3 Ac was separated from REE by TRU Resin (Triskem) in 3 M HNO3 media. About 6 mCi 225Ac were separated in hot cell with chemical yield 85%. The method may be upscaled for production of Ci amounts of the radionuclide. The main impurity is 227Ac (0.1% at the EOB) but it does not hinder 225Ac from being used for medical 225Ac/213Bi generators. (author)

  4. Vitamin D Pooling Project

    Science.gov (United States)

    The Vitamin D Pooling Project of Rarer Cancers brought together investigators from 10 cohorts to conduct a large prospective epidemiologic study of the association between vitamin D status and seven rarer cancers.

  5. D-xylose absorption

    Science.gov (United States)

    ... this page: //medlineplus.gov/ency/article/003606.htm D-xylose absorption To use the sharing features on this page, please enable JavaScript. D-xylose absorption is a laboratory test to determine ...

  6. D and C - slideshow

    Science.gov (United States)

    ... this page: //medlineplus.gov/ency/presentations/100013.htm D and C - series—Normal anatomy To use the ... Update Date 6/11/2014 Updated by: Cynthia D. White, MD, Fellow American College of Obstetricians and ...

  7. Breastfeeding: Vitamin D Supplementation

    Science.gov (United States)

    ... Weight Breastfeeding Micronutrient Malnutrition State and Local Programs Vitamin D Supplementation Recommend on Facebook Tweet Share Compartir ... not provide infants with an adequate intake of vitamin D. Most breastfed infants are able to synthesize ...

  8. Enterovirus D68 Infection

    NARCIS (Netherlands)

    Esposito, Susanna; Bosis, Samantha; Niesters, Hubert; Principi, Nicola

    2015-01-01

    First described in 1962 in children hospitalized for pneumonia and bronchiolitis, the Enterovirus D68 (EV-D68) is an emergent viral pathogen. Since its discovery, during the long period of surveillance up to 2005, EV-D68 was reported only as a cause of sporadic outbreaks. In recent years, many repor

  9. Vitamin D endocrinology

    Energy Technology Data Exchange (ETDEWEB)

    DeLuca, H.F.

    1976-09-01

    Current status of our understanding of the metabolism of vitamin D and its implications in metabolic bone disease is reviewed. The details of metabolism of vitamin D/sub 3/ to 25-hydroxyvitamin D/sub 3/ in the liver and its further conversion in the kidney to either 1,25-dihydroxyvitamin D/sub 3/ or 24,25-dihydroxyvitamin D/sub 3/ are presented. The latter conversions are regulated by the vitamin D status, serum calcium through the parathyroid gland system, and serum inorganic phosphorus concentration. The 1,25-dihydroxyvitamin D/sub 3/ can now be regarded as a calcium- and a phosphate-mobilizing hormone and must be considered as one of the most important serum calcium-regulating hormones. Disruption of the vitamin D metabolic sequence or the signal system for 1,25-dihydroxyvitamin D/sub 3/ results in several bone and calcium metabolism disorders such as renal osteodystrophy, hypoparathyroidism, pseudohypoparathyroidism, and vitamin D-dependency rickets. The use of the synthetic analogs of 1,25-dihydroxyvitamin D/sub 3/ as well as 1,25-dihydroxyvitamin D/sub 3/ itself in the management of these disease states is discussed.

  10. Nonclassical Vitamin D Actions

    Directory of Open Access Journals (Sweden)

    Armin Zittermann

    2010-03-01

    Full Text Available It is becoming increasingly clear that vitamin D has a broad range of actions in the human body. Besides its well-known effects on calcium/phosphate homeostasis, vitamin D influences muscle function, cardiovascular homeostasis, nervous function, and the immune response. Vitamin D deficiency/insufficiency has been associated with muscle weakness and a high incidence of various chronic diseases such as cardiovascular disease, cancer, multiple sclerosis, and type 1 and 2 diabetes. Most importantly, low vitamin D status has been found to be an independent predictor of all-cause mortality. Several recent randomized controlled trials support the assumption that vitamin D can improve muscle strength, glucose homeostasis, and cardiovascular risk markers. In addition, vitamin D may reduce cancer incidence and elevated blood pressure. Since the prevalence of vitamin D deficiency/insufficiency is high throughout the world, there is a need to improve vitamin D status in the general adult population. However, the currently recommended daily vitamin D intake of 5–15 µg is too low to achieve an adequate vitamin D status in individuals with only modest skin synthesis. Thus, there is a need to recommend a vitamin D intake that is effective for achieving adequate circulating 25-hydroxyvitamin D concentrations (>75 nmol/L.

  11. Vitamin D and diabetes

    Science.gov (United States)

    On the basis of evidence from animal and human studies, vitamin D has emerged as a potential risk modifier for type 1 and type 2 diabetes (t1DM and t2DM). Vitamin D is thought to have both direct (through activation of the vitamin D receptor) and indirect (via regulation of calcium homeostasis) eff...

  12. Drug: D09054 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available codon root [DR:D06703], Angelica dahurica root [DR:D06779], Perilla herb [DR:D06755], Patchouli [DR:D09125],... [DR:D06778], Poria sclerotium [DR:D06783], Magnolia bark [DR:D06720], Citrus unshiu peel [DR:D06764], Platy

  13. Drug: D07201 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available classification [BR:br08303] D DERMATOLOGICALS D07 CORTICOSTEROIDS, DERMATOLOGICA...L PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AB Corticosteroids, moderately potent (group II) D07AB07 Flupr...ednidene D07201 Fluprednidene (INN) D07X CORTICOSTEROIDS, OTHER COMBINATIONS D07XB Corticosteroids, moderate

  14. Drug: D04208 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available ssification [BR:br08303] D DERMATOLOGICALS D07 CORTICOSTEROIDS, DERMATOLOGICAL PR...ne D04208 Flumethasone (USAN); Flumetasone (INN) D07X CORTICOSTEROIDS, OTHER COMBINATIONS D07XB Corticostero...EPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AB Corticosteroids, moderately potent (group II) D07AB03 Flumetaso

  15. Drug: D07203 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available STEROIDS, PLAIN D07AA Corticosteroids, weak (group I) D07AA01 Methylprednisolone D07203 Methylprednisolone a...ceponate (INN) D07AC Corticosteroids, potent (group III) D07AC14 Methylprednisolo...S FOR TOPICAL USE D10AA Corticosteroids, combinations for treatment of acne D10AA02 Methylprednisolone D0720

  16. Helix-coil transition of the self-complementary dG-dG-dA-dA-dT-dT-dC-dC duplex.

    Science.gov (United States)

    Patel, D J; Canuel, L L

    1979-05-15

    The helix-coil transition of the octanucleotide self-complementary duplex dG-dG-dA-dA-dT-dT-dC-dC has been monitored at the Watson-Crick protons, the base and sugar nonexchangeable protons and the backbone phosphates by high-resolution nuclear magnetic resonance (NMR) spectroscopy. The melting transition of the octanucleotide monitored by ultraviolet absorbance spectroscopy is characterized by the thermodynamic parameters delta H degree = -216.7 kJ/mol and delta S degree (25 degrees C) = -0.632 KJ mol-1 K-1 in 0.1 M NaCl, 10 mM phosphate solution. Correlation of the transition midpoint values monitored by the ultraviolet absorbance studies at strand concentrations below 0.2 mM and by NMR studies at 5.3 mM suggest that both methods are monitoring the octanucleotide duplex-to-strand transition. The NMR spectra of the Watson-Crick ring NH protons of the octanucleotide duplex have been followed as a function of temperature. The resonance from the terminal dG.dC base pairs broadens out at room temperature while the resonances from the other base pairs broaden simultaneously with the onset of the melting transition. The nonexchangeable base and sugar H-1' protons are resolved in the duplex and strand states and shift as average peaks through the melting transition. The experimental shifts on duplex formation have been compared with calculated values based on ring-current and atomic diamagnetic anisotropy contributions for a B-DNA base-pair-overlap geometry in solution. Several nonexchangeable proton resonances broaden in the fast-exchange region during the duplex-to-strand transition and the excess widths yield a duplex dissociation rate constant for the octanucleotide of 1.9 x 10(3) s-1 at 32 degrees C (fraction of duplex = 0.86) in 0.1 M NaCl, 10 mM phosphate buffer. The 31P resonances of the seven internucleotide phosphates are distributed over 0.6 ppm in the duplex state, shift downfield during the duplex-to-strand transition and undergo additional downfield shifts

  17. Drug: D01910 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09A MEDICATED DRESSINGS D09AA Medicated dressings with antiinfectives D09AA13 Iodofo...10 Iodoform (JP16/USP) Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D09 MEDICATED DRESSINGS

  18. Drug: D07719 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available ication [BR:br08303] D DERMATOLOGICALS D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROI...DS, PLAIN D07AB Corticosteroids, moderately potent (group II) D07AB21 Clocortolone

  19. Drug: D08313 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available cal (ATC) classification [BR:br08303] D DERMATOLOGICALS D01 ANTIFUNGALS FOR DERMATOLOGICAL USE D01A ANTIFU...NGALS FOR TOPICAL USE D01AC Imidazole and triazole derivatives D01AC11 Oxiconazole

  20. Drug: D01046 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available cal (ATC) classification [BR:br08303] D DERMATOLOGICALS D01 ANTIFUNGALS FOR DERMATOLOGICAL USE D01A ANTIFU...NGALS FOR TOPICAL USE D01AE Other antifungals for topical use D01AE02 Methylrosanil

  1. Drug: D04921 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available IFUNGALS FOR DERMATOLOGICAL USE D01A ANTIFUNGALS FOR TOPICAL USE D01AA Antibiotics ...ptics for local oral treatment A01AB16 Mepartricin D04921 Mepartricin (USAN/INN) D DERMATOLOGICALS D01 ANT

  2. Drug: D01938 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available ode: D11AX12 Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D11 OTHER DERMATOLOGICAL PREPARATION...S D11A OTHER DERMATOLOGICAL PREPARATIONS D11AX Other der

  3. Drug: D09053 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09053 Formula, Drug Bukuryotakushato Poria sclerotium [DR:D06783], Alisma rhizome ...:D06712], Ginger [DR:D06744], Glycyrrhiza [DR:D04365] Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formula

  4. Drug: D05463 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available matologicals D11AX03 Calcium gluconate D05463 Calcium gluconate hydrate (JP16) PubC...RMATOLOGICALS D11 OTHER DERMATOLOGICAL PREPARATIONS D11A OTHER DERMATOLOGICAL PREPARATIONS D11AX Other der

  5. Drug: D02815 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available matitis, excluding corticosteroids D11AH04 Alitretinoin D02815 Alitretinoin (USAN) ...LOGICALS D11 OTHER DERMATOLOGICAL PREPARATIONS D11A OTHER DERMATOLOGICAL PREPARATIONS D11AH Agents for der

  6. Drug: D00862 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available ESSINGS D09AA Medicated dressings with antiinfectives D09AA03 Nitrofural D00862 Nitrofurazone (USP); Nitrofu...2 Nitrofurazone (USP); Nitrofural (INN) D09 MEDICATED DRESSINGS D09A MEDICATED DR

  7. Vitamin D-mangel

    DEFF Research Database (Denmark)

    Hey, Henrik; Schmedes, Anne; Horn, Peer;

    2009-01-01

    The importance of vitamin D for osteoporosis and fractures has been known for more than 40 years. Vitamin D deficiency is diagnosed by measuring 25-hydroxyvitamin D (25-OHD), which should be > 50 nmol/l year round. Recent research suggests that a number of severe diseases could be prevented...... by increasing 25-OHD to 80 nmol/l. Despite a strong focus on such increase, recommendations for intake of Vitamin D have not been changed and the present recommendations are too low even to ensure > 50 nmol/l. To achieve optimal concentrations > 80 nmol/l, we estimate that 50-70 microgram of vitamin D per day...

  8. IZDELAVA TISKALNIKA 3D

    OpenAIRE

    Brdnik, Lovro

    2015-01-01

    Diplomsko delo analizira trenutno stanje 3D tiskalnikov na trgu. Prikazan je razvoj in principi delovanja 3D tiskalnikov. Predstavljeni so tipi 3D tiskalnikov, njihove prednosti in slabosti. Podrobneje je predstavljena zgradba in delovanje koračnih motorjev. Opravljene so meritve koračnih motorjev. Opisana je programska oprema za rokovanje s 3D tiskalniki in komponente, ki jih potrebujemo za izdelavo. Diploma se oklepa vprašanja, ali je izdelava 3D tiskalnika bolj ekonomična kot pa naložba v ...

  9. Drug: D07801 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available A ALIMENTARY TRACT AND METABOLISM A01 STOMATOLOGICAL PREPARATIONS A01A STOMATOLOGICAL PREPARATION...xamethasone phenylpropionate D DERMATOLOGICALS D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS D07A CORTICO... combinations D07XB05 Dexamethasone D07801 Dexamethasone phenylpropionate D10 ANTI-ACNE PREPARATION...S D10A ANTI-ACNE PREPARATIONS FOR TOPICAL USE D10AA Corticosteroids, combinations for trea...tment of acne D10AA03 Dexamethasone D07801 Dexamethasone phenylpropionate H SYSTEMIC HORMONAL PREPARATIONS,

  10. Drug: D09096 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09096 Formula, Drug Keimeisankabukuryo Areca [DR:D06782], Chaenomeles fruit [DR:D09192], Aurantii nobilis pericarpium [DR:D06897], Platycodon root [DR:D06703], Evodia fruit [DR:D00173], Perilla herb [DR:D06755], Dry ginger [DR:D06744], Poria sclerotium [DR:D06783] Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formulas for dampness Diuretic formulas D09096 Keimeisankabukuryo PubChem: 96025776 ...

  11. Drug: D09113 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09113 Formula, Drug Shokyoshashinto Pinellia tuber [DR:D06778], Ginseng [DR:D06772], Scutellaria root [DR:D06688], Glycyrrhiza [DR:D04365], Jujube [DR:D06758], Coptis rhizome [DR:D00092], Processed ginger [DR:D06702], Ginger [DR:D06744] Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formulas for stomach Antidiarrheal formulas D09113 Shokyoshashinto PubChem: 96025793 ...

  12. Pragmatic and cost efficient D and D

    International Nuclear Information System (INIS)

    A great deal of effort is expended by remediation professionals in the pursuit of new technologies to assist them in performing their tasks more efficiently. These individuals understand the cost savings associated with volume reduction and waste minimization and routinely incorporate these practices into their planning. However, the largest cost component on many D and D projects is labor. Increasing the efficiency of work force utilization is frequently the most overlooked technique that can be instituted and which can easily offer major cost savings. Granted, some D and D jobs require highly specialized tools and equipment which are quite expensive. Decreasing these costs is often not an option or will yield minimal results. Conversely, the increase in worker efficiency can usually decrease costs dramatically. During the performance of the Safe Shutdown Project at the Fernald Environmental Management Project (the Fernald site), a process improvement initiative was instituted in support of the development of the Ten Year Plan. Costs associated with the removal of hundreds of thousands of pounds of nuclear material from formerly utilized equipment piping, and ductwork in nuclear facilities at the Fernald site were analyzed. This analysis indicated that the labor component was large enough to merit further inspection. A new approach to the activities was instituted and the results were significant. A macroscopic overview of all work activities utilized work evolution control (sequencing), building segmentation, and efficient use of engineering controls to streamline the D and D process. Overall costs on the first facility were reduced by over 20%. The increased labor efficiency resulted in decreased Personal Protective Equipment costs for field personnel. This approach will be discussed in detail

  13. D & D screening risk evaluation guidance

    Energy Technology Data Exchange (ETDEWEB)

    Robers, S.K.; Golden, K.M.; Wollert, D.A.

    1995-09-01

    The Screening Risk Evaluation (SRE) guidance document is a set of guidelines provided for the uniform implementation of SREs performed on decontamination and decommissioning (D&D) facilities. Although this method has been developed for D&D facilities, it can be used for transition (EM-60) facilities as well. The SRE guidance produces screening risk scores reflecting levels of risk through the use of risk ranking indices. Five types of possible risk are calculated from the SRE: current releases, worker exposures, future releases, physical hazards, and criticality. The Current Release Index (CRI) calculates the current risk to human health and the environment, exterior to the building, from ongoing or probable releases within a one-year time period. The Worker Exposure Index (WEI) calculates the current risk to workers, occupants and visitors inside contaminated D&D facilities due to contaminant exposure. The Future Release Index (FRI) calculates the hypothetical risk of future releases of contaminants, after one year, to human health and the environment. The Physical Hazards Index (PHI) calculates the risks to human health due to factors other than that of contaminants. Criticality is approached as a modifying factor to the entire SRE, due to the fact that criticality issues are strictly regulated under DOE. Screening risk results will be tabulated in matrix form, and Total Risk will be calculated (weighted equation) to produce a score on which to base early action recommendations. Other recommendations from the screening risk scores will be made based either on individual index scores or from reweighted Total Risk calculations. All recommendations based on the SRE will be made based on a combination of screening risk scores, decision drivers, and other considerations, as determined on a project-by-project basis.

  14. D ampersand D screening risk evaluation guidance

    International Nuclear Information System (INIS)

    The Screening Risk Evaluation (SRE) guidance document is a set of guidelines provided for the uniform implementation of SREs performed on decontamination and decommissioning (D ampersand D) facilities. Although this method has been developed for D ampersand D facilities, it can be used for transition (EM-60) facilities as well. The SRE guidance produces screening risk scores reflecting levels of risk through the use of risk ranking indices. Five types of possible risk are calculated from the SRE: current releases, worker exposures, future releases, physical hazards, and criticality. The Current Release Index (CRI) calculates the current risk to human health and the environment, exterior to the building, from ongoing or probable releases within a one-year time period. The Worker Exposure Index (WEI) calculates the current risk to workers, occupants and visitors inside contaminated D ampersand D facilities due to contaminant exposure. The Future Release Index (FRI) calculates the hypothetical risk of future releases of contaminants, after one year, to human health and the environment. The Physical Hazards Index (PHI) calculates the risks to human health due to factors other than that of contaminants. Criticality is approached as a modifying factor to the entire SRE, due to the fact that criticality issues are strictly regulated under DOE. Screening risk results will be tabulated in matrix form, and Total Risk will be calculated (weighted equation) to produce a score on which to base early action recommendations. Other recommendations from the screening risk scores will be made based either on individual index scores or from reweighted Total Risk calculations. All recommendations based on the SRE will be made based on a combination of screening risk scores, decision drivers, and other considerations, as determined on a project-by-project basis

  15. Pragmatic and cost efficient D and D

    Energy Technology Data Exchange (ETDEWEB)

    Morris, M. [Nuclear Fuel Services, Erwin, TN (United States)

    1998-03-01

    A great deal of effort is expended by remediation professionals in the pursuit of new technologies to assist them in performing their tasks more efficiently. These individuals understand the cost savings associated with volume reduction and waste minimization and routinely incorporate these practices into their planning. However, the largest cost component on many D and D projects is labor. Increasing the efficiency of work force utilization is frequently the most overlooked technique that can be instituted and which can easily offer major cost savings. Granted, some D and D jobs require highly specialized tools and equipment which are quite expensive. Decreasing these costs is often not an option or will yield minimal results. Conversely, the increase in worker efficiency can usually decrease costs dramatically. During the performance of the Safe Shutdown Project at the Fernald Environmental Management Project (the Fernald site), a process improvement initiative was instituted in support of the development of the Ten Year Plan. Costs associated with the removal of hundreds of thousands of pounds of nuclear material from formerly utilized equipment piping, and ductwork in nuclear facilities at the Fernald site were analyzed. This analysis indicated that the labor component was large enough to merit further inspection. A new approach to the activities was instituted and the results were significant. A macroscopic overview of all work activities utilized work evolution control (sequencing), building segmentation, and efficient use of engineering controls to streamline the D and D process. Overall costs on the first facility were reduced by over 20%. The increased labor efficiency resulted in decreased Personal Protective Equipment costs for field personnel. This approach will be discussed in detail.

  16. 3d-3d correspondence revisited

    Science.gov (United States)

    Chung, Hee-Joong; Dimofte, Tudor; Gukov, Sergei; Sułkowski, Piotr

    2016-04-01

    In fivebrane compactifications on 3-manifolds, we point out the importance of all flat connections in the proper definition of the effective 3d {N}=2 theory. The Lagrangians of some theories with the desired properties can be constructed with the help of homological knot invariants that categorify colored Jones polynomials. Higgsing the full 3d theories constructed this way recovers theories found previously by Dimofte-Gaiotto-Gukov. We also consider the cutting and gluing of 3-manifolds along smooth boundaries and the role played by all flat connections in this operation.

  17. 3D and Education

    Science.gov (United States)

    Meulien Ohlmann, Odile

    2013-02-01

    Today the industry offers a chain of 3D products. Learning to "read" and to "create in 3D" becomes an issue of education of primary importance. 25 years professional experience in France, the United States and Germany, Odile Meulien set up a personal method of initiation to 3D creation that entails the spatial/temporal experience of the holographic visual. She will present some different tools and techniques used for this learning, their advantages and disadvantages, programs and issues of educational policies, constraints and expectations related to the development of new techniques for 3D imaging. Although the creation of display holograms is very much reduced compared to the creation of the 90ies, the holographic concept is spreading in all scientific, social, and artistic activities of our present time. She will also raise many questions: What means 3D? Is it communication? Is it perception? How the seeing and none seeing is interferes? What else has to be taken in consideration to communicate in 3D? How to handle the non visible relations of moving objects with subjects? Does this transform our model of exchange with others? What kind of interaction this has with our everyday life? Then come more practical questions: How to learn creating 3D visualization, to learn 3D grammar, 3D language, 3D thinking? What for? At what level? In which matter? for whom?

  18. Drug: D02863 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09A MEDICATED DRESSINGS D09AA Medicated dressings with antiinfectives D09AA08 Aluminium chlorohydrate D02863 Aluminum sesquichlorohydrate (USP) PubChem: 17397020 ... ...ode: D09AA08 Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D09 MEDICATED DRESSINGS

  19. Drug: D02856 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09A MEDICATED DRESSINGS D09AA Medicated dressings with antiinfectives D09AA08 Aluminium chlorohydrate D02856 Aluminum dichlorohydrate (USP) PubChem: 17397013 ... ...: D09AA08 Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D09 MEDICATED DRESSINGS

  20. Drug: D01764 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available alerate (JP16) Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D07 CORTICOSTEROIDS..., DERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AC Corticosteroids, potent (group III...) D07AC06 Diflucortolone D01764 Diflucortolone valerate (JP16) D07X CORTICOSTEROIDS

  1. Drug: D07980 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available IDS, DERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AB Corticosteroids,... moderately potent (group II) D07AB07 Fluprednidene D07980 Fluprednidene acetate D07X CORTICOSTEROIDS, OTHER...ction Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D07 CORTICOSTERO

  2. Drug: D01464 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available utic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D07 CORTICOSTEROIDS..., DERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AB Corticosteroids, moderately potent (grou...p II) D07AB03 Flumetasone D01464 Flumetasone pivalate (JAN/BAN); Flumethasone pivalate (USP) D07X CORTICOSTEROIDS

  3. Drug: D00209 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available ation [BR:br08303] D DERMATOLOGICALS D01 ANTIFUNGALS FOR DERMATOLOGICAL USE D01A ANTIFUNGAL...S FOR TOPICAL USE D01AA Antibiotics D01AA08 Griseofulvin D00209 Griseofulvin (JP16/USP/INN) D01B ANTIFUNGAL

  4. Drug: D02375 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D01 ANTIFUNGALS FOR DERMATOLOGICAL USE D01A ANTIFUNGAL...ine D02375 Terbinafine (USAN/INN) D01B ANTIFUNGALS FOR SYSTEMIC USE D01BA Antifungals for systemic use D01BA

  5. Drug: D08407 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D08407 Drug Pramocaine (INN) C17H27NO3 293.1991 293.4012 D08407.gif Local anestheti... TOPICAL USE C05AD Local anesthetics C05AD07 Pramocaine D08407 Pramocaine (INN) D...STAMINES, ANESTHETICS, ETC. D04AB Anesthetics for topical use D04AB07 Pramocaine D08407 Pramocaine (INN) CAS

  6. Drug: D04707 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D04707 Mixture, Drug Lithospermum root extract - ethyl aminobenzoate - dibucaine hydrochloride - diphenhydr...amine hydrochloride - cetrimide mixt; Borraginol N (TN) Lithospermum root extract [D...R:D04705], Ethyl aminobenzoate [DR:D00552], Dibucaine hydrochloride [DR:D02220], Diphenhydramine hydrochloride [DR:D00669], Cetrimide [DR:D02164] PubChem: 17398145 ...

  7. Drug: D09079 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09079 Formula, Drug Dokkatsukakkonto Pueraria root [DR:D06693], Ephedra herb [DR:D...e in Japan [BR:br08304] Formulas Formulas for dampness Antirheumatic formulas D09079 Dokkatsukakkonto PubChem: 96025760 ... ...za [DR:D04365], Araliae cardatae rhizoma [DR:D06909], Rehmannia root [DR:D06736] Traditional Chinese Medicin

  8. Drug: D09103 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09103 Formula, Drug Goshitsusan Achyranthes root [DR:D06722], Cinnamon bark [DR:D0...:D06769], Corydalis tuber [DR:D06686], Saussurea root [DR:D06795] Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formula...s for blood Formulas for removing blood stasis D09103 Goshitsusan PubChem: 96025783 ...

  9. Vitamin D and Skin

    Directory of Open Access Journals (Sweden)

    Ibrahim Ozmen

    2008-09-01

    Full Text Available Vitamin D was originally discovered as a factor that regulates calcium and bone metabolism. Recent advances in investigation have shown that vitamin D also functions as a regulator of cellular growth and differentiation in various tissues. Evidence has accumulated showing that the active form of vitamin D and its analogs suppress growth and stimulate the terminal differentiation of keratinocytes. Also, vitamin D stimulates the synthesis of melanin and release of interleukins. On the other hand, vitamin D has been used in the treatment of psoriasis, vitiligo and morfea for a long time. In this review, we summarize the fundamental features of vitamin D and the clinical application for psoriasis and other dermatological disorders.

  10. 4-D Photoacoustic Tomography

    Science.gov (United States)

    Xiang, Liangzhong; Wang, Bo; Ji, Lijun; Jiang, Huabei

    2013-01-01

    Photoacoustic tomography (PAT) offers three-dimensional (3D) structural and functional imaging of living biological tissue with label-free, optical absorption contrast. These attributes lend PAT imaging to a wide variety of applications in clinical medicine and preclinical research. Despite advances in live animal imaging with PAT, there is still a need for 3D imaging at centimeter depths in real-time. We report the development of four dimensional (4D) PAT, which integrates time resolutions with 3D spatial resolution, obtained using spherical arrays of ultrasonic detectors. The 4D PAT technique generates motion pictures of imaged tissue, enabling real time tracking of dynamic physiological and pathological processes at hundred micrometer-millisecond resolutions. The 4D PAT technique is used here to image needle-based drug delivery and pharmacokinetics. We also use this technique to monitor 1) fast hemodynamic changes during inter-ictal epileptic seizures and 2) temperature variations during tumor thermal therapy.

  11. Outsourcing R&D

    DEFF Research Database (Denmark)

    Hsuan, Juliana; Mahnke, Volker

    2011-01-01

    Outsourcing R&D is an increasingly explored corporate practice. Extant research advanced our initial understanding of its increasing importance and benefits. While the associated literature has blossomed, the enthusiasm of R&D managers is tenured by an increasing realization of the possible...... downsides, risks, and costs that come with increasing use of external sources of innovation. Here, we suggest that research on outsourcing R&D has to move towards a balanced view on the profitability of such arrangements. To this end, we offer a review of what we know and need to know about outsourcing R......&D, suggest a simple, yet integrative model on the relation between outsourcing R&D and performance, and offer a research agenda that is instrumental in guiding companies’ process-management and design strategies when seeking to benefit from the outsourcing of R&D....

  12. Nonclassical Vitamin D Action

    OpenAIRE

    Armin Zittermann; Jan F Gummert

    2010-01-01

    It is becoming increasingly clear that vitamin D has a broad range of actions in the human body. Besides its well-known effects on calcium/phosphate homeostasis, vitamin D influences muscle function, cardiovascular homeostasis, nervous function, and the immune response. Vitamin D deficiency/insufficiency has been associated with muscle weakness and a high incidence of various chronic diseases such as cardiovascular disease, cancer, multiple sclerosis, and type 1 and 2 diabetes. Most important...

  13. ‘Den sociale død' - ‘det sociales død'

    DEFF Research Database (Denmark)

    Jacobsen, Michael Hviid

    2009-01-01

    Det er nu snart et kvart århundrede siden, at Norbert Elias udgav sin bog De døendes ensomhed, hvori han fremsætter tesen om de ældres og døendes tiltagende marginalisering og heraf følgende oplevelse af ensomhed i det moderne samfund. Denne artikel fokuserer i forlængelse heraf på en kort præsen...... præsentation af fænomenet ‘social død'....

  14. D^- mesic atoms

    OpenAIRE

    García Recio, Carmen; Nieves Pamplona, Juan Miguel; Salcedo, Lorenzo Luis; Tolós Rigueiro, Laura

    2011-01-01

    The anti-D meson self-energy is evaluated self-consistently, using unitarized coupled-channel theory, by computing the in-medium meson-baryon T-matrix in the C=-1,S=0 sector. The heavy pseudo-scalar and heavy vector mesons, anti-D and anti-D^*, are treated on equal footing as required by heavy quark spin symmetry. Results for energy levels and widths of D^- mesic atoms in 12C, 40Ca, 118Sn and 208Pb are presented. The spectrum contains states of atomic and of nuclear types for all nuclei. anti...

  15. Offshoring R&D

    DEFF Research Database (Denmark)

    Hansen, Zaza Nadja Lee; Rasmussen, Lauge Baungaard

    2010-01-01

    Companies are increasingly offshoring R&D activities. Many firms, however, experience difficulties related to virtual teamwork across cultures and time zones. The research question is: How does increasing R&D offshoring impact transparency of communication structures and knowledge sharing? Using...... case studies from Danish multinational corporations with R&D activities in China, India or Eastern Europe this paper analyses the impact observed in these companies in regard to communication structures and knowledge sharing in management of offshored R&D activities. The findings show that companies...

  16. Drug: D08227 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available 303] D DERMATOLOGICALS D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AC Corticosteroids...TIONS FOR TOPICAL USE R01AD Corticosteroids R01AD09 Mometasone D08227 Mometasone (INN) R03 DRUGS FOR OBSTRUC...lmonary Agents Anti-inflammatories, Inhaled Corticosteroids Mometasone D08227 Mometasone (INN) Target-based ...BINATIONS D07XC Corticosteroids, potent, other combinations D07XC03 Mometasone D0..., potent (group III) D07AC13 Mometasone D08227 Mometasone (INN) D07X CORTICOSTEROIDS, OTHER COM

  17. Anatomy of $B\\rightarrow D\\bar{D}$ Decays

    CERN Document Server

    Bel, Lennaert; Fleischer, Robert; Mulder, Mick; Tuning, Niels

    2015-01-01

    The decays $B_d^0\\rightarrow D_d^-D_d^+$ and $B_s^0\\rightarrow D_s^-D_s^+$ probe the CP-violating mixing phases $\\phi_d$ and $\\phi_s$, respectively. The theoretical uncertainty of the corresponding determinations is limited by contributions from penguin topologies, which can be included with the help of the $U$-spin symmetry of the strong interaction. We analyse the currently available data for $B^0_{d,s}\\rightarrow D_{d,s}^-D_{d,s}^+$ decays and those with similar dynamics to constrain the involved non-perturbative parameters. Using further information from semileptonic $B_d^0\\rightarrow D_d^-\\ell^+\

  18. Hyperelliptic plane curves of type (d,d-2)

    OpenAIRE

    Sakai, Fumio; Saleem, Mohammad; Tono, Keita

    2008-01-01

    In a previous paper, we classified and constructed all rational plane curves of type (d,d-2). In this paper, we generalize these results to irreducible plane curves of type (d,d-2) with positive genus.

  19. Alternative D and D Planning Tool - 12466

    International Nuclear Information System (INIS)

    On August 1, 2011, URS - CH2M Oak Ridge LLC (UCOR) began cleanup of the East Tennessee Technology Park (ETTP). UCOR's $2.2 billion contract has an initial five-year term and a four-year option period for completing the cleanup of ETTP and performing surveillance and maintenance and waste management operations at both the Oak Ridge National Laboratory and the Y-12 National Security Complex. ETTP D and D work includes disposition of large, complex, contaminated, Manhattan Project-era facilities such as the K-25 and K-27 uranium enrichment facilities. At ETTP, UCOR views the D and D process as a 'Waste Factory' with waste production lines from the point-of-generation to the point-of-disposal. Safely transforming vertically-standing buildings into horizontally-lying waste in a disposal facility is the primary cleanup objective. Whereas a factory produces widgets, D and D produces waste-lots of waste. In support of the Waste Factory view, UCOR is developing a systems planning tool to help better plan how to effect cleanup by improving waste planning, uniting waste generator with waste dis-positioner, and represent the 'waste factory' in a computer model that allows the D and D and waste management teams to better understand available disposal paths, waste uncertainties and potential consequences, driving variables, and sensitivity to changes. Any model of reality represents a compromise. Part of the Waste Factory Model's value may be in providing standardization and relative direction for assisting decision making as opposed to absolute cost or schedule answers. From that relative direction, management can commission detailed planning and estimating. Also, the model's output credibility is tied directly to its input quality. That is why, as discussed above, the Waste Factory Model's key informational component will be the standardized waste streams (e.g., Structure/Debris disposed at EMWMF) and associated standardized unit costs. The model development process generally

  20. Enterovirus D68 Infection

    Directory of Open Access Journals (Sweden)

    Susanna Esposito

    2015-11-01

    Full Text Available First described in 1962 in children hospitalized for pneumonia and bronchiolitis, the Enterovirus D68 (EV-D68 is an emergent viral pathogen. Since its discovery, during the long period of surveillance up to 2005, EV-D68 was reported only as a cause of sporadic outbreaks. In recent years, many reports from different countries have described an increasing number of patients with respiratory diseases due to EV-D68 associated with relevant clinical severity. In particular, an unexpectedly high number of children have been hospitalized for severe respiratory disease due to EV-D68, requiring intensive care such as intubation and mechanical ventilation. Moreover, EV-D68 has been associated with acute flaccid paralysis and cranial nerve dysfunction in children, which has caused concerns in the community. As no specific antiviral therapy is available, treatment is mainly supportive. Moreover, because no vaccines are available, conventional infection control measures (i.e., standard, for contacts and droplets in both community and healthcare settings are recommended. However, further studies are required to fully understand the real importance of this virus. Prompt diagnosis and continued surveillance of EV-D68 infections are essential to managing and preventing new outbreaks. Moreover, if the association between EV-D68 and severe diseases will be confirmed, the development of adequate preventive and therapeutic approaches are a priority.

  1. HYBRID R&D

    NARCIS (Netherlands)

    Goyal, Sanjeev; Moraga González, José; Konovalov, Alexander

    2008-01-01

    We develop a model of R&D collaboration in which individual firms carry out in-house research on core activities and undertake bilateral joint projects on non-core activities with other firms. We develop conditions on the profit functions of the firm under which R&D investments in different projects

  2. ACTINOMYCIN D ANALOGUES

    DEFF Research Database (Denmark)

    1997-01-01

    The present invention relates to new compounds being structurally and functionally similar to Actinomycin D and to combinatorial libraries of such compounds. The Actinomycin D analogues according to the present invention comprise two linear or cyclic peptide moieties constituted by $g...

  3. Beyond Type D personality

    DEFF Research Database (Denmark)

    Pelle, Aline J; Pedersen, Susanne S.; Szabó, Balázs M;

    2009-01-01

    Type D personality has been associated with impaired health status in chronic heart failure (CHF), but other psychological factors may also be important.......Type D personality has been associated with impaired health status in chronic heart failure (CHF), but other psychological factors may also be important....

  4. Calcium D-saccharate

    DEFF Research Database (Denmark)

    Garcia, André Castilho; Hedegaard, Martina Vavrusova; Skibsted, Leif Horsfelt

    2016-01-01

    Molar conductivity of saturated aqueous solutions of calcium d-saccharate, used as a stabilizer of beverages fortified with calcium d-gluconate, increases strongly upon dilution, indicating complex formation between calcium and d-saccharate ions, for which, at 25 °C, Kassoc = 1032 ± 80, ΔHassoc......° = -34 ± 6 kJ mol-1, and ΔSassoc° = -55 ± 9 J mol-1 K-1, were determined electrochemically. Calcium d-saccharate is sparingly soluble, with a solubility product, Ksp, of (6.17 ± 0.32) × 10-7 at 25 °C, only moderately increasing with the temperature: ΔHsol° = 48 ± 2 kJ mol-1, and ΔSassoc° = 42 ± 7 J mol-1...... K-1. Equilibria in supersaturated solutions of calcium d-saccharate seem only to adjust slowly, as seen from calcium activity measurements in calcium d-saccharate solutions made supersaturated by cooling. Solutions formed by isothermal dissolution of calcium d-gluconate in aqueous potassium d...

  5. 3D virtuel udstilling

    DEFF Research Database (Denmark)

    Tournay, Bruno; Rüdiger, Bjarne

    2006-01-01

    3d digital model af Arkitektskolens gård med virtuel udstilling af afgangsprojekter fra afgangen sommer 2006. 10 s.......3d digital model af Arkitektskolens gård med virtuel udstilling af afgangsprojekter fra afgangen sommer 2006. 10 s....

  6. Vitamin D and Mortality.

    Science.gov (United States)

    Pilz, Stefan; Grübler, Martin; Gaksch, Martin; Schwetz, Verena; Trummer, Christian; Hartaigh, Bríain Ó; Verheyen, Nicolas; Tomaschitz, Andreas; März, Winfried

    2016-03-01

    In this narrative review, we aim to summarize and discuss the current evidence linking vitamin D and mortality. Low 25-hydroxyvitamin D [25(OH)D] concentrations are associated with an increased risk of mortality. This has been shown in different cohort studies including general populations, as well as various patient cohorts. Some single-study results and meta-analyses indicate that the shape of the relationship between 25(OH)D and mortality follows a U- or a reverse J-shaped curve. Interassay and laboratory differences are, however, a limitation of most previous surveys, and standardization of 25(OH)D measurements is needed for future investigations. Apart from observational data, it has been documented in meta-analyses of randomized controlled trials that vitamin D3 supplementation is associated with a moderate, yet statistically significant, reduction in mortality. This latter finding must be interpreted in light of some limitations such as incomplete follow-up data, but such a reduction of mortality with vitamin D3 supplementation as the finding of meta-analyses of randomized controlled trials strongly argues for the benefits and, importantly, also the safety of vitamin D. PMID:26977039

  7. Drug: D02120 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D02120 Mixture, Drug Citric acid monohydrate - potassium bicarbonate mixt; K-lyte (...TN) Citric acid monohydrate [DR:D01222], Potassium bicarbonate [DR:D02077] PubChem: 7849181 LigandBox: D02120 ...

  8. Drug: D00979 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available 08303] D DERMATOLOGICALS D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AA .../USP) H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS H02 CORTICOSTEROIDS FOR SYSTEMIC USE H02A CORTICOSTEROIDS

  9. Drug: D10299 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available iasis ATC code: D07CB01 Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D07 CORTICOSTEROIDS..., DERMATOLOGICAL PREPARATIONS D07C CORTICOSTEROIDS, COMBINATIO

  10. Drug: D00372 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available :1544] Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D01 ANTIFUNGALS F...OR DERMATOLOGICAL USE D01A ANTIFUNGALS FOR TOPICAL USE D01AC Imidazole and triazo

  11. Drug: D00323 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available 3 Flucytosine (JP16/USP/INN) Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D01 ANTIFUNGAL...S FOR DERMATOLOGICAL USE D01A ANTIFUNGALS FOR TOPICAL USE D01A

  12. Drug: D01664 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available Steroid biosynthesis Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D01 ANTIFUNGAL...S FOR DERMATOLOGICAL USE D01A ANTIFUNGALS FOR TOPICAL USE D01AC Imida

  13. Drug: D02557 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available 026 Antifungal agents Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D01 ANTIFUNGAL...S FOR DERMATOLOGICAL USE D01A ANTIFUNGALS FOR TOPICAL USE D01AC Imida

  14. Drug: D01094 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available 1AA07 natural product Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D01 ANTIFUNGAL...S FOR DERMATOLOGICAL USE D01A ANTIFUNGALS FOR TOPICAL USE D01AA Antib

  15. Drug: D00881 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available e (JAN/USP) Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D01 ANTIFUNGAL...S FOR DERMATOLOGICAL USE D01A ANTIFUNGALS FOR TOPICAL USE D01AC Imidazole and t

  16. Drug: D00886 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available azole nitrate (JAN/USP) Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D01 ANTIFUNGAL...S FOR DERMATOLOGICAL USE D01A ANTIFUNGALS FOR TOPICAL USE D01AC Imi

  17. Drug: D00381 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available P/INN) Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D01 ANTIFUNGALS F...OR DERMATOLOGICAL USE D01A ANTIFUNGALS FOR TOPICAL USE D01AE Other antifungals fo

  18. Drug: D04624 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available l agents Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D01 ANTIFUNGA...LS FOR DERMATOLOGICAL USE D01A ANTIFUNGALS FOR TOPICAL USE D01AC Imidazole and tria

  19. Drug: D02582 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available hesis Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D01 ANTIFUNGALS FO...R DERMATOLOGICAL USE D01A ANTIFUNGALS FOR TOPICAL USE D01AC Imidazole and triazol

  20. Drug: D02923 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available s map07026 Antifungal agents Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D01 ANTIFUNGAL...S FOR DERMATOLOGICAL USE D01A ANTIFUNGALS FOR TOPICAL USE D01A

  1. Drug: D01093 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available ne hydrochloride (JP16/USAN) Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D01 ANTIFUNGAL...S FOR DERMATOLOGICAL USE D01A ANTIFUNGALS FOR TOPICAL USE D01A

  2. Drug: D00883 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available agents Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D01 ANTIFUNGAL...S FOR DERMATOLOGICAL USE D01A ANTIFUNGALS FOR TOPICAL USE D01AE Other antifungals f

  3. Drug: D00097 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available FUNGALS FOR DERMATOLOGICAL USE D01A ANTIFUNGALS FOR TOPI...c acids D00097 Salicylic acid (JP16/USP) Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D01 ANTI

  4. Drug: D07031 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available oria sclerotium [DR:D06783], Moutan bark [DR:D06788], Cinnamon bark [DR:D06712], Processed aconite root [DR:D06784] Nephritis; Diabet...es; Oscheitis; Sciatic pain; High pressure (HP); Geriatr

  5. Drug: D09110 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09110 Formula, Drug Shakosaito; Sammishakosaito Digenea [DR:D06792], Rhubarb [DR:D...elling parasites Anthelmintic formulas D09110 Shakosaito; Sammishakosaito PubChem: 96025790 ...

  6. Drug: D09093 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09093 Formula, Drug Seikiankaito Bupleurum root [DR:D06727], Scutellaria root [DR:...ea [DR:D06792], Ophiopogon tuber [DR:D06775] Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formula

  7. Drug: D09089 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09089 Formula, Drug Senkinkeimeisan Rhubarb [DR:D06756], Peach kernel [DR:D06769],... Japanese angelica root [DR:D06768] Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formulas for blood Formula

  8. Drug: D09061 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09061 Formula, Drug Kankyoninjinhangegan Processed ginger [DR:D06702], Ginseng [DR...:D06772], Pinellia tuber [DR:D06778] Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formulas fo

  9. Drug: D09107 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09107 Formula, Drug Jiketsujunchoto Japanese angelica root [DR:D06768], Rehmannia ...rb [DR:D06756], Safflower [DR:D06717] Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formulas for blood Formula

  10. Vitamin D and Disease Prevention

    Science.gov (United States)

    Vitamin D and Disease Prevention Why is vitamin D important for health? Vitamin D is a hot topic in the news, thanks ... is controversy, though, over the effects of vitamin D on health other than the bones. Doctors have ...

  11. Drug: D00378 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available nzyme: CYP2D6 [HSA:1565] Genomic biomarker: CYP2D6 [HSA:1565] map07054 Antiglaucoma...ic Blocking Agents Timolol D00378 Timolol (USAN) Ophthalmic Agents Ophthalmic Antiglaucoma Agents Timolol D0

  12. Drug: D06250 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D06250 Mixture, Drug Trisulfapyrimidines (USP); Lantrisul (TN) Sulfamerazine [DR:D0...2435], Sulfadiazine [DR:D00587], Sulfamethazine [DR:D02436] Antibacterial CAS: 8017-57-0 PubChem: 47207908 ...

  13. Drug: D10040 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available ], Immature orange [DR:D06706], Glycyrrhiza [DR:D04365], Cyperus rhizome [DR:D06719], Cnidium rhizome [DR:D06748], Citrus immature fruit and fruit peel [ED:E00338] PubChem: 135626760 ...

  14. Drug: D06417 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available N) Cresol [DR:D01960], Vegetable oil, (Potassium hydroxide [DR:D01168] | Sodium hydroxide [DR:D01169]), Wate...D06417 Mixture, Drug Saponated cresol solution (JP16); Saponated cresol solution (T

  15. Drug: D04366 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D04366 Mixture, Drug Pipethanate hydrochloride - magnesium aluminometasilicate - liqourice extract... mixt; Geschwur (TN) Pipethanate hydrochloride [DR:D01521], Magunesium aluminometasilicate [DR:D03242], Crude glycyrrhiza extract [DR:D06811] PubChem: 17398077 ...

  16. Drug: D07010 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available Eczema; Bedsore; Eczema infantile Therapeutic category: 5200 Therapeutic category...06773], Glycyrrhiza [DR:D04365], Schizonepeta spike [DR:D06711], Safflower [DR:D06717], Rhubarb [DR:D06756

  17. Drug: D06233 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D06233 Mixture, Drug Trikates (USP) Potassium acetate [DR:D01154], Potassium bicarbonate [DR:D02077], Potass...ium citrate [DR:D05578] Replenisher [electrolyte] PubChem: 47207891 ...

  18. Drug: D08809 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D08809 Formula, Drug Aromatic powder; Cinnamon bark - zanthoxylum fruit - ginger mi...xt; Aromatic powder (TN) Cinnamon bark [DR:D06712], Zanthoxylum fruit [DR:D06733], Ginger [DR:D06744] Therap

  19. Drug: D05815 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D05815 Drug Selenium sulfide (USP); Exsel (TN) SeS2 143.8607 143.09 D05815.gif Anti... antifungals for topical use D01AE13 Selenium sulfide D05815 Selenium sulfide (US...P) D11 OTHER DERMATOLOGICAL PREPARATIONS D11A OTHER DERMATOLOGICAL PREPARATIONS D11AC Medicated shampoos D11AC03 Selenium... compounds D05815 Selenium sulfide (USP) USP drug classification [BR:br08302] Dermatological Agents Selenium D05815 Sele...olytes Electrolyte/Mineral Replacement Selenium D05815 Selenium sulfide (USP) CAS: 7488-56-4 PubChem: 472074

  20. Drug: D09108 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09108 Formula, Drug Jippiin; Jippito (Atractylodes lancea rhizome [DR:D06752] | At...ractylodes rhizome [DR:D06780]), Poria sclerotium [DR:D06783], Citrus unshiu peel [DR:D06764], Magnolia bark [DR:D06720], Cyperu...s rhizome [DR:D06719], Polyporus sclerotium [DR:D06763], Alisma rhizome [DR:D06759], Imm...rea root [DR:D06795], Ginger [DR:D06744], Rush [ED:E00299] Traditional Chinese Medicine in Japan [BR:br08304

  1. Drug: D09049 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09049 Formula, Drug Bunshoto (Atractylodes lancea rhizome [DR:D06752] | Atractylod...es rhizome [DR:D06780]), Poria sclerotium [DR:D06783], Citrus unshiu peel [DR:D06764], Magnolia bark [DR:D06720], Cyperu...s rhizome [DR:D06719], Polyporus sclerotium [DR:D06763], Alisma rhizome [DR:D06759], Immature or... [DR:D06795], Ginger [DR:D06744], Rush [ED:E00299] Traditional Chinese Medicine in Japan [BR:br08304] Formul

  2. Drug: D04470 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D04470 Mixture, Drug Dilute iodine tincture (JP16); Dilute iodine tincture (TN) Iod...ine [DR:D00108], Potassium iodine [DR:D01016], (70 percent Alcohol [DR:D00068] | Isopropanol [DR:D00137] | M...nts 2612 Iodates D04470 Dilute iodine tincture (JP16) Anatomical Therapeutic Chemical (ATC) classification [...ine products D08AG03 Iodine D04470 Dilute iodine tincture (JP16) PubChem: 47206326 ...

  3. Drug: D03101 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D03101 Drug beta Carotene (USP); Betacarotene (INN); Solatene (TN) C40H56 536.4382 ...INCL. COMBINATIONS OF THE TWO A11CA Vitamin A, plain A11CA02 Betacarotene D03101 ...AINST UV-RADIATION D02BB Protectives against UV-radiation for systemic use D02BB01 Betacarotene D03101 beta Carotene (USP); Betacaro...beta Carotene (USP); Betacarotene (INN) D DERMATOLOGICALS D02 EMOLLIENTS AND PROTECTIVES D02B PROTECTIVES AG

  4. INEL D&D long-range plan

    Energy Technology Data Exchange (ETDEWEB)

    Buckland, R.J.; Kenoyer, D.J.; LaBuy, S.A.

    1995-09-01

    This Long-Range Plan presents the Decontamination and Dismantlement (D&D) Program planning status for facilities at the Idaho National Engineering Laboratory (INEL). The plan provides a general description of the D&D Program objectives, management criteria, and policy; discusses current activities; and documents the INEL D&D Program cost and schedule estimate projections for the next 15 years. Appendices are included that provide INEL D&D project historical information, a comprehensive descriptive summary of each current D&D surplus facility, and a summary database of all INEL contaminated facilities awaiting or undergoing the facility transition process.

  5. Drug: D03135 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available FOR TOPICAL USE D10AB Preparations containing sulfur D10AB01 Bithionol D03135 Bi...l (ATC) classification [BR:br08303] D DERMATOLOGICALS D10 ANTI-ACNE PREPARATIONS D10A ANTI-ACNE PREPARATIONS

  6. Drug: D00202 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available IVES A07AA Antibiotics A07AA02 Nystatin D00202 Nystatin (JP16/USP/INN) D DERMATOLOGICALS D01 ANTIFUNGALS FOR... DERMATOLOGICAL USE D01A ANTIFUNGALS FOR TOPICAL USE D01AA Antibiotics D01AA01 Ny

  7. Drug: D00282 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available s for local oral treatment A01AB18 Clotrimazole D00282 Clotrimazole (JP16/USP/INN) D DERMATOLOGICALS D01 ANTIFUNGAL...S FOR DERMATOLOGICAL USE D01A ANTIFUNGALS FOR TOPICAL USE D01AC Imidazole and triazole derivatives D0

  8. Drug: D08894 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available ATC code: D01AE04 Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D01 ANTIFUNGAL...S FOR DERMATOLOGICAL USE D01A ANTIFUNGALS FOR TOPICAL USE D01AE Other antifungals for topical use D

  9. Drug: D02219 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available ification [BR:br08303] D DERMATOLOGICALS D01 ANTIFUNGALS FOR DERMATOLOGICAL USE D01A ANTIFUNGAL...ne hydrochloride (JP16/USP) D01B ANTIFUNGALS FOR SYSTEMIC USE D01BA Antifungals for systemic use D01BA02 Ter

  10. Drug: D06139 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available ATC code: D01AE08 Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D01 ANTIFUNGAL...S FOR DERMATOLOGICAL USE D01A ANTIFUNGALS FOR TOPICAL USE D01AE Other antifungals for topical use D0

  11. Drug: D07213 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available 1 OTHER DERMATOLOGICAL PREPARATIONS D11A OTHER DERMATOLOGICAL PREPARATIONS D11AX Other dermatologicals D11AX...426 ATC code: D11AX02 Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D1

  12. Drug: D07211 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available B03 Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D10 ANTI-ACNE PREPARATIONS D10A ANTI-ACNE PRE...PARATIONS FOR TOPICAL USE D10AB Preparations containing sulfur D10AB03 Tioxolone D0

  13. Drug: D07214 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available fication [BR:br08303] D DERMATOLOGICALS D11 OTHER DERMATOLOGICAL PREPARATIONS D11A OTHER DERMATOLOGICAL PREPARATION...S D11AX Other dermatologicals D11AX08 Tiratricol D07214 Tiratricol (INN) H SYSTEMIC HORMONAL PREPARATION...S, EXCL. SEX HORMONES AND INSULINS H03 THYROID THERAPY H03A THYROID PREPARATION

  14. Drug: D00056 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available AA Enzymes B06AA07 Trypsin D00056 Trypsin (JAN); Trypsin, crystallized (USP) D DERMATOLOGICALS D03 PREPARA...TIONS FOR TREATMENT OF WOUNDS AND ULCERS D03B ENZYMES D03BA Proteolytic enzymes D03

  15. Drug: D06661 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D06661 Drug Dimethisoquin hydrochloride (USAN); Quinisocaine hydrochloride C17H24N2...O. HCl 308.1655 308.8462 D06661.gif ATC code: D04AB05 Dimethisoquin is called Quinisocaine in INN. Anatomica...ETC. D04AB Anesthetics for topical use D04AB05 Quinisocaine D06661 Dimethisoquin hydrochloride (USAN) CAS: 2

  16. Drug: D03965 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D03965 Mixture, Drug Salsocain; Salsocain (TN) Sulpyrine [DR:D01762], Sodium salicy...late [DR:D00566], Allobarbital [DR:D02817], Procaine hydrochloride [DR:D00740], Caffeine [DR:D01453] CAS: 85886-25-5 PubChem: 47205951 ...

  17. Drug: D09082 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09082 Formula, Drug Tokisan Japanese angelica root [DR:D06768], Peony root [DR:D06...ractylodes lancea rhizome [DR:D06752] | Atractylodes rhizome [DR:D06780]) Traditional Chinese Medicine in Japan [BR:br08304] Formula...s Formulas for blood Formulas for replenishing blood D09082 Tokisan PubChem: 96025763 ...

  18. Drug: D09112 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09112 Formula, Drug Jogan'ippo Glycyrrhiza [DR:D04365], Coptis rhizome [DR:D00092]..., Phellodendron bark [DR:D06689], Safflower [DR:D06717] Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formula...s for external use Formulas for external use D09112 Jogan'ippo PubChem: 96025792 ...

  19. Drug: D09062 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09062 Formula, Drug Kanzoshashinto Pinellia tuber [DR:D06778], Scutellaria root [D...D04365], Jujube [DR:D06758], Coptis rhizome [DR:D00092] Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formula

  20. Drug: D09084 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09084 Formula, Drug Chuoko Sesame oil [DR:D03314], Yellow beewax [DR:D04968], Term...eric [DR:D06695], Phellodendron bark [DR:D06689] Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formula...s for external use Formulas for external use D09084 Chuoko PubChem: 96025765 ...

  1. Drug: D09051 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09051 Formula, Drug Oren'akyoto Coptis rhizome [DR:D00092], Peony root [DR:D06739]..., Scutellaria root [DR:D06688], Asini corii collas [DR:D06892], Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formula...s for replenishing Ying Formulas for replenishing Ying D09051 Oren'akyoto PubChem: 96025732 ...

  2. Drug: D09073 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09073 Formula, Drug Byakkoto Gypsum [DR:D01728], Anemarrhena rhizome [DR:D06761], ...Oryzae semen [DR:D06900], Glycyrrhiza [DR:D04365] Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formula...s for clearing heat Formulas for clearing heat D09073 Byakkoto PubChem: 96025754 ...

  3. Drug: D09111 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09111 Formula, Drug Jashoshito Cnidium monnieri fruit [DR:D06740], Japanese angeli...ca root [DR:D06768], Clematis root [DR:D06694], Sophora root [DR:D06710] Traditional Chinese Medicine in Japan [BR:br08304] Formula...s Formulas for external use Formulas for external use D09111 Jashoshito PubChem: 96025791 ...

  4. Drug: D09090 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09090 Formula, Drug Sesshoin Japanese angelica root [DR:D06768], Peony root [DR:D0...yranthes root [DR:D06722], Safflower [DR:D06717] Traditional Chinese Medicine in Japan [BR:br08304] Formul...as Formulas for blood Formulas for removing blood stasis D09090 Sesshoin PubChem: 96025770 ...

  5. Drug: D09088 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09088 Formula, Drug Senshibyakujutsusan (Atractylodes lancea rhizome [DR:D06752] |...e in Japan [BR:br08304] Formulas Formulas for dampness Formulas for resolving dampness D09088 Senshibyakujutsusan PubChem: 96025768 ... ...772], Patchouli [DR:D09125], Saussurea root [DR:D06795], Glycyrrhiza [DR:D04365] Traditional Chinese Medicin

  6. Drug: D09116 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09116 Formula, Drug Bukuryukanto Bukuryukan, Pinellia tuber [DR:D06778], Ginger [D...R:D06744], Poria sclerotium [DR:D06783] Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formulas for stomach Antiemetic formulas D09116 Bukuryukanto PubChem: 96025796 ...

  7. Drug: D09039 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09039 Formula, Drug Ifuto Japanese angelica root [DR:D06768], Peony root [DR:D0673...:D06783], Cinnamon bark [DR:D06712], Millet Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formulas for stomach Antidiarrheal formulas D09039 Ifuto PubChem: 96025722 ...

  8. Drug: D09055 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09055 Formula, Drug Kakkon'oren'ogonto Pueraria root [DR:D06693], Coptis rhizome [...DR:D00092], Scutellaria root [DR:D06688], Glycyrrhiza [DR:D04365] Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formula...s for clearing heat Formulas for clearing heat D09055 Kakkon'oren'ogonto PubChem: 96025736 ...

  9. Drug: D03283 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D03283 Mixture, Drug Cadexomer iodine (USAN); Iodine - cadexomer mixt; Iodosorb (TN... Epidermides 269 Miscellaneous 2699 Others D03283 Cadexomer iodine (USAN) Anatomi...OF WOUNDS AND ULCERS D03A CICATRIZANTS D03AX Other cicatrizants D03AX01 Cadexomer iodine D03283 Cadexomer iodine (USAN) CAS: 94820-09-4 PubChem: 17397435 ...

  10. Drug: D04875 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D04875 Mixture, Drug Zinc sulfate - iodine - sodium iodine - glycerin mixt; Neoglyc...erol (TN) Zinc sulfate [DR:D01081], Iodine [DR:D00108], Sodium iodine [DR:D04874], Glycerin [DR:D00028] Ther...ans 27 Dental preparations 279 Miscellaneous 2790 Miscellaneous D04875 Zinc sulfate - iodine - sodium iodine - glycerin mixt PubChem: 17398205 ...

  11. Drug: D02273 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D02273 Mixture, Drug Isoproterenol sulfate - dexamethasone - atropine methybromide ...mixt; Stmerin D (TN) Isoproterenol sulfate [DR:D02066], Atropine methylbromide [DR:D03814], Dexamethasone [D...9 Others D02273 Isoproterenol sulfate - dexamethasone - atropine methybromide mixt PubChem: 7849332 ...

  12. Drug: D06816 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D06816 Mixture, Drug Arsenical paste (JP16) Arsenic trioxide [DR:D02106], Procaine hydrochloride [DR:D00740], Hydrophilic ointment [DR:D05237], Clove oil [DR:D06823], Medicinal carbon [DR:D03251] PubChem: 47208467 ...

  13. Drug: D00526 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available TIONS D11AH Agents for dermatitis, excluding corticosteroids D11AH03 Cromoglicic acid D00526 Sodium cromogli...ation [BR:br08303] D DERMATOLOGICALS D11 OTHER DERMATOLOGICAL PREPARATIONS D11A OTHER DERMATOLOGICAL PREPARA

  14. Drug: D10052 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available ea rhizome [DR:D06752]), Poria sclerotium [DR:D06783], Bupleurum root [DR:D06727], Glycyrrhiza [DR:D04365], Peony root [DR:D06739], Coptis rhizome [DR:D00092] PubChem: 135626772 ...

  15. Drug: D06959 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available DR:D06731], Rehmannia root [DR:D06736], Plantago seed [DR:D05525], Alisma rhizome [DR:D06759], Akebia stem [DR:D06794], Aluminum sili...cate hydrate with silicon dioxide [DR:D06895] Pollakiuri

  16. Drug: D03697 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available A CORTICOSTEROIDS, PLAIN D07AC Corticosteroids, potent (group III) D07AC03 Desoximetasone D03697 Desoximetas...one (USP/INN) D07X CORTICOSTEROIDS, OTHER COMBINATIONS D07XC Corticosteroids, potent, other combinations D07

  17. Measurements of $B \\to D_{s^{(*)+}} D^{*(*)}$ Branching Fractions

    CERN Document Server

    Ahmed, S; Athar, S B; Jian, L; Ling, L; Saleem, M; Timm, S; Wappler, F; Anastassov, A; Duboscq, J E; Eckhart, E; Gan, K K; Gwon, C; Hart, T; Honscheid, K; Hufnagel, D; Kagan, H; Kass, R; Pedlar, T K; Schwarthoff, H; Thayer, J B; Von Törne, E; Zoeller, M M; Richichi, S J; Severini, H; Skubic, P L; Undrus, A; Chen, S; Fast, J; Hinson, J W; Lee, J; Miller, D H; Shibata, E I; Shipsey, I P J; Pavlunin, V; Cronin-Hennessy, D; Lyon, A L; Thorndike, E H; Jessop, C P; Marsiske, H; Perl, Martin Lewis; Savinov, V; Zhou, X; Coan, T E; Fadeev, V; Maravin, Y; Narsky, I; Stroynowski, R; Ye, J; Wlodek, T; Artuso, M; Ayad, R; Boulahouache, C; Bukin, K; Dambasuren, E; Karamov, S; Majumder, G; Moneti, G C; Mountain, R; Schuh, S; Skwarnicki, T; Stone, S; Viehhauser, G; Wang, J C; Wolf, A; Wu, J; Kopp, S E; Mahmood, A H; Csorna, S E; Danko, I; McLean, K W; Marka, S; Xu, Z; Godang, R; Kinoshita, K; Lai, I C; Schrenk, S; Bonvicini, G; Cinabro, D; McGee, S A; Perera, L P; Zhou, G J; Lipeles, E; Pappas, S P; Schmidtler, M; Shapiro, A; Sun, W M; Weinstein, A J; Würthwein, F; Jaffe, D E; Masek, G E; Paar, H P; Potter, E M; Prell, S; Sharma, V; Asner, D M; Eppich, A; Hill, T S; Morrison, R J; Nelson, H N; Richman, J D; Witherell, M S; Briere, R A; Chen, G P; Behrens, B H; Ford, W T; Gritsan, A; Roy, J D; Smith, J G; Alexander, J P; Baker, R; Bebek, C; Berger, B E; Berkelman, K; Blanc, F; Boisvert, V; Cassel, David G; Dickson, M; Drell, P S; Ecklund, K M; Ehrlich, R; Foland, A D; Gaidarev, P B; Gibbons, L K; Gittelman, B; Gray, S W; Hartill, D L; Heltsley, B K; Hopman, P I; Jones, C D; Kreinick, D L; Lohner, M; Magerkurth, A; Meyer, T O; Mistry, N B; Nordberg, E; Patterson, J R; Peterson, D; Riley, D; Thayer, J G; Urner, D; Valant-Spaight, B L; Warburton, A; Avery, P; Prescott, C; Rubiera, A I; Yelton, J; Zheng, J; Brandenburg, G; Ershov, A; Gao, Y S; Kim, D Y J; Wilson, R; Browder, T E; Li, Y; Rodríguez, J L; Yamamoto, H; Bergfeld, T; Eisenstein, B I; Ernst, J; Gladding, G E; Gollin, G D; Hans, R M; Johnson, E; Karliner, I; Marsh, M A; Palmer, M; Plager, C; Sedlack, C; Selen, M; Thaler, J J; Williams, J; Edwards, K W; Janicek, R; Patel, P M; Sadoff, A J; Ammar, R; Bean, A; Besson, D; Davis, R; Kwak, N; Zhao, X; Anderson, S; Frolov, V V; Kubota, Y; Lee, S J; Mahapatra, R; O'Neill, J J; Poling, R A; Riehle, T; Smith, A; Stepaniak, C J; Urheim, J

    2000-01-01

    This article describes improved measurements by CLEO of the $B^0 \\to D_s^+ D^{*-}$ and $B^0 \\to D_s^{*+} D^{*-}$ branching fractions, and first evidence for the decay $B^+ \\to D_s^{(*)+} \\bar{D}^{**0}$, where $\\bar{D}^{**0}$ represents the sum of the $\\bar{D}_1(2420)^0$, $\\bar{D}_2^*(2460)^0 $, and $\\bar{D}_1(j=1/2)^0$ L=1 charm meson states. Also reported is the first measurement of the $D_s^{*+}$ polarization in the decay $B^0 \\to D_s^{*+} D^{*-}$. A partial reconstruction technique, employing only the fully reconstructed $D_s^+$ and slow pion $\\pi_s^-$ from the $D^{*-} \\to \\bar{D}^0 \\pi^-_s$ decay, enhances sensitivity. The observed branching fractions are $ {\\mathcal B} (B^0 \\to D_s^+ D^{*-}) = (1.10 \\pm 0.18 \\pm 0.10 \\pm 0.28)%$, $ {\\mathcal B} (B^0 \\to D_s^{*+} D^{*-}) = (1.82 \\pm 0.37 \\pm 0.24 \\pm 0.46)%$, and $ {\\mathcal B} (B^+ \\to D_s^{(*)+} \\bar{D}^{**0}) = (2.73 \\pm 0.78 \\pm 0.48 \\pm 0.68)%$, where the first error is statistical, the second systematic, and the third is due to the uncertainty in th...

  18. X(3872) and Bound State Problem of D~0(D)*~0((D)~0D*~0)

    Institute of Scientific and Technical Information of China (English)

    LIU Tan-rui; LIU Xiang; DENG Wei-zhen

    2009-01-01

    We have performed a dynamical calculation of the bound state problem of D~0(D)~(*0) by considering the pion and sigma meson exchange potential.Our preliminary analysis disfavors the molecular interpretation of X(3872) if we use the experimental D~* Dπ coupling constant g=0.59 and a reasonable cutoff around 1 GeV,which is the typical hadronic scale.In contrast,there probably exists a loosely bound S-wave B (-B)~* molecular state.Such a molecular state would be rather stable since its dominant decay mode is the radiative decay through B~*→Bγ.

  19. TOWARDS: 3D INTERNET

    OpenAIRE

    Ms. Swapnali R. Ghadge

    2013-01-01

    In today’s ever-shifting media landscape, it can be a complex task to find effective ways to reach your desired audience. As traditional media such as television continue to lose audience share, one venue in particular stands out for its ability to attract highly motivated audiences and for its tremendous growth potential the 3D Internet. The concept of '3D Internet' has recently come into the spotlight in the R&D arena, catching the attention of many people, and leading to a lot o...

  20. Blender 3D cookbook

    CERN Document Server

    Valenza, Enrico

    2015-01-01

    This book is aimed at the professionals that already have good 3D CGI experience with commercial packages and have now decided to try the open source Blender and want to experiment with something more complex than the average tutorials on the web. However, it's also aimed at the intermediate Blender users who simply want to go some steps further.It's taken for granted that you already know how to move inside the Blender interface, that you already have 3D modeling knowledge, and also that of basic 3D modeling and rendering concepts, for example, edge-loops, n-gons, or samples. In any case, it'

  1. Drug: D02174 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available RY TRACT AND METABOLISM A01 STOMATOLOGICAL PREPARATIONS A01A STOMATOLOGICAL PREPARATION...ne acetate (JAN/USP) D DERMATOLOGICALS D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROIDS...ations D07XB05 Dexamethasone D02174 Dexamethasone acetate (JAN/USP) D10 ANTI-ACNE PREPARATION...S D10A ANTI-ACNE PREPARATIONS FOR TOPICAL USE D10AA Corticosteroids, combinations for treatment ...of acne D10AA03 Dexamethasone D02174 Dexamethasone acetate (JAN/USP) H SYSTEMIC HORMONAL PREPARATIONS, EXCL.

  2. Drug: D02592 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available ssification [BR:br08303] A ALIMENTARY TRACT AND METABOLISM A01 STOMATOLOGICAL PREPARATIONS A01A STOMATOLOGICAL PREPARATION...thasone beloxil (USAN) D DERMATOLOGICALS D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROI...ately potent, other combinations D07XB05 Dexamethasone D02592 Dexamethasone beloxil (USAN) D10 ANTI-ACNE PREPARATION...S D10A ANTI-ACNE PREPARATIONS FOR TOPICAL USE D10AA Corticosteroids, combinations for treatment of a...cne D10AA03 Dexamethasone D02592 Dexamethasone beloxil (USAN) H SYSTEMIC HORMONAL PREPARATION

  3. Drug: D01775 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D01775 Drug Bifonazole (JP16/USAN/INN); Mycospor (TN) C22H18N2 310.147 310.3917 D0177...ntiparasitic dermatosis agents 2655 Imidazoles D01775 Bifonazole (JP16/USAN/INN) Anatomical Therapeutic Chem...GALS FOR TOPICAL USE D01AC Imidazole and triazole derivatives D01AC10 Bifonazole D0177...sterol 14alpha-demethylase inhibitor [KO:K05917] Imidazoles Bifonazole [ATC:D01AC10] D01775 Bifonazole (JP16.../USAN/INN) CAS: 60628-96-8 PubChem: 7848838 LigandBox: D01775 NIKKAJI: J17.988D A

  4. Drug: D00863 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available ANTISEPTICS AND DISINFECTANTS D08AG Iodine products D08AG02 Povidone-iodine D0086... antiinfectives D09AA09 Povidone-iodine D00863 Povidone-Iodine (JP16/USP) D11 OTHER DERMATOLOGICAL PREPARATI...ONS D11A OTHER DERMATOLOGICAL PREPARATIONS D11AC Medicated shampoos D11AC06 Povidone-iodine...X Other antiinfectives and antiseptics G01AX11 Povidone-iodine D00863 Povidone-Iodine (JP16/USP) R RESPIRATO...RY SYSTEM R02 THROAT PREPARATIONS R02A THROAT PREPARATIONS R02AA Antiseptics R02AA15 Povidone-iodine

  5. Drug: D01948 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available TRACT AND METABOLISM A01 STOMATOLOGICAL PREPARATIONS A01A STOMATOLOGICAL PREPARATIONS A01AC Corticosteroid... TOPICAL USE C05AA Corticosteroids C05AA09 Dexamethasone D01948 Dexamethasone valerate (JAN) D DERMATOLOGICA...LS D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AB Corticosteroids... D07X CORTICOSTEROIDS, OTHER COMBINATIONS D07XB Corticosteroids, moderately potent, other combinations D07XB...10A ANTI-ACNE PREPARATIONS FOR TOPICAL USE D10AA Corticosteroids, combinations for treatment of acne D10AA03

  6. $X(3872)$ production from reactions involving $D$ and $D^*$ mesons

    CERN Document Server

    Torres, A Martinez; Navarra, F S; Nielsen, M; Abreu, Luciano M

    2014-01-01

    In this proceeding we show the results found for the cross sections of the processes $\\bar D D\\to\\pi X(3872)$, $\\bar D^* D\\to \\pi X(3872)$ and $\\bar D^* D^*\\to\\pi X(3872)$, information needed for calculations of the $X(3872)$ abundance in heavy ion collisions. Our formalism is based on the generation of $X(3872)$ from the interaction of the hadrons $\\bar D^0 D^{*0} - \\textrm{c.c}$, $D^- D^{*+} - \\textrm{c.c}$ and $D^-_s D^{*+}_s - \\textrm{c.c}$. The evaluation of the cross section associated with processes having $D^*$ meson(s) involves an anomalous vertex, $X\\bar D^* D^*$, which we have determined by considering triangular loops motivated by the molecular nature of $X(3872)$. We find that the contribution of this vertex is important. Encouraged by this finding we estimate the $X\\bar D^* D^*$ coupling, which turns out to be $1.95\\pm 0.22$. We then use it to obtain the cross section for the reaction $\\bar D^* D^*\\to\\pi X$ and find that the $X\\bar D^* D^*$ vertex is also relevant in this case. We also discuss t...

  7. Pau D'arco

    Science.gov (United States)

    ... is applied directly to the skin for Candida yeast infections. Commercial products containing pau d'arco are available in capsule, tablet, extract, powder, and tea forms. But sometimes it's hard ...

  8. Donato D'Urbino

    Index Scriptorium Estoniae

    2005-01-01

    Itaalia arhitektide-disainerite Jonathan De Pasi, Donato D'Urbino, Paolo Lomazzi ja Carla Scolari kavandatud ning Itaalia firmas Zanotta S.p.A. toodetud täispuhutavast plastikust tugitoolist "Blow" (1967)

  9. Reflectometry on D17

    Energy Technology Data Exchange (ETDEWEB)

    Cubitt, R. [Institut Max von Laue - Paul Langevin (ILL), 38 - Grenoble (France)

    1997-04-01

    As part of the package of instrument upgrades planned over the next few years, D17 is based on a straightened cold neutron-guide and converted into a dedicated and versatile reflectometer. In the meantime, in order for ILL to become as fully involved as possible in this growing area of activity, the current D17 has been optimised for reflectometry. Results of this project are presented. (author).

  10. Tachyon condensation in unbalanced D-anti D system

    OpenAIRE

    Ishida, Akira; Uehara, Shozo; Yada, Tomoki

    2006-01-01

    The tachyon condensation is studied in asymmetric D-anti D systems. Taking a system of two pairs of D5-anti D5 in type IIB superstring theory in the background of large N D5-branes, we show that one BPS D1-brane comes out after the condensation. It is also seen that the BPS D1-brane feels no force from the background D5-branes. We also show that the inclusion of the fluctuation fields gives an expected Dirac-Born-Infeld (DBI) action of the resultant D1-brane. On the other hand, in the case of...

  11. Observation of the Radiative Decay D*+→D

    International Nuclear Information System (INIS)

    We have observed a signal for the decay D*+→D+γ at a significance of 4standard deviations. From the measured branching ratio B(D*+→D+γ) /B(D*+→D+π0)=0.055±0.014±0.010 we find B(D*+→D+γ) =0.017±0.004±0.003, where the first uncertainty is statistical and the second is systematic. We also report the highest precision determination of the remaining D*+ branching fractions. copyright 1998 The American Physical Society

  12. Drug: D04819 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D04819 Mixture, Drug Arsenic trioxide - dibucaine hydrochloride - dl-methylephedrine hydr...ochloride - p-butylaminobenzoyldiethylaminoethyl hydrochloride - benzyl alcohol mixt; Neoarsen black (...TN) Arsenic trioxide [DR:D02106], Dibucaine hydrochloridide [DR:D02220], dl-Methylephedrine hydrochloride [D...R:D02109], p-Butylaminobenzoyldiethylaminoethyl hydrochloride [DR:D01967], Benzyl alcohol [DR:D00077] PubChem: 17398187 ...

  13. Drug: D09047 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09047 Formula, Drug En'nenhangeto Pinellia tuber [DR:D06778], Bupleurum root [DR:D... ginger [DR:D06744], Immature orange [DR:D06706], Evodia fruit [DR:D00173] Traditional Chinese Medicine in Japan [BR:br08304] Formula...s Formulas for stomach Formulas for calming stomachache D09047 En'nenhangeto PubChem: 96025728 ...

  14. Drug: D07002 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D07002 Formula, Drug Daiobotampito Peach kernel [DR:D06769], Moutan bark [DR:D06788...cines D07002 Daiobotampito Traditional Chinese Medicine in Japan [BR:br08304] Formulas Purgative formulas Pu...rgative formulas D07002 *Daiobotampito Formulas for blood Formulas for removing b...lood stasis D07002 *Daiobotampito Formulas for pus discharge Formulas for pus discharge D07002 *Daiobotampito PubChem: 51091344 ...

  15. Drug: D03325 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available OSTEROIDS, DERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AC Corticosteroids... OTHER COMBINATIONS D07XC Corticosteroids, potent, other combinations D07XC03 Mometasone D03325 Mometasone f...TS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE R01AD Corticosteroids R01AD09 Mometasone D03325 Mometasone f...l) Mometasone D03325 Mometasone furoate hydrate (JAN) Respiratory Tract/Pulmonary Agents Anti-inflammatories, Inhaled Corticosteroids

  16. Drug: D00193 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D00193 Drug Panthenol (JAN); Dexpanthenol (USP/INN); Ilopan (TN) C9H19NO4 205.1314 ... preparations 3133 Pantothenic acids D00193 Panthenol (JAN); Dexpanthenol (USP/IN...ITAMINS A11H OTHER PLAIN VITAMIN PREPARATIONS A11HA Other plain vitamin preparations A11HA30 Dexpanthenol D0...0193 Panthenol (JAN); Dexpanthenol (USP/INN) D DERMATOLOGICALS D03 PREPARATIONS F...OR TREATMENT OF WOUNDS AND ULCERS D03A CICATRIZANTS D03AX Other cicatrizants D03AX03 Dexpanthenol D00193 Panthenol (JAN); Dexpantheno

  17. Drug: D07800 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available NTARY TRACT AND METABOLISM A01 STOMATOLOGICAL PREPARATIONS A01A STOMATOLOGICAL PREPARATION...21-valerate D DERMATOLOGICALS D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D...Dexamethasone D07800 Dexamethasone 21-valerate D10 ANTI-ACNE PREPARATIONS D10A ANTI-ACNE PREPARATION...ethasone D07800 Dexamethasone 21-valerate H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS ... H02AB Glucocorticoids H02AB02 Dexamethasone D07800 Dexamethasone 21-valerate R RESPIRATORY SYSTEM R01 NASAL PREPARATION

  18. Drug: D00733 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D00733 Drug Dibucaine (USP); Cinchocaine (INN); Nupercaine (TN) C20H29N3O2 343.226 ...l anesthetics C05AD04 Cinchocaine D00733 Dibucaine (USP); Cinchocaine (INN) D DERMATOLOGICALS D04 ANTIPRURIT...AB Anesthetics for topical use D04AB02 Cinchocaine D00733 Dibucaine (USP); Cinchocaine (INN) N NERVOUS SYSTE...M N01 ANESTHETICS N01B ANESTHETICS, LOCAL N01BB Amides N01BB06 Cinchocaine D00733...l anesthetics S01HA06 Cinchocaine D00733 Dibucaine (USP); Cinchocaine (INN) S02 OTOLOGICALS S02D OTHER OTOLO

  19. Drug: D05720 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D05720 Drug Retapamulin (USAN/INN); Altabax (TN) C30H47NO4S 517.3226 517.7635 D0572...S FOR DERMATOLOGICAL USE D06A ANTIBIOTICS FOR TOPICAL USE D06AX Other antibiotics for topical use D06AX13 Retapamulin D05720 Retapa...bacterials Antibacterials, Other Retapamulin D05720 Retapamulin (USAN/INN) Antiinfectives [BR:br08307] Antib...acterials Protein biosynthesis inhibitor 23S rRNA of 50S ribosomal subunit inhibitor [KO:K01980] Pleuromutilin derivatives Retapa...mulin [ATC:D06AX13] D05720 Retapamulin (USAN/INN) CAS: 22445

  20. Drug: D02435 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D02435 Drug Sulfamerazine (INN) C11H12N4O2S 264.0681 264.3036 D02435.gif Antibacter...CAL USE D06B CHEMOTHERAPEUTICS FOR TOPICAL USE D06BA Sulfonamides D06BA06 Sulfamerazine D02435 Sulfamerazine...RIM J01ED Long-acting sulfonamides J01ED07 Sulfamerazine D02435 Sulfamerazine (IN...ibitor [KO:K00796] Sulfonamides Sulfamerazine [ATC:D06BA06 J01ED07] D02435 Sulfamerazine (INN) CAS: 127-79-7

  1. Drug: D04221 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available S FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE C05AA Corticosteroids C05AA06 Fluorometholo...ERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AB Corticosteroids, moderately potent (group II) D...07AB06 Fluorometholone D04221 Fluorometholone acetate (USAN) D07X CORTICOSTEROIDS, OTHER COMBINATIONS D07XB Corticosteroids...4221 Fluorometholone acetate (USAN) D10 ANTI-ACNE PREPARATIONS D10A ANTI-ACNE PREPARATIONS FOR TOPICAL USE D10AA Corticosteroids...ate (USAN) S SENSORY ORGANS S01 OPHTHALMOLOGICALS S01B ANTIINFLAMMATORY AGENTS S01BA Corticosteroids, plain

  2. Drug: D01367 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available C05A AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE C05AA Corticosteroids C05AA06 Fl...EPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AB Corticosteroids, moderately potent (...group II) D07AB06 Fluorometholone D01367 Fluorometholone (JP16/USP/INN) D07X CORTICOSTEROIDS, OTHER COMBINATIONS D07XB Corticosteroid...lone (JP16/USP/INN) D10 ANTI-ACNE PREPARATIONS D10A ANTI-ACNE PREPARATIONS FOR TOPICAL USE D10AA Corticosteroids...holone (JP16/USP/INN) S SENSORY ORGANS S01 OPHTHALMOLOGICALS S01B ANTIINFLAMMATORY AGENTS S01BA Corticosteroids

  3. Drug: D00385 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available EMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE C05AA Corticosteroids C05AA12 Triamcinolone D00385 Triamcinolon...e (JP16/USP/INN) D DERMATOLOGICALS D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AB Corticosteroids.../INN) D07X CORTICOSTEROIDS, OTHER COMBINATIONS D07XB Corticosteroids, moderately ...FOR TOPICAL USE R01AD Corticosteroids R01AD11 Triamcinolone D00385 Triamcinolone (JP16/USP/INN) R03 DRUGS FO...1 OPHTHALMOLOGICALS S01B ANTIINFLAMMATORY AGENTS S01BA Corticosteroids, plain S01BA05 Triamcinolone D00385 T

  4. Drug: D00980 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available A07 ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS A07E INTESTINAL ANTIINFLAMMATORY AGENTS A07EA Corticosteroids...D ANAL FISSURES FOR TOPICAL USE C05AA Corticosteroids C05AA04 Prednisolone D00980 Prednisolone acetate (JP16.../USP/INN) D DERMATOLOGICALS D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AA Corticosteroids...te (JP16/USP/INN) D07X CORTICOSTEROIDS, OTHER COMBINATIONS D07XA Corticosteroids, weak, other combinations D...R RESPIRATORY SYSTEM R01 NASAL PREPARATIONS R01A DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE R01AD Corticosteroids

  5. Drug: D01468 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D01468 Drug Nemonapride (JAN/INN); Emilace (TN) C21H26ClN3O2 387.1714 387.903 D0146...ting central nervous system 117 Psychotropics 1179 Others D01468 Nemonapride (JAN...e dopamine D2-receptor [HSA:1813] [KO:K04145] Nemonapride D01468 Nemonapride (JAN/INN) dopamine D3-receptor ...[HSA:1814] [KO:K04146] Nemonapride D01468 Nemonapride (JAN/INN) dopamine D4-recep...tor [HSA:1815] [KO:K04147] Nemonapride D01468 Nemonapride (JAN/INN) CAS: 75272-39-8 PubChem: 7848531 LigandB

  6. Drug: D02845 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D02845 Drug Aluminum chloride (USP) AlCl3. 6H2O 239.9515 241.4322 D02845.gif Astringent [topic...LOGICALS D10 ANTI-ACNE PREPARATIONS D10A ANTI-ACNE PREPARATIONS FOR TOPICAL USE D10AX Other anti-acne preparations for topic

  7. Drug: D09091 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available ese angelica root [DR:D06768], (Cnidium rhizome [DR:D06748] | Chinese cnidium rhizome [ED:E00321]), Angeli...ca dahurica root [DR:D06779], Vitex fruit [DR:D09191], Asiasarum root [DR:D06728],

  8. Drug: D04218 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available ocortolone D04218 Fluocortolone (USAN/INN) D DERMATOLOGICALS D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROIDS...luocortolone D04218 Fluocortolone (USAN/INN) H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS H02 CORTICOSTEROIDS... FOR SYSTEMIC USE H02A CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN H02AB Glucocorticoids H

  9. Drug: D04219 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available 08 Fluocortolone D04219 Fluocortolone caproate (USAN) D DERMATOLOGICALS D07 CORTICOSTEROIDS, DERMATOLOGICAL ...PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AC Corticosteroids, potent (group III...MONES AND INSULINS H02 CORTICOSTEROIDS FOR SYSTEMIC USE H02A CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN H02AB G

  10. Drug: D05000 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D07 CORTICOSTEROIDS, DE...RMATOLOGICAL PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AA Corticosteroids, weak (group I) D07AA01 Methylpr...ORMONES AND INSULINS H02 CORTICOSTEROIDS FOR SYSTEMIC USE H02A CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN H02AB

  11. Drug: D01335 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available NGALS FOR DERMATOLOGICAL USE D01A ANTIFUNGALS FOR TOPICAL USE D01AE Other antifunga....gif Same as: C12767 ATC code: D01AE09 Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D01 ANTIFU

  12. Drug: D00339 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available ALS FOR DERMATOLOGICAL USE D01A ANTIFUNGALS FOR TOPICAL USE D01AE Other antifungals...339.gif Antifungal ATC code: D01AE11 Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D01 ANTIFUNG

  13. Drug: D00351 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available es D00351 Ketoconazole (JP16/USP) Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D01 ANTIFUNGAL...S FOR DERMATOLOGICAL USE D01A ANTIFUNGALS FOR TOPICAL USE D01AC Imidazole and triazo

  14. Drug: D03315 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available Antifungal ATC code: D01AE04 Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D01 ANTIFUNGAL...S FOR DERMATOLOGICAL USE D01A ANTIFUNGALS FOR TOPICAL USE D01AE Other antifungals for to

  15. Drug: D07882 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available imidazole, topic ATC code: D01AC17 Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D01 ANTIFUNGA...LS FOR DERMATOLOGICAL USE D01A ANTIFUNGALS FOR TOPICAL USE D01AC Imidazole and tria

  16. Drug: D07193 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available TC code: D01AC16 G01AF18 Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D01 ANTIFUNGAL...S FOR DERMATOLOGICAL USE D01A ANTIFUNGALS FOR TOPICAL USE D01AC Imidazole and triazole deriva

  17. Drug: D06883 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available al ATC code: D01AC14 Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D01 ANTIFUNGAL...S FOR DERMATOLOGICAL USE D01A ANTIFUNGALS FOR TOPICAL USE D01AC Imidazole and triazole derivative

  18. Drug: D04967 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available (TN) Carbazochrome [DR:D01864], Phytonadione [DR:D00148], Ascorbic acid [DR:D00018] Hemostatics Therapeutic ...d body fluid agents 332 Hemostatics 3329 Others D04967 Carbazochrome - phytonadione - ascorbic acid mixt PubChem: 17398238 ...

  19. Drug: D06978 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D06978 Formula, Drug Shakanzoto Rehmannia root [DR:D06736], Ophiopogon tuber [DR:D0...52 Traditional Chinese medicines 520 Traditional Chinese medicines 5200 Traditional Chinese medicines D06978 Shakan...for replenishing Ying Formulas for replenishing Ying D06978 Shakanzoto PubChem: 51091320 ...

  20. Drug: D07212 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available 03AA03 Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D10 ANTI-ACNE PREPARATION...S D10A ANTI-ACNE PREPARATIONS FOR TOPICAL USE D10AB Preparations containing sulfur D10AB05 Mesulfen

  1. Drug: D08462 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D08462 Drug Quinisocaine (INN); Dimethisoquin C17H24N2O 272.1889 272.3853 D08462.gi...INES, ANESTHETICS, ETC. D04AB Anesthetics for topical use D04AB05 Quinisocaine D08462 Quinisocai

  2. Drug: D04052 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D04052 Mixture, Drug Adrenaline - lidocaine hydrochloride mixt; Epinephrine - lidocai...ne hydrochloride mixt; Xylocaine (TN) Adrenaline [DR:D00095], Lidcaine hydrochloride [DR:D02086] Anestheti...ns 12 Agents affecting peripheral nervous system 121 Local anesthetics 1214 Xylidines D04052 Adrenaline - lidocai... 2710 Local anesthetics D04052 Adrenaline - lidocaine hydrochloride mixt PubChem: 17398016 ...

  3. Drug: D04930 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D04930 Mixture, Drug Benfotiamine - pyridoxine hydrochloride - Hydroxocobalamin hydr...ochloride mixt; Vitamedin-S (TN) Benfotiamine [DR:D01255], Pyridoxine hydrochloride [DR:D02179], Hydroxocobalamin hydrochloride [DR:D04929] See [DR:D04911] PubChem: 17398222 ...

  4. Drug: D04844 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D04844 Mixture, Drug Paraformaldehyde - dibucaine hydrochloride mixt; Periodon (TN)... Paraformaldehyde [DR:D01494], Dibucaine hydrochloride [DR:D02220] Therapeutic category: 2730 Therapeutic category of dr...sics and sedatives 2730 Analgesics and sedatives D04844 Paraformaldehyde - dibucaine hydrochloride mixt CAS: 617-48-1 PubChem: 17398192 NIKKAJI: J237.180D ...

  5. Drug: D05239 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D04969], Sorbitan sesquioleate [DR:D05282], White petrolatum [DR:D05304] Pharmaceutic aid [ointment base, Ol...eaginous] Therapeutic category: 7121 Mixture of White beewax [DR:D04969], Sorbitan sesquioleate [DR:D05282] and White petrolatum

  6. Drug: D04856 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available loride - iodoform - calcium hydroxide mixt; Calvital (TN) Sulfathiazole [DR:D01047], Diethylaminoethyl p-but...ylaminobenzoate hydrochloride [DR:D01967], Iodoform [DR:D01910], Calcium hydroxide [DR:D01083] Therapeutic c...50 Pulp capping agents D04856 Sulfathiazole - diethylaminoethyl p-butylaminobenzoate hydrochloride - iodoform - calcium hydroxide mixt PubChem: 17398197 ...

  7. Drug: D10259 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D10259 Mixture, Drug Famotidine - calcium carbonate - magnesium hydroxide mixt; Com...plete (TN) Famotidine [DR:D00318], Magnesium hydroxide [DR:D00731], Precipitated calcium carbonate [DR:D0093...tagonists A02BA53 Famotidine, combinations D10259 Famotidine - calcium carbonate - magnesium hydroxide mixt PubChem: 163312290 ...

  8. Drug: D09077 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09077 Formula, Drug Hainosan Immature orange [DR:D06706], Peony root [DR:D06739], ...Platycodon root [DR:D06703] Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formulas for pus discharge Formulas for pus discharge D09077 Hainosan PubChem: 96025758 ...

  9. Drug: D06958 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D06958 Formula, Drug Goshuyuto Jujube [DR:D06758], Evodia fruit [DR:D00173], Ginsen...se medicines 5200 Traditional Chinese medicines D06958 Goshuyuto Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formula...s for stomach Formulas for calming stomachache D06958 *Goshuyuto Formulas for warming the interior Formula

  10. Drug: D07035 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D07035 Formula, Drug Byakkokaninjinto Gypsum [DR:D01728], Anemarrhena rhizome [DR:D...hinese Medicine in Japan [BR:br08304] Formulas Formulas for clearing heat Formulas for clearing heat D07035 *Byakkokaninjinto Formula...s for replenishing Ying Formulas for replenishing Ying D07035 *Byakkokaninjinto PubChem: 51091377 ...

  11. Drug: D09085 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09085 Formula, Drug Daihangeto Pinellia tuber [DR:D06778], Ginseng [DR:D06772], Ho...ney [DR:D06776] Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formulas for stomach Antiemetic formulas D09085 Daihangeto PubChem: 96025766 ...

  12. Drug: D06944 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D06944 Formula, Drug Keishikajutsubuto Cinnamon bark [DR:D06712], Peony root [DR:D0... Keishikajutsubuto Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formulas for warming the interior Formula...s for warming the interior D06944 *Keishikajutsubuto Formulas for dampness Antirheumatic formulas D06944 *Keishikajutsubuto PubChem: 51091286 ...

  13. Drug: D09076 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09076 Formula, Drug Hainoto Glycyrrhiza [DR:D04365], Platycodon root [DR:D06703], ...Ginger [DR:D06744], Jujube [DR:D06758] Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formulas for pus discharge Formula

  14. Drug: D09080 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09080 Formula, Drug Tokibaimokujinganryo Japanese angelica root [DR:D06768], Friti...llaria bulb [DR:D06774], Sophora root [DR:D06710] Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formula...s for clearing heat Formulas for clearing heat D09080 Tokibaimokujinganryo PubChem: 96025761 ...

  15. Drug: D09063 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09063 Formula, Drug Kigikenchuto Cinnamon bark [DR:D06712], Peony root [DR:D06739]...arum granorum [ED:E00250], Astragalus root [DR:D06687] Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formula...s for Qi Formulas for replenishing Qi D09063 Kigikenchuto PubChem: 96025744 ...

  16. Drug: D09199 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09199 Formula, Drug Shigyakuto Glycyrrhiza [DR:D04365], Processed ginger [DR:D0670...2], Processed aconite root [DR:D06784] Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formulas ...for warming the interior Formulas for warming the interior D09199 Shigyakuto PubChem: 96025879 ...

  17. Drug: D09100 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09100 Formula, Drug Koshayoito Ginseng [DR:D06772], Atractylodes rhizome [DR:D0678...omum seed [DR:D06743] Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formulas for dampness Formulas for resolving dampness D09100 Koshayoito PubChem: 96025780 ...

  18. Drug: D09097 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09097 Formula, Drug Kenchuto Pinellia tuber [DR:D06778], Poria sclerotium [DR:D067...ycyrrhiza [DR:D04365] Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formulas for stomach Antiemetic formulas D09097 Kenchuto PubChem: 96025777 ...

  19. Drug: D09119 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09119 Formula, Drug Shojokito Rhubarb [DR:D06756], Immature orange [DR:D06706], Ma...gnolia bark [DR:D06720] Traditional Chinese Medicine in Japan [BR:br08304] Formulas Purgative formulas Purgative formulas D09119 Shojokito PubChem: 96025799 ...

  20. Drug: D09040 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09040 Formula, Drug Ryokeikansoto Poria sclerotium [DR:D06783], Cinnamon bark [DR:...D06712], Glycyrrhiza [DR:D04365], Jujube [DR:D06758] Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formula

  1. Drug: D09056 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09056 Formula, Drug Kakkonkokato Pueraria root [DR:D06693], Peony root [DR:D06739]... Glycyrrhiza [DR:D04365], Rhubarb [DR:D06756] Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formulas for blood Formula

  2. Drug: D09109 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09109 Formula, Drug Shiteito Clove [DR:D03570], Persimmon calyx [DR:D07154], Ginge...r [DR:D06744] Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formulas for Qi Formulas for regulating Qi D09109 Shiteito PubChem: 96025789 ...

  3. Drug: D09098 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09098 Formula, Drug Kojito Cinnamon bark [DR:D06712], Poria sclerotium [DR:D06783]...nger [DR:D06744] Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formulas for blood Formulas for removing blood stasis D09098 Kojito PubChem: 96025778 ...

  4. Drug: D06966 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available , Jujube [DR:D06758], Ginseng [DR:D06772], Glycyrrhiza [DR:D04365], Perilla herb [DR:D06755], Ginger [DR:D06744] Child asthma...; Bronchial asthma; Bronchitis; Cough; Anxiety neurosis [DS:H000

  5. Drug: D10273 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D10273 Mixture, Drug Metoprolol - hydrochlorothiazide mixt; Dutoprol (TN); Lopresso...r hct (TN) (Metoprolol tartrate [DR:D00601] | Metoprolol succinate [DR:D00635]), Hydrochlorothiazide [DR:D00...ZIDES C07BB Beta blocking agents, selective, and thiazides C07BB02 Metoprolol and thiazides D10273 Metoprolol - hydrochlorothiazide mixt PubChem: 163312304 ...

  6. Drug: D10267 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D10267 Mixture, Drug Methyldopa - hydrochlorothiazide mixt; Methyldopa and hydrochlorothiazide... (TN) (Methyldopa hydrate [DR:D00405] | Methyldopa [DR:D08205]), Hydrochlorothiazide [DR:D00340] ...MBINATION C02LB Methyldopa and diuretics in combination C02LB01 Methyldopa (levorotatory) and diuretics D10267 Methyldopa - hydrochlorothiazide mixt PubChem: 163312298 ...

  7. Drug: D10286 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D10286 Mixture, Drug Amlodipine - valsartan -hydrochlorothiazide mixt; Exforge hct ...(TN) Amlodipine besilate [DR:D00615], Hydrochlorothiazide [DR:D00340], Valsartan [DR:D00400] Antihypertensiv...TS, COMBINATIONS C09DX Angiotensin II antagonists, other combinations C09DX01 Valsartan, amlodipine and hydrochlorothiazide... D10286 Amlodipine - valsartan -hydrochlorothiazide mixt PubChem: 163312317 ...

  8. Drug: D10280 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D10280 Mixture, Drug Fosinopril - hydrochlorothiazide mixt; Fosinopril sodium and hydrochlorothiazide... (TN) (Fosinopril sodium [DR:D00622] | Fosinopril [DR:D07992]), Hydrochlorothiazide [DR:D0... INHIBITORS, COMBINATIONS C09BA ACE inhibitors and diuretics C09BA09 Fosinopril and diuretics D10280 Fosinopril - hydrochlorothiazide mixt PubChem: 163312311 ...

  9. Drug: D10268 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D10268 Mixture, Drug Hydrochlorothiazide - lisinopril mixt; Prinzide (TN); Zestoretic (TN) Hydrochlorothiazi...MBINATIONS C09BA ACE inhibitors and diuretics C09BA03 Lisinopril and diuretics D10268 Hydrochlorothiazide - lisinopril mixt PubChem: 163312299 ... ...de [DR:D00340], (Lisinopril hydrate [DR:D00362] | Lisinopril [DR:D08131]) Antihyper

  10. Drug: D06392 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D06392 Drug d-Camphor (JP16); d-Camphor (TN) C10H16O 152.1201 152.2334 D06392.gif Cinnamomum...phenic (TN), Sulfur and camphor [DR:D04811] In case of crude: Lauraceae (laurel family) Cinnamomum camphora

  11. Drug: D04340 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D04340 Mixture, Drug Dextromethorphan hydrobromide - potassium cresolsulfonate mixt...; Medicon (TN) Dextromethorphan hydrobromide [DR:D00848], Potassium cresolsulfonate [DR:D04339] Antitussive ...24 Antitussives and expectorants 2249 Others D04340 Dextromethorphan hydrobromide - potassium cresolsulfonat...ium derivatives and expectorants R05FA02 Opium derivatives and expectorants D04340 Dextromethorphan hydrobromide - potassium cresolsulfonate mixt PubChem: 17398062 ...

  12. Drug: D08835 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D08835 Mixture, Drug Zinc oxide - lard - hardened oil - white beeswax mixt; Wilson'...s (TN) Zinc oxide [DR:D01170], Lard [DR:D05301], Hardened oil, White beeswax [DR:D04969] Therapeutic categor...ers D08835 Zinc oxide - lard - hardened oil - white beeswax mixt PubChem: 96025518 ...

  13. Drug: D08789 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D08789 Drug Freeze-dried human anti-D (Rho) immunoglobulin; Anti D globulin (TN) Th...anisms and parasites 63 Biological preparations 634 Human blood preparations 6343 Plasma preparations D08789 Freeze-dried human anti-D (Rho) immunoglobulin PubChem: 96025472 ...

  14. Drug: D08708 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D08708 Mixture, Drug Licase (alpha Amylase) - aluminum hydroxide, dried - magnesium...e) [DR:D02831], Aluminum hydroxide, dried [DR:D02416], Magnesium carbonate [DR:D01446], Sodium bicarbonate [...2339 Others D08708 Licase (alpha Amylase) - aluminum hydroxide, dried - magnesium carbonate - sodium bicarbonate - precipitated calcium carbonate mixt PubChem: 96025391 ...

  15. Drug: D08707 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D08707 Mixture, Drug l-Menthol - gentian - scopolia extract powder - sodium bicarbo...nate mixt; Bellsan (TN) l-Menthol [DR:D00064], Gentian [DR:D06716], Scopolia extract powder [DR:D06875], Sod...digestives 2339 Others D08707 l-Menthol - gentian - scopolia extract powder - sodium bicarbonate mixt PubChem: 96025390 ...

  16. Drug: D08723 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D08723 Mixture, Drug dl-Camphor - capsicum extract - methyl salicylate mixt; Rakool... (TN) dl-Camphor [DR:D00098], Capsicum extract [DR:D06455], Methyl salicylate [DR:D01087] Therapeutic catego...hers D08723 dl-Camphor - capsicum extract - methyl salicylate mixt PubChem: 96025406 ...

  17. Subsidizing R&D cooperatives

    NARCIS (Netherlands)

    J. Hinloopen

    2001-01-01

    A framework is developed with which the implementation of two commonly used R&D-stimulating policies can be evaluated: providing R&D subsidies and sustaining the formation of R&D cooperatives. Subsidized R&D cooperatives can also be analyzed. The analysis shows that providing R&D subsidies is more e

  18. Drug: D07116 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available SENSORY ORGANS S01 OPHTHALMOLOGICALS S01B ANTIINFLAMMATORY AGENTS S01BA Corticosteroids, plain S01BA10 Alcl...OLOGICALS D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AB Corticosteroi...ds, moderately potent (group II) D07AB10 Alclometasone D07116 Alclometasone (INN) S

  19. Drug: D03418 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D03418 Drug Aromatic castor oil (JP16); Aromatic castor oil (TN) Therapeutic catego...ry: 2356 ATC code: A06AB05 contains: Castor oil [DR:D06462], Orange oil [DR:D05186], Mentha oil [DR:D06461] Therapeutic...agents 235 Purgatives, clysters 2356 Oils and fats D03418 Aromatic castor oil (JP16) Anatomical Therapeuti

  20. Ph.D. shortage

    Science.gov (United States)

    The late 1990s will see a shortage of Ph.D. graduates, according to the Association of American Universities, Washington, D.C. AAU's new comprehensive study, “The Ph.D. Shortage: The Federal Role,” reports that competition for new Ph.D.s is already intense and can only intensify because demand is greater than supply in both academic and nonacademic markets.Doctoral education plays an increasingly important role in U.S. research and development programs. Students have a pivotal part in doing research and enriching it with new ideas. The AAU report says that graduate students are “major determinants of the creativity and productivity of U.S. academic research, the source of more than 50% of the nation's basic research.’ The market for doctoral education extends beyond the university. In 1985, about 43% of all Ph.D.s employed in this country were working outside higher education; the demand for doctorate recipients in nonacademic sectors continues to grow.

  1. INEL D&D Long-Range Plan

    Energy Technology Data Exchange (ETDEWEB)

    Buckland, R.J.; Kenoyer, D.J.; Preussner, D.H.

    1993-10-01

    This Long-Range Plan presents the Decontamination and Decommissioning (D&D) Program planning status for facilities at the Idaho National Engineering Laboratory (INEL). The plan provides a general description of the D&D Program objectives, management criteria, and philosophy; discusses current activities; and documents the INEL D&D Program cost and schedule estimate projections for the next 15 years. appendices are included that provide INEL D&D project historical information and a comprehensive descriptive summary of each current surplus facility.

  2. INEL D ampersand D Long-Range Plan

    International Nuclear Information System (INIS)

    This Long-Range Plan presents the Decontamination and Decommissioning (D ampersand D) Program planning status for facilities at the Idaho National Engineering Laboratory (INEL). The plan provides a general description of the D ampersand D Program objectives, management criteria, and philosophy; discusses current activities; and documents the INEL D ampersand D Program cost and schedule estimate projections for the next 15 years. appendices are included that provide INEL D ampersand D project historical information and a comprehensive descriptive summary of each current surplus facility

  3. Radiochromic 3D Detectors

    Science.gov (United States)

    Oldham, Mark

    2015-01-01

    Radiochromic materials exhibit a colour change when exposed to ionising radiation. Radiochromic film has been used for clinical dosimetry for many years and increasingly so recently, as films of higher sensitivities have become available. The two principle advantages of radiochromic dosimetry include greater tissue equivalence (radiologically) and the lack of requirement for development of the colour change. In a radiochromic material, the colour change arises direct from ionising interactions affecting dye molecules, without requiring any latent chemical, optical or thermal development, with important implications for increased accuracy and convenience. It is only relatively recently however, that 3D radiochromic dosimetry has become possible. In this article we review recent developments and the current state-of-the-art of 3D radiochromic dosimetry, and the potential for a more comprehensive solution for the verification of complex radiation therapy treatments, and 3D dose measurement in general.

  4. 3D Projection Installations

    DEFF Research Database (Denmark)

    Halskov, Kim; Johansen, Stine Liv; Bach Mikkelsen, Michelle

    2014-01-01

    Three-dimensional projection installations are particular kinds of augmented spaces in which a digital 3-D model is projected onto a physical three-dimensional object, thereby fusing the digital content and the physical object. Based on interaction design research and media studies, this article...... contributes to the understanding of the distinctive characteristics of such a new medium, and identifies three strategies for designing 3-D projection installations: establishing space; interplay between the digital and the physical; and transformation of materiality. The principal empirical case, From...... Fingerplan to Loop City, is a 3-D projection installation presenting the history and future of city planning for the Copenhagen area in Denmark. The installation was presented as part of the 12th Architecture Biennale in Venice in 2010....

  5. Drug: D05820 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D05820 Drug Semduramicin (USAN/INN) C45H76O16 872.5133 873.0753 D05820.gif Coccidiostat ionophore... Antiinfectives [BR:br08307] Antibacterials Others Others Polyether ionophores Semduramicin D0

  6. Drug: D07875 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available epin D07875 Doxepin (INN) Dermatological Agents Doxepin D07875 Doxepin (INN) Sleep Disorder... Agents Sleep Disorders, Other Doxepin D07875 Doxepin (INN) CAS: 1668-19-5 PubChem: 96024571 DrugB

  7. Drug: D08296 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available UNGALS FOR DERMATOLOGICAL USE D01A ANTIFUNGALS FOR TOPIC...7] ko00100(K05917) Steroid biosynthesis Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D01 ANTIF

  8. Drug: D02583 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available 0100(K05917) Steroid biosynthesis Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D01 ANTIFUNGAL...S FOR DERMATOLOGICAL USE D01A ANTIFUNGALS FOR TOPICAL USE

  9. Drug: D03162 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D03162 Drug Bromelain (JAN); Bromelains (USAN/INN); Edemase D (TN) Ananas comosus [TAX:4615] Anti-inflammato...ry Therapeutic category: 3959 ATC code: D03BA03 cysteine protease fibrin depolymeri

  10. Drug: D07817 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available drug classification [BR:br08302] Analgesics Nonsteroidal Anti-inflammatory Drugs Diclofenac D07817 Diclofenac diethylamine Anti-infl...ammatory Agents Nonsteroidal Anti-inflammatory Drugs Diclofenac D07817 Diclofenac d

  11. Drug: D07540 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available ication [BR:br08303] D DERMATOLOGICALS D11 OTHER DERMATOLOGICAL PREPARATIONS D11A OTHER DERMATOLOGICAL PREPARATION...LMOLOGICALS S01E ANTIGLAUCOMA PREPARATIONS AND MIOTICS S01EA Sympathomimetics in

  12. Drug: D07049 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available Insomnia; Night cry in childhood Therapeutic category: 5200 Therapeutic category...a [DR:D04365], (Atractylodes rhizome [DR:D06780] | Atractylodes lancea rhizome [DR:D06752]) Nervous disease;

  13. Drug: D10210 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available cin [DR:D00211], Isoniazid [DR:D00346], Pyrazinamide [DR:D00144] Antibacterial, Treatment of pulmonary tuberculosis [DS:H00342] Genomic biomarker: NAT [HSA:9 10] PubChem: 163312241 ...

  14. Drug: D06965 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available adenoiditis; Ecozema in childhood Therapeutic category: 5200 Therapeutic category of drugs in Japan [BR:br08...Trichosanthes root [DR:D06701], Burdock fruit [DR:D06723], Glycyrrhiza [DR:D04365] Nervous disease; Chronic

  15. Drug: D04249 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D04249 Mixture, Drug Oxytetracycline hydrochloride - hydrocortisone acetate mixt; T...erra-cortril (TN); Tetrazol (TN) Oxytetracycline hydrochloride [DR:D01596], Hydrocortisone acetate [DR:D00165] combination adrenocorticoid and antibiotic PubChem: 17398033 ...

  16. Drug: D09095 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09095 Formula, Drug Keibohaidokusan Schizonepeta spike [DR:D06711], Saposhnikovia ...Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formulas for pus discharge Formulas for pus discharge D09095 Keibohaidokusan PubChem: 96025775 ...

  17. Drug: D04809 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D04809 Mixture, Drug Glycerin and potash solution (JP16); Glycerin and potash solution (TN) Potassium hydrox...ide [DR:D01168], Glycerin [DR:D00028] Therapeutic category: 2662 Therapeutic catego

  18. Drug: D04753 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available COMBINATIONS WITH ANTIBIOTICS D07CA Corticosteroids, weak, combinations with antibiotics... D07CA03 Prednisolone and antibiotics D04753 Chloramphenicol - fradiomycin sulfate - prednisolone mixt PubChem: 17398155 ...

  19. Drug: D04769 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS D07CA Corticosteroids, weak, combinations with antibiotics... D07CA03 Prednisolone and antibiotics D04769 Fradiomycin sulfate - prednisolone mixt PubChem: 17398159 ...

  20. Drug: D09105 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09105 Formula, Drug Saishakurikkunshito Ginseng [DR:D06772], (Atractylodes lancea ...pan [BR:br08304] Formulas Formulas for stomach Antidiarrheal formulas D09105 Saishakurikkunshito PubChem: 96025785 ...

  1. Vitamin D and Breast Cancer

    OpenAIRE

    Shao, Theresa; Klein, Paula; Grossbard, Michael L.

    2012-01-01

    Vitamin D metabolism and its mechanism of action, the current evidence on the relationship between vitamin D and breast cancer, and the optimal dosing of vitamin D for breast cancer prevention are summarized.

  2. Drug: D09094 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09094 Formula, Drug Jinreibyakujutsusan Ginseng [DR:D06772], Poria sclerotium [DR:...ine in Japan [BR:br08304] Formulas Formulas for Qi Formulas for replenishing Qi D09094 Jinreibyakujutsusan PubChem: 96025774 ...

  3. Drug: D09050 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09050 Formula, Drug Oshosan; Kyuosan Rhubarb [DR:D06756], (Cnidium rhizome [DR:D06...748] | Chinese cnidium rhizome [ED:E00321]) Traditional Chinese Medicine in Japan [BR:br08304] Formulas Purg

  4. Drug: D09075 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09075 Formula, Drug Hachimishoyosan Japanese angelica root [DR:D06768], Peony root...] Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formulas for Qi Sedative formulas D09075 Hachimishoyosan PubChem: 96025756 ...

  5. Drug: D09070 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09070 Formula, Drug Keishikashakuyakushokyoninjinto Cinnamon bark [DR:D06712], Peo...aditional Chinese Medicine in Japan [BR:br08304] Formulas Formulas for Qi Formulas for replenishing Qi D09070 Keishikashakuyakushokyoninjinto PubChem: 96025751 ...

  6. Drug: D09099 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09099 Formula, Drug Koshaheiisan (Atractylodes lancea rhizome [DR:D06752] | Atract... [DR:D09125] Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formulas for dampness Formula

  7. Drug: D09048 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09048 Formula, Drug Boibukuryoto Sinomenium stem [DR:D06785], Astragalus root [DR:...e Medicine in Japan [BR:br08304] Formulas Formulas for dampness Diuretic formulas D09048 Boibukuryoto PubChem: 96025729 ...

  8. Drug: D09102 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09102 Formula, Drug Kobokushokyohangeninjinkanzoto Magnolia bark [DR:D06720], Ging... Medicine in Japan [BR:br08304] Formulas Formulas for stomach Antiemetic formulas D09102 Kobokushokyohangeninjinkanzoto PubChem: 96025782 ...

  9. Drug: D09059 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09059 Formula, Drug Kamishoyosangoshimotsuto Japanese angelica root [DR:D06768], P...cine in Japan [BR:br08304] Formulas Formulas for clearing heat Formulas for clearing heat D09059 *Kamishoyosangoshimotsuto Formula

  10. Drug: D09071 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09071 Formula, Drug Bukuryoinkahange Poria sclerotium [DR:D06783], (Atractylodes l...ese Medicine in Japan [BR:br08304] Formulas Formulas for stomach Antiemetic formulas D09071 Bukuryoinkahange PubChem: 96025752 ...

  11. Drug: D09118 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09118 Formula, Drug Shobaito Prunus mume fruit [DR:D09233], Zanthoxylum fruit [DR:...edicine in Japan [BR:br08304] Formulas Formulas for expelling parasites Anthelmintic formulas D09118 Shobaito PubChem: 96025798 ...

  12. Drug: D09081 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09081 Formula, Drug Tokishigyakuto Japanese angelica root [DR:D06768], Cinnamon ba...28], Glycyrrhiza [DR:D04365] Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formulas for warming the interior Formula

  13. Drug: D09068 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09068 Formula, Drug Kufugedokusan; Kufugedokuto Saposhnikovia root [DR:D06787], Bu...mulas Diaphoretic dformulas pungent in flavor and cool in property D09068 Kufugedokusan; Kufugedokuto PubChem: 96025749 ...

  14. Vitamin D and Your Child

    Science.gov (United States)

    ... 5 Things to Know About Zika & Pregnancy Vitamin D and Your Child KidsHealth > For Parents > Vitamin D ... to get it. Who's at Risk for Vitamin D Deficiency? Things like a lack of direct sunlight ...

  15. Drug: D08600 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available [HSA:1565] Genomic biomarker: CYP2D6 [HSA:1565] map07054 Antiglaucoma agents Anat...s Timolol D08600 Timolol (INN) Ophthalmic Agents Ophthalmic Antiglaucoma Agents Timolol D08600 Timolol (INN)

  16. Drug: D10292 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D10292 Mixture, Drug Niacin - lovastatin mixt; Advicor (TN) Nicotinic acid [DR:D000...er lipid modifying agents C10BA01 Lovastatin and nicotinic acid D10292 Niacin - lovastatin mixt PubChem: 163312323 ...

  17. Drug: D10274 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D10274 Mixture, Drug Propranolol hydrochloride - hydrochlorothiazide mixt; Inderide... (TN); Propranolol hydrochloride and hydrochlorothiazide (TN) Propranolol hydrochloride [DR:D00483], Hydrochlorothiazide...hiazides D10274 Propranolol hydrochloride - hydrochlorothiazide mixt PubChem: 163312305 ...

  18. Drug: D00088 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available rtisone (JP16/USP/INN) Inflammatory Bowel Disease Agents Glucocorticoids Hydrocortisone D00088 Hydrocortison...Hydrocortisone D00088 Hydrocortisone (JP16/USP/INN) Hydrocortisone D00088 Hydroco

  19. Drug: D00292 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available lammatory Bowel Disease Agents Glucocorticoids Dexamethasone D00292 Dexamethasone (...placement/Modifying (Adrenal) Dexamethasone D00292 Dexamethasone (JP16/USP/INN) Dexamethasone D00292 Dexamethasone (JP16/USP/INN) Inf

  20. Drug: D08753 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D08753 Mixture, Drug Bromelain - trypsin, crystallized mixt; Bromelains - trypsin, crystal...lized mixt; Kimotab (TN) Bromelain [DR:D03162], Trypsin, crystallized [DR:D00056] PubChem: 96025436 ...

  1. Drug: D04324 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D04324 Mixture, Drug Noscapine hydrochloride - dl-methylephedrine hydrochloride - d...ratory organ agents 222 Antitussives 2229 Others D04324 Noscapine hydrochloride - dl-methylephedrine hydrochloride - diphenhydramine hydrochloride mixt PubChem: 17398052 ...

  2. Drug: D04818 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D04818 Mixture, Drug Propitocaine hydrochloride - Epinephrine bitartrate mixt; Cita...nest (TN) Propitocaine hydrochloride [DR:D01243], Epinephrine bitartrate [DR:D02149] PubChem: 17398186 ...

  3. Drug: D08696 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D08696 Mixture, Drug Acetaminophen - ephedra herb - scopolia extract - caffeine and... sodium benzoate - magnesium oxide mixt; Asgen (TN) Acetaminophen [DR:D00217], Ephedra herb [DR:D06791], Scopolia extract

  4. Drug: D09196 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available ); Ecard LD (TN) Candesartan cilexetil [DR:D00626], Hydrochlorothiazide [DR:D00340] Antihypertensive Therape... individual organs 21 Cardiovascular agents 214 Antihypertensives 2149 Others D09

  5. Drug: D10243 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available DR:D00523], Amlodipine besilate [DR:D00615] Antihypertensive Therapeutic category: 2149 ATC code: C09DB05 En...gans 21 Cardiovascular agents 214 Antihypertensives 2149 Others D10243 Irbesartan

  6. Drug: D08054 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available CYP3A5 [HSA:1577] CYP inhibition: CYP2D6 [HSA:1565] map07030 Anxiolytics map0703...ics Antiemetics, Other Hydroxyzine D08054 Hydroxyzine (INN) Anxiolytics Anxiolytics, Other Hydroxyzine D0805

  7. Drug: D02135 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available pa [DR:D00059], Benserazide hydrochloride [DR:D01653] Antiparkinsonian [DS:H00057] Therapeutic category: 116...d sensory organs 11 Agents affecting central nervous system 116 Antiparkinsonian

  8. Drug: D09052 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available DR:D06744], Glycyrrhiza [DR:D04365] Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formulas for stomach Antidiarrheal formulas D09052 Kashokuyohito PubChem: 96025733 ...

  9. D2-tree

    DEFF Research Database (Denmark)

    Brodal, Gerth Stølting; Sioutas, Spyros; Pantazos, Kostas;

    2015-01-01

    We present a new overlay, called the Deterministic Decentralized tree (D2-tree). The D2-tree compares favorably to other overlays for the following reasons: (a) it provides matching and better complexities, which are deterministic for the supported operations; (b) the management of nodes (peers......-balancing scheme of elements into nodes is deterministic and general enough to be applied to other hierarchical tree-based overlays. This load-balancing mechanism is based on an innovative lazy weight-balancing mechanism, which is interesting in its own right....

  10. Herramientas SIG 3D

    Directory of Open Access Journals (Sweden)

    Francisco R. Feito Higueruela

    2010-04-01

    Full Text Available Applications of Geographical Information Systems on several Archeology fields have been increasing during the last years. Recent avances in these technologies make possible to work with more realistic 3D models. In this paper we introduce a new paradigm for this system, the GIS Thetrahedron, in which we define the fundamental elements of GIS, in order to provide a better understanding of their capabilities. At the same time the basic 3D characteristics of some comercial and open source software are described, as well as the application to some samples on archeological researchs

  11. RGB-D SLAM

    OpenAIRE

    García Bueno, Jorge

    2011-01-01

    This project has been developed as an implementation of a SLAM technique called GraphSLAM. This technique applies the theory of graphs to create an on-line optimization system that allows robots to map the scenario and locate themselves using a Time of Flight camera as the input source. To do that, a RGB-D system has been calibrated and used to create color 3D point clouds. With this information, the feature detector module estimates, as a first approximation, the pose of the camera. Therefor...

  12. Bootstrapping 3D fermions

    Science.gov (United States)

    Iliesiu, Luca; Kos, Filip; Poland, David; Pufu, Silviu S.; Simmons-Duffin, David; Yacoby, Ran

    2016-03-01

    We study the conformal bootstrap for a 4-point function of fermions in 3D. We first introduce an embedding formalism for 3D spinors and compute the conformal blocks appearing in fermion 4-point functions. Using these results, we find general bounds on the dimensions of operators appearing in the ψ × ψ OPE, and also on the central charge C T . We observe features in our bounds that coincide with scaling dimensions in the GrossNeveu models at large N . We also speculate that other features could coincide with a fermionic CFT containing no relevant scalar operators.

  13. Interaktiv 3D design

    DEFF Research Database (Denmark)

    Villaume, René Domine; Ørstrup, Finn Rude

    2002-01-01

    Projektet undersøger potentialet for interaktiv 3D design via Internettet. Arkitekt Jørn Utzons projekt til Espansiva blev udviklet som et byggesystem med det mål, at kunne skabe mangfoldige planmuligheder og mangfoldige facade- og rumudformninger. Systemets bygningskomponenter er digitaliseret som...... 3D elementer og gjort tilgængelige. Via Internettet er det nu muligt at sammenstille og afprøve en uendelig  række bygningstyper som  systemet blev tænkt og udviklet til....

  14. Search for the Decays B0→D(*)+D(*)-

    International Nuclear Information System (INIS)

    Using the CLEO-II data set we have searched for the decays B0→D(*)+D(*)- . We observe one candidate signal event for the decay B0→D*+D*- with an expected background of 0.022±0.011 events. This yield corresponds to a branching fraction of B(B0→D*+D*- )=[5.3+7.1-3.7(stat )±1.0(syst)]x 10-4 and an upper limit of B(B0→D*+D*- )-3 at the 90% C.L. We see no significant excess of signal above the expected background level in the other modes, and we calculate the 90% C.L.upper limits on the branching fractions to be B(B0→D*±Dminus-plus)-3 and B(B0→D+D-)-3 . copyright 1997 The American Physical Society

  15. Drug: D08477 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available onate D DERMATOLOGICALS D10 ANTI-ACNE PREPARATIONS D10A ANTI-ACNE PREPARATIONS FO...ATIONS R01A DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE R01AX Other ...R TOPICAL USE D10AD Retinoids for topical use in acne D10AD02 Retinol D08477 Retinol propionate R RESPIRATORY SYSTEM R01 NASAL PREPAR

  16. Drug: D05332 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D05332 Mixture, Drug Hydrophilic petrolatum (JP16); Petrolatum, hydrophilic (USP) W...hite beewax [DR:D04969], Stearyl alcohol [DR:D01924], Cholesterol [DR:D00040], White petrolatum [DR:D05304] ...71 Dispensing medicines 712 Ointment bases 7121 Oil bases D05332 Hydrophilic petrolatum (JP16); Petrolatum, hydrophilic (USP) CAS: 8027-64-3 PubChem: 17398285 ...

  17. Drug: D09087 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09087 Formula, Drug Soshikokito (Perilla herb [DR:D06755] | Perilla fruit [DR:D094...6905], Cinnamon bark [DR:D06712] Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formula...s for Qi Formulas for regulating Qi D09087 *Soshikokito Formulas for dampness Cough suppressant and expectorant formulas D09087 *Soshikokito PubChem: 96025767 ...

  18. Drug: D07027 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D07027 Formula, Drug Ninjinto; Richugan Ginseng [DR:D06772], Glycyrrhiza [DR:D04365...las Formulas for stomach Antidiarrheal formulas D07027 *Ninjinto; Richugan Formul...as for warming the interior Formulas for warming the interior D07027 *Ninjinto; Richugan PubChem: 51091369 ... ...itional Chinese medicines 5200 Traditional Chinese medicines D07027 Ninjinto Traditional Chinese Medicine in Japan [BR:br08304] Formu

  19. Drug: D04266 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D04266 Mixture, Drug Benzylhydrochlorothiazide - Reserpine - Carbazochrome mixt; Be...LLY ACTING C02AA Rauwolfia alkaloids C02AA52 Reserpine, combinations D04266 Benzylhydrochlorothiazide...r drugs D04266 Benzylhydrochlorothiazide - Reserpine - Carbazochrome mixt PubChem: 17398040 ... ...hyd RA (TN) Benzylhydrochlorothiazide [DR:D01246], Reserpine [DR:D00197], Carbazochrome [DR:D01864] Therapeu...orothiazide - Reserpine - Carbazochrome mixt Anatomical Therapeutic Chemical (ATC)

  20. Drug: D00540 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D00540 Drug Glycopyrronium bromide (JAN/INN); Glycopyrrolate (USP); Robinul (TN); S...an agents 225 Bronchodilators 2259 Others D00540 Glycopyrronium bromide (JAN/INN)...02 Glycopyrronium D00540 Glycopyrronium bromide (JAN/INN); Glycopyrrolate (USP) R RESPIRATORY SYSTEM R03 DRU...linergics R03BB06 Glycopyrronium bromide D00540 Glycopyrronium bromide (JAN/INN); Glycopyrrolate (USP) USP d...estinal Glycopyrrolate D00540 Glycopyrronium bromide (JAN/INN); Glycopyrrolate (USP) Target-based classifica

  1. Drug: D02136 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D02136 Mixture, Drug Ampicillin - dicloxacillin sodium mixt Ampicillin [DR:D00204],... J01CA Penicillins with extended spectrum J01CA51 Ampicillin, combinations D02136 Ampicillin - dicloxacillin...cillins D02136 Ampicillin - dicloxacillin sodium mixt J01R COMBINATIONS OF ANTIBA...CTERIALS J01RA Combinations of antibacterials J01RA01 Penicillins, combinations with other antibacterials D02136 Ampicillin - dicloxa...cillin sodium mixt PubChem: 7849197 LigandBox: D02136 ...

  2. Drug: D08697 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D08697 Mixture, Drug Platycodon fluidextract - glycyrrhiza extract - plantago herb extract - peony root extr...act - dihydrocodeine phosphate mixt; Opisezol codeine (TN) Platycodon fluidextract ...[DR:D06812], Glycyrrhiza extract [DR:D06811], Plantago herb extract [DR:D04333], Peony root extract [DR:D067... Antitussives and expectorants 2249 Others D08697 Platycodon fluidextract - glycyrrhiza extract - plantago herb extract... - peony root extract - dihydrocodeine phosphate mixt PubChem: 96025380 ...

  3. Drug: D05480 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D05480 Drug Pimecrolimus (JAN/USAN/INN); Elidel (TN) C43H68ClNO11 809.4481 810.4531...ATOLOGICAL PREPARATIONS D11AH Agents for dermatitis, excluding corticosteroids D11AH02 Pimecrolimus D05480 Pimecrolimus... (JAN/USAN/INN) USP drug classification [BR:br08302] Dermatological Agents Pimecrolimus... D05480 Pimecrolimus (JAN/USAN/INN) Immunological Agents Immune Suppressants Pimecrolimus D05480 Pimecrolimus...neurin [HSA:5530 5532 5533 5534 5535 11261 63928] [KO:K04348 K06268] Pimecrolimus [ATC:D11AH02] D05480 Pim

  4. Drug: D10519 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D10519 Mixture, Drug Rabeprazole - amoxicillin - clarithromycin mixt; Rabecure (TN)...tibiotics 619 Miscellaneous 6199 Miscellaneous D10519 Rabeprazole - amoxicillin - clarithromycin mixt ...

  5. Drug: D10520 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D10520 Mixture, Drug Rabeprazole - amoxicillin - metronidazole mixt; Rabefine (TN) ...1 Antibiotics 619 Miscellaneous 6199 Miscellaneous D10520 Rabeprazole - amoxicillin - metronidazole mixt ...

  6. Drug: D07796 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available TIONS A01A STOMATOLOGICAL PREPARATIONS A01AC Corticosteroids for local oral treatme...steroids C05AA09 Dexamethasone D07796 Dexamethasone 21-acetate D DERMATOLOGICALS D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATION...one 21-acetate D10 ANTI-ACNE PREPARATIONS D10A ANTI-ACNE PREPARATIONS FOR TOPICAL USE D10AA Corticosteroids,... combinations for treatment of acne D10AA03 Dexamethasone D07796 Dexamethasone 21-acetate H SYSTEMIC HORMONAL PREPARATION...asone 21-acetate R RESPIRATORY SYSTEM R01 NASAL PREPARATIONS R01A DECONGESTANTS AND OTHER NASAL PREPARATIONS

  7. Drug: D07802 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available RY TRACT AND METABOLISM A01 STOMATOLOGICAL PREPARATIONS A01A STOMATOLOGICAL PREPARATION...hate D DERMATOLOGICALS D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AB Co...sone D07802 Dexamethasone phosphate D10 ANTI-ACNE PREPARATIONS D10A ANTI-ACNE PREPARATION...7802 Dexamethasone phosphate H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS H02 CORTICOST...orticoids H02AB02 Dexamethasone D07802 Dexamethasone phosphate R RESPIRATORY SYSTEM R01 NASAL PREPARATIONS R

  8. Drug: D04814 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D04814 Mixture, Drug Ethyl aminobenzoate - p-butylaminobenzoyldiethylaminoethyl hyd...rochloride mixt; Neozalocaine (TN) Ethyl aminobenzoate [DR:D00552], p-Butylaminobenzoyldiethylaminoethyl hyd

  9. Drug: D06315 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D06315 Drug Fluticasone furoate (JAN/USAN/INN); Veramyst (TN) C27H29F3O6S 538.1637 ... nasal agents 1329 Others D06315 Fluticasone furoate (JAN/USAN/INN) Anatomical Th...REPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AC Corticosteroids, potent (group III) D07AC17 Fluticasone D06315 Fluticaso...01A DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE R01AD Corticosteroids R01AD12 Fluticasone furoate D06315 Fluticaso...R OBSTRUCTIVE AIRWAY DISEASES, INHALANTS R03BA Glucocorticoids R03BA05 Fluticasone D06315 Fluticasone furoat

  10. Drug: D07981 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D07981 Drug Fluticasone (INN); Fluticaps (TN) C22H27F3O4S 444.1582 444.5076 D07981....TICOSTEROIDS, DERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AC Corticosteroids, potent (group III) D07AC17 Fluticaso...ne D07981 Fluticasone (INN) R RESPIRATORY SYSTEM R01 NASAL P...REPARATIONS R01A DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE R01AD Corticosteroids R01AD08 Fluticasone D07981 Fluticas...E AIRWAY DISEASES, INHALANTS R03BA Glucocorticoids R03BA05 Fluticasone D07981 Fluticaso

  11. Drug: D08330 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available Immunological Agents Immune Suppressants Penicillamine D08330 Penicillamine hydrochloride Therapeutic Nutr...ients/Minerals/Electrolytes Electrolyte/Mineral Modifiers Penicillamine D08330 Peni

  12. Drug: D01596 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D01596 Drug Oxytetracycline hydrochloride (JP16/USP); OTC; Terramycin (TN) C22H24N2...s 2760 Antibiotics D01596 Oxytetracycline hydrochloride (JP16/USP) Anatomical Therapeutic Chemical (ATC) cla...FOR DERMATOLOGICAL USE D06A ANTIBIOTICS FOR TOPICAL USE D06AA Tetracycline and derivatives D06AA03 Oxytetracycline D01596 Oxytetracyc...OMBINATIONS WITH CORTICOSTEROIDS G01AA Antibiotics G01AA07 Oxytetracycline D01596 Oxytetracycline hydrochlor...A Tetracyclines J01AA06 Oxytetracycline D01596 Oxytetracycline hydrochloride (JP16/USP) S SENSORY ORGANS S01

  13. Drug: D00205 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D00205 Drug Oxytetracycline (JAN/USP/INN); Oxytetracycline dihydrate; OTC; Terramyc... FOR DERMATOLOGICAL USE D06A ANTIBIOTICS FOR TOPICAL USE D06AA Tetracycline and derivatives D06AA03 Oxytetracycline D00205 Oxytetracy...S WITH CORTICOSTEROIDS G01AA Antibiotics G01AA07 Oxytetracycline D00205 Oxytetracycline (JAN/USP/INN) J ANTI...S J01AA Tetracyclines J01AA06 Oxytetracycline D00205 Oxytetracycline (JAN/USP/INN) S SENSORY ORGANS S01 OPHT...HALMOLOGICALS S01A ANTIINFECTIVES S01AA Antibiotics S01AA04 Oxytetracycline D00205 Oxytetracycline (JAN/USP/

  14. Drug: D05840 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D05840 Drug Silver nitrate, toughened (USP) 2Ag. NO3. Cl 310.7669 313.1943 D05840.g...if Caustic ATC code: D08AL01 S01AX02 A mixture of Silver nitrate [DR:D01730] and Silver chloride Anatomical ...08A ANTISEPTICS AND DISINFECTANTS D08AL Silver compounds D08AL01 Silver nitrate D05840 Silver... antiinfectives S01AX02 Silver compounds D05840 Silver nitrate, toughened (USP) CAS: 8007-31-6 PubChem: 4720... nitrate, toughened (USP) S SENSORY ORGANS S01 OPHTHALMOLOGICALS S01A ANTIINFECTIVES S01AX Other

  15. Drug: D06700 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available 4], (Atractylodes rhizome [DR:D06780] | Atractylodes lancea rhizome [DR:D06752]) Cold constitution...; Weak constitution; Disorder of menstruation; Dysmenorrhea; Climacteric disturbance Therap

  16. Drug: D01327 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D01327 Drug Diflorasone diacetate (JAN/USP); Florone (TN); Psorcon (TN) C26H32F2O7 ...A CORTICOSTEROIDS, PLAIN D07AC Corticosteroids, potent (group III) D07AC10 Diflorasone D01327 Diflorasone di...acetate (JAN/USP) USP drug classification [BR:br08302] Hormonal Agents, Stimulant/Replacement/Modifying (Adrenal) Diflor...asone D01327 Diflorasone diacetate (JAN/USP) Diflorasone D01327 Diflor... receptors 3-Ketosteroid receptor glucocorticoid receptor [HSA:2908] [KO:K05771] Diflorasone [ATC:D07AC10] D01327 Diflor

  17. Drug: D04099 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D04099 Mixture, Drug Erythromycin lactobionate - colistin sodium methanesulfonate m...Others D04099 Erythromycin lactobionate - colistin sodium methanesulfonate mixt PubChem: 17398025 ...

  18. Drug: D08144 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D08144 Drug Loperamide (INN); Diamide (TN) C29H33ClN2O2 476.2231 477.0375 D08144.gi... Antipropulsives A07DA03 Loperamide D08144 Loperamide (INN) USP drug classification [BR:br08302] Gastrointes...tinal Agents Gastrointestinal Agents, Other Loperamide D08144 Loperamide (INN) Ta...d receptor [HSA:4988] [KO:K04215] Loperamide D08144 Loperamide (INN) CAS: 53179-11-6 PubChem: 96024834 DrugB...ank: DB00836 LigandBox: D08144 NIKKAJI: J10.085D ATOM 34 1 C8x C 21.7000 -23.1700

  19. Drug: D00985 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available mmatory Bowel Disease Agents Glucocorticoids Triamcinolone D00985 Triamcinolone hex...00985 Triamcinolone hexacetonide (USP/INN) Triamcinolone D00985 Triamcinolone hexacetonide (USP/INN) Infla

  20. Drug: D08413 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available INTESTINAL ANTIINFLAMMATORY AGENTS A07EA Corticosteroids acting locally A07EA01 Prednisolone D08413 Prednis...RHOIDS AND ANAL FISSURES FOR TOPICAL USE C05AA Corticosteroids C05AA04 Prednisolo...TIONS D07A CORTICOSTEROIDS, PLAIN D07AA Corticosteroids, weak (group I) D07AA03 Prednisolone D08413 Predniso...lone sodium metazoate (USAN) D07X CORTICOSTEROIDS, OTHER COMBINATIONS D07XA Corticosteroids, weak, other com...THER NASAL PREPARATIONS FOR TOPICAL USE R01AD Corticosteroids R01AD02 Prednisolone D08413 Prednisolone sodiu

  1. Drug: D00982 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available INFLAMMATORY AGENTS A07EA Corticosteroids acting locally A07EA01 Prednisolone D00... HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE C05AA Corticosteroids C05AA04 Prednisolone D00982 Prednisolon...ATIONS D07A CORTICOSTEROIDS, PLAIN D07AA Corticosteroids, weak (group I) D07AA03 Prednisolone D00982 Prednis...olone tebutate (JAN/USP) D07X CORTICOSTEROIDS, OTHER COMBINATIONS D07XA Corticosteroids, weak, other combina... RESPIRATORY SYSTEM R01 NASAL PREPARATIONS R01A DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE R01AD Corticosteroids

  2. Drug: D01357 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available NFLAMMATORY AGENTS A07EA Corticosteroids acting locally A07EA04 Betamethasone D01...OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE C05AA Corticosteroids C05AA05 Betamethasone D01357 Betameth...ROIDS, PLAIN D07AC Corticosteroids, potent (group III) D07AC01 Betamethasone D013...57 Betamethasone valerate (JP16/USP) D07X CORTICOSTEROIDS, OTHER COMBINATIONS D07XC Corticosteroids, potent,...NS FOR TOPICAL USE R01AD Corticosteroids R01AD06 Betamethasone D01357 Betamethaso

  3. Drug: D02156 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available FLAMMATORY AGENTS A07EA Corticosteroids acting locally A07EA01 Prednisolone D0215...S C05A AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE C05AA Corticosteroids C05AA04 P...) D DERMATOLOGICALS D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AA Corticosteroids...nate (USP) D07X CORTICOSTEROIDS, OTHER COMBINATIONS D07XA Corticosteroids, weak, other combinations D07XA02 ...REPARATIONS R01A DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE R01AD Corticosteroids R01AD02 Pr

  4. Drug: D02032 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available ALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS A07E INTESTINAL ANTIINFLAMMATORY AGENTS A07EA Corticosteroids...SURES FOR TOPICAL USE C05AA Corticosteroids C05AA05 Betamethasone D02032 Betamethasone butyrate propionate (...JAN) D DERMATOLOGICALS D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AC Corticosteroids...rate propionate (JAN) D07X CORTICOSTEROIDS, OTHER COMBINATIONS D07XC Corticosteroids, potent, other combinat...FOR TOPICAL USE R01AD Corticosteroids R01AD06 Betamethasone D02032 Betamethasone

  5. Drug: D02286 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available ANAL FISSURES FOR TOPICAL USE C05AA Corticosteroids C05AA05 Betamethasone D02286 Betamethasone benzoate (US...OSTEROIDS, PLAIN D07AC Corticosteroids, potent (group III) D07AC01 Betamethasone D02286 Betamethasone benzoa...te (USP) D07X CORTICOSTEROIDS, OTHER COMBINATIONS D07XC Corticosteroids, potent, other combinations D07XC01 ...M R01 NASAL PREPARATIONS R01A DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE R01AD Corticosteroids...MATORY AGENTS S01BA Corticosteroids, plain S01BA06 Betamethasone D02286 Betametha

  6. Drug: D01510 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available CAL PREPARATIONS A01AC Corticosteroids for local oral treatment A01AC02 Dexamethasone D01510 Dexamethasone m...ENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE C05AA Corticosteroids C05AA09 Dexamethas...L PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AB Corticosteroids, moderately pote..., OTHER COMBINATIONS D07XB Corticosteroids, moderately potent, other combinations D07XB05 Dexamethasone D015...NTI-ACNE PREPARATIONS FOR TOPICAL USE D10AA Corticosteroids, combinations for treatment of acne D10AA03 Dexa

  7. Drug: D00977 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available T AND METABOLISM A01 STOMATOLOGICAL PREPARATIONS A01A STOMATOLOGICAL PREPARATIONS A01AC Corticosteroids for ...MATORY AGENTS A07EA Corticosteroids acting locally A07EA02 Hydrocortisone D00977 Hydrocortisone sodium phosp...L FISSURES FOR TOPICAL USE C05AA Corticosteroids C05AA01 Hydrocortisone D00977 Hy...D07A CORTICOSTEROIDS, PLAIN D07AA Corticosteroids, weak (group I) D07AA02 Hydrocortisone D00977 Hydrocortiso...ne sodium phosphate (JP16/USP) D07X CORTICOSTEROIDS, OTHER COMBINATIONS D07XA Corticosteroids

  8. Drug: D01402 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available TIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS A07E INTESTINAL ANTIINFLAMMATORY AGENTS A07EA Corticosteroids...SSURES FOR TOPICAL USE C05AA Corticosteroids C05AA05 Betamethasone D01402 Betamethasone acetate (JAN/USP) D ...OIDS, PLAIN D07AC Corticosteroids, potent (group III) D07AC01 Betamethasone D01402 Betamethasone acetate (JA...N/USP) D07X CORTICOSTEROIDS, OTHER COMBINATIONS D07XC Corticosteroids, potent, other combinations D07XC01 Be...YSTEM R01 NASAL PREPARATIONS R01A DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE R01AD Corticosteroids

  9. Drug: D03301 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available RRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS A07E INTESTINAL ANTIINFLAMMATORY AGENTS A07EA Corticosteroids...URES FOR TOPICAL USE C05AA Corticosteroids C05AA04 Prednisolone D03301 Prednisolone valerate acetate (JAN) D... DERMATOLOGICALS D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AA Corticosteroids... (JAN) D07X CORTICOSTEROIDS, OTHER COMBINATIONS D07XA Corticosteroids, weak, other combinations D07XA02 Pred...RY SYSTEM R01 NASAL PREPARATIONS R01A DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE R01AD Corticosteroids

  10. The 6D superswirl

    Energy Technology Data Exchange (ETDEWEB)

    Parameswaran, S.L. [Centre for Mathematical Sciences, DAMTP, University of Cambridge, Cambridge CB3 0WA (United Kingdom); Perimeter Institute for Theoretical Physics, 31 Caroline St. N., Waterloo, ON, N2L 2Y5 (Canada); Tasinato, G. [Rudolf Peierls Centre for Theoretical Physics, Oxford University, 1 Keble Road, Oxford OX1 3NP (United Kingdom)]. E-mail: tasinato@thphys.ox.ac.uk; Zavala, I. [IPPP, Physics Department, Durham University, Durham DH1 3LE (United Kingdom)

    2006-03-06

    We present a novel supersymmetric solution to a nonlinear sigma model coupled to supergravity. The solution represents a static, supersymmetric, codimension-two object, which is different to the familiar cosmic strings. In particular, we consider 6D chiral gauged supergravity, whose spectrum contains a number of hypermultiplets. The scalar components of the hypermultiplet are charged under a gauge field, and supersymmetry implies that they experience a simple paraboloid-like (or 2D infinite well) potential, which is minimised when they vanish. Unlike conventional vortices, the energy density of our configuration is not localized to a string-like core. The solutions have two timelike singularities in the internal manifold, which provide the necessary boundary conditions to ensure that the scalars do not lie at the minimum of their potential. The 4D spacetime is flat, and the solution is a continuous deformation of the so-called 'rugby ball' solution, which has been studied in the context of the cosmological constant problem. It represents an unexpected class of supersymmetric solutions to the 6D theory, which have gravity, gauge fluxes and hyperscalars all active in the background.

  11. Ma(d)skulinitet

    DEFF Research Database (Denmark)

    Leer, Jonatan

    , forstås i forhold til en større revision af den maskuline identitet i den aktuelle (flydende) modernitet? Afhandlingen er informeret af poststrukturalistisk kønsteori og har med begrebet Ma(d)skulinitet ønsket at fange afhandlingens grundlæggende forståelse af madlavning og ”mandelavning” som to gensidigt...

  12. Bruno D'Amicis

    Index Scriptorium Estoniae

    2008-01-01

    Bioloogist ja loodusemehest itaalia fotograafist Bruno D'Amicist, kes vaatamata oma noorusele (28), on võtnud ette suuri projekte - Berliini metropolis elutsevate loomade jäädvustamine, Kesk-Euroopa viimase metsiku mägismaa päästmine Slovakkias. Fotod, õigemini keskkonnaportreed on pärit seeriast "Intimate landscapes"

  13. Course d'Orientation

    CERN Multimedia

    Course d'Orientation

    2012-01-01

      Coupe de printemps La deuxième étape de la coupe de printemps organisée par le club d’orientation du CERN s’est déroulée le samedi 21 avril dans la forêt de Pougny-Challex. étant donné le temps très humide qui domine depuis début avril, les coureurs ne pouvaient trouver qu’un terrain gras et trempé, mais cela fait partie des défis de la course d’orientation. Le parcours technique long a été remporté par Yvan Balliot, CO Annecy en 51:18 devant Jean-Charles Baritaux en 56:21 et Bruno Barge, CO CERN en 59:39. La prochaine CO populaire se courra à Vulbens le samedi 28 avril. Les inscriptions et les départs se feront entre 13h et 15h. A noter les courses en mai : • Samedi 5 mai : Trelex • Samedi 12 mai : Chancy / Valleiry • Samedi 19 mai : Lausan...

  14. Vann on 3D

    Index Scriptorium Estoniae

    2006-01-01

    Aivar Habakukest, kes on 2005. aastast AS Balteco peadisainer. A. Habakukk AS Balteco tootegruppidest, tööstusdisainist. A. Habakuke projektid, objektid ja tööd. Ill.: värv. foto A. Habakukest, tema disainitud AS Balteco vann Metro

  15. 3D terrestrisk laserscanning

    DEFF Research Database (Denmark)

    Christoffersen, Morten Thoft

    2004-01-01

    Forfatteren til denne artikel er pr. juni 2004 påbegyndt et ph.d.-studie i terrestrisk laserscanning ved Aalborg Universitet, Institut for Samfundsudvikling og Planlægning. De næste 3 år skal derfor benyttes til forskning inden for dette fagfelt....

  16. Tangible 3D Modelling

    DEFF Research Database (Denmark)

    Hejlesen, Aske K.; Ovesen, Nis

    2012-01-01

    This paper presents an experimental approach to teaching 3D modelling techniques in an Industrial Design programme. The approach includes the use of tangible free form models as tools for improving the overall learning. The paper is based on lecturer and student experiences obtained through facil...

  17. Hybrid R&D

    NARCIS (Netherlands)

    S. Goyal (Sanjeev); A. Konovalov; J.L. Moraga-Gonzalez (José Luis)

    2003-01-01

    textabstractWe develop a model of R&D competition and collaboration in which individual firms carry out independent in-house research and also undertake joint research projects with other firms. We examine the impact of collaboration on in-house research and explore the circumstances under which a h

  18. 3D monitor

    OpenAIRE

    Szkandera, Jan

    2009-01-01

    Tato bakalářská práce se zabývá návrhem a realizací systému, který umožní obraz scény zobrazovaný na ploše vnímat prostorově. Prostorové vnímání 2D obrazové informace je umožněno jednak stereopromítáním a jednak tím, že se obraz mění v závislosti na poloze pozorovatele. Tato práce se zabývá hlavně druhým z těchto problémů. This Bachelor's thesis goal is to design and realize system, which allows user to perceive 2D visual information as three-dimensional. 3D visual preception of 2D image i...

  19. 3D Harmonic Echocardiography:

    NARCIS (Netherlands)

    M.M. Voormolen

    2007-01-01

    textabstractThree dimensional (3D) echocardiography has recently developed from an experimental technique in the ’90 towards an imaging modality for the daily clinical practice. This dissertation describes the considerations, implementation, validation and clinical application of a unique

  20. Substitutional 4d and 5d impurities in graphene.

    Science.gov (United States)

    Alonso-Lanza, Tomás; Ayuela, Andrés; Aguilera-Granja, Faustino

    2016-08-21

    We describe the structural and electronic properties of graphene doped with substitutional impurities of 4d and 5d transition metals. The adsorption energies and distances for 4d and 5d metals in graphene show similar trends for the later groups in the periodic table, which are also well-known characteristics of 3d elements. However, along earlier groups the 4d impurities in graphene show very similar adsorption energies, distances and magnetic moments to the 5d ones, which can be related to the influence of the 4d and 5d lanthanide contraction. Surprisingly, within the manganese group, the total magnetic moment of 3 μB for manganese is reduced to 1 μB for technetium and rhenium. We find that compared with 3d elements, the larger size of the 4d and 5d elements causes a high degree of hybridization with the neighbouring carbon atoms, reducing spin splitting in the d levels. It seems that the magnetic adjustment of graphene could be significantly different if 4d or 5d impurities are used instead of 3d impurities. PMID:27439363

  1. Vitamin D deficiency in Europe

    DEFF Research Database (Denmark)

    Cashman, Kevin D.; Dowling, Kirsten G; Škrabáková, Zuzana;

    2016-01-01

    BACKGROUND: Vitamin D deficiency has been described as being pandemic, but serum 25-hydroxyvitamin D [25(OH)D] distribution data for the European Union are of very variable quality. The NIH-led international Vitamin D Standardization Program (VDSP) has developed protocols for standardizing existing...... 25(OH)D values from national health/nutrition surveys. OBJECTIVE: This study applied VDSP protocols to serum 25(OH)D data from representative childhood/teenage and adult/older adult European populations, representing a sizable geographical footprint, to better quantify the prevalence of vitamin D...... sera. These data were combined with standardized serum 25(OH)D data from 4 previously standardized studies (for a total n = 55,844). Prevalence estimates of vitamin D deficiency [using various serum 25(OH)D thresholds] were generated on the basis of standardized 25(OH)D data. RESULTS: An overall pooled...

  2. D/antiD Dark Energy in String Warped Compactification

    CERN Document Server

    Piao, Y S

    2005-01-01

    We study the evolution of relic D3-branes in the bulk after D3/antiD3-brane inflation in string warped compactification. The motion of D3-branes can be frozen under certain condition during radiation/matter domination, and will be relaxed until D3/antiD3-branes potential starts to dominate the universe at late time. These relic D3-branes will be attract and move toward to antiD3-branes with the role of uplifting AdS minimum to dS's near the apex of throats. This provides a rapid channel inducing to the subsiding of dS vacuum with observed value. We discuss the required parameter spaces and calculate the decay time for this process.

  3. Exclusive initial-state-radiation production of the D Dmacr , D* Dmacr , and D* Dmacr * systems

    Science.gov (United States)

    Aubert, B.; Karyotakis, Y.; Lees, J. P.; Poireau, V.; Prencipe, E.; Prudent, X.; Tisserand, V.; Garra Tico, J.; Grauges, E.; Lopez, L.; Palano, A.; Pappagallo, M.; Eigen, G.; Stugu, B.; Sun, L.; Battaglia, M.; Brown, D. N.; Kerth, L. T.; Kolomensky, Yu. G.; Lynch, G.; Osipenkov, I. L.; Tackmann, K.; Tanabe, T.; Hawkes, C. M.; Soni, N.; Watson, A. T.; Koch, H.; Schroeder, T.; Asgeirsson, D. J.; Fulsom, B. G.; Hearty, C.; Mattison, T. S.; McKenna, J. A.; Barrett, M.; Khan, A.; Randle-Conde, A.; Blinov, V. E.; Bukin, A. D.; Buzykaev, A. R.; Druzhinin, V. P.; Golubev, V. B.; Onuchin, A. P.; Serednyakov, S. I.; Skovpen, Yu. I.; Solodov, E. P.; Todyshev, K. Yu.; Bondioli, M.; Curry, S.; Eschrich, I.; Kirkby, D.; Lankford, A. J.; Lund, P.; Mandelkern, M.; Martin, E. C.; Stoker, D. P.; Abachi, S.; Buchanan, C.; Atmacan, H.; Gary, J. W.; Liu, F.; Long, O.; Vitug, G. M.; Yasin, Z.; Zhang, L.; Sharma, V.; Campagnari, C.; Hong, T. M.; Kovalskyi, D.; Mazur, M. A.; Richman, J. D.; Beck, T. W.; Eisner, A. M.; Heusch, C. A.; Kroseberg, J.; Lockman, W. S.; Martinez, A. J.; Schalk, T.; Schumm, B. A.; Seiden, A.; Winstrom, L. O.; Cheng, C. H.; Doll, D. A.; Echenard, B.; Fang, F.; Hitlin, D. G.; Narsky, I.; Piatenko, T.; Porter, F. C.; Andreassen, R.; Mancinelli, G.; Meadows, B. T.; Mishra, K.; Sokoloff, M. D.; Bloom, P. C.; Ford, W. T.; Gaz, A.; Hirschauer, J. F.; Nagel, M.; Nauenberg, U.; Smith, J. G.; Wagner, S. R.; Ayad, R.; Soffer, A.; Toki, W. H.; Wilson, R. J.; Feltresi, E.; Hauke, A.; Jasper, H.; Karbach, M.; Merkel, J.; Petzold, A.; Spaan, B.; Wacker, K.; Kobel, M. J.; Nogowski, R.; Schubert, K. R.; Schwierz, R.; Volk, A.; Bernard, D.; Bonneaud, G. R.; Latour, E.; Verderi, M.; Clark, P. J.; Playfer, S.; Watson, J. E.; Andreotti, M.; Bettoni, D.; Bozzi, C.; Calabrese, R.; Cecchi, A.; Cibinetto, G.; Franchini, P.; Luppi, E.; Negrini, M.; Petrella, A.; Piemontese, L.; Santoro, V.; Baldini-Ferroli, R.; Calcaterra, A.; de Sangro, R.; Finocchiaro, G.; Pacetti, S.; Patteri, P.; Peruzzi, I. M.; Piccolo, M.; Rama, M.; Zallo, A.; Contri, R.; Guido, E.; Lo Vetere, M.; Monge, M. R.; Passaggio, S.; Patrignani, C.; Robutti, E.; Tosi, S.; Chaisanguanthum, K. S.; Morii, M.; Adametz, A.; Marks, J.; Schenk, S.; Uwer, U.; Bernlochner, F. U.; Klose, V.; Lacker, H. M.; Bard, D. J.; Dauncey, P. D.; Tibbetts, M.; Behera, P. K.; Chai, X.; Charles, M. J.; Mallik, U.; Cochran, J.; Crawley, H. B.; Dong, L.; Meyer, W. T.; Prell, S.; Rosenberg, E. I.; Rubin, A. E.; Gao, Y. Y.; Gritsan, A. V.; Guo, Z. J.; Arnaud, N.; Béquilleux, J.; D'Orazio, A.; Davier, M.; da Costa, J. Firmino; Grosdidier, G.; Le Diberder, F.; Lepeltier, V.; Lutz, A. M.; Pruvot, S.; Roudeau, P.; Schune, M. H.; Serrano, J.; Sordini, V.; Stocchi, A.; Wormser, G.; Lange, D. J.; Wright, D. M.; Bingham, I.; Burke, J. P.; Chavez, C. A.; Fry, J. R.; Gabathuler, E.; Gamet, R.; Hutchcroft, D. E.; Payne, D. J.; Touramanis, C.; Bevan, A. J.; Clarke, C. K.; di Lodovico, F.; Sacco, R.; Sigamani, M.; Cowan, G.; Paramesvaran, S.; Wren, A. C.; Brown, D. N.; Davis, C. L.; Denig, A. G.; Fritsch, M.; Gradl, W.; Hafner, A.; Alwyn, K. E.; Bailey, D.; Barlow, R. J.; Jackson, G.; Lafferty, G. D.; West, T. J.; Yi, J. I.; Anderson, J.; Chen, C.; Jawahery, A.; Roberts, D. A.; Simi, G.; Tuggle, J. M.; Dallapiccola, C.; Salvati, E.; Saremi, S.; Cowan, R.; Dujmic, D.; Fisher, P. H.; Henderson, S. W.; Sciolla, G.; Spitznagel, M.; Yamamoto, R. K.; Zhao, M.; Patel, P. M.; Robertson, S. H.; Schram, M.; Lazzaro, A.; Lombardo, V.; Palombo, F.; Stracka, S.; Bauer, J. M.; Cremaldi, L.; Godang, R.; Kroeger, R.; Summers, D. J.; Zhao, H. W.; Simard, M.; Taras, P.; Nicholson, H.; de Nardo, G.; Lista, L.; Monorchio, D.; Onorato, G.; Sciacca, C.; Raven, G.; Snoek, H. L.; Jessop, C. P.; Knoepfel, K. J.; Losecco, J. M.; Wang, W. F.; Corwin, L. A.; Honscheid, K.; Kagan, H.; Kass, R.; Morris, J. P.; Rahimi, A. M.; Regensburger, J. J.; Sekula, S. J.; Wong, Q. K.; Blount, N. L.; Brau, J.; Frey, R.; Igonkina, O.; Kolb, J. A.; Lu, M.; Rahmat, R.; Sinev, N. B.; Strom, D.; Strube, J.; Torrence, E.; Castelli, G.; Gagliardi, N.; Margoni, M.; Morandin, M.; Posocco, M.; Rotondo, M.; Simonetto, F.; Stroili, R.; Voci, C.; Del Amo Sanchez, P.; Ben-Haim, E.; Briand, H.; Chauveau, J.; Hamon, O.; Leruste, Ph.; Ocariz, J.; Perez, A.; Prendki, J.; Sitt, S.; Gladney, L.; Biasini, M.; Manoni, E.; Angelini, C.; Batignani, G.; Bettarini, S.; Calderini, G.; Carpinelli, M.; Cervelli, A.; Forti, F.; Giorgi, M. A.; Lusiani, A.; Marchiori, G.; Morganti, M.; Neri, N.; Paoloni, E.; Rizzo, G.; Walsh, J. J.; Pegna, D. Lopes; Lu, C.; Olsen, J.; Smith, A. J. S.; Telnov, A. V.; Anulli, F.; Baracchini, E.; Cavoto, G.; Faccini, R.; Ferrarotto, F.; Ferroni, F.; Gaspero, M.; Jackson, P. D.; Gioi, L. Li; Mazzoni, M. A.; Morganti, S.; Piredda, G.; Renga, F.

    2009-05-01

    We perform a study of the exclusive production of D Dmacr , D* Dmacr , and D* Dmacr * in initial-state-radiation events, from e+e- annihilations at a center-of-mass energy near 10.58 GeV, to search for charmonium and possible new resonances. The data sample corresponds to an integrated luminosity of 384fb-1 and was recorded by the BABAR experiment at the PEP-II storage rings. The D Dmacr , D* Dmacr , and D* Dmacr * mass spectra show clear evidence of several ψ resonances. However, there is no evidence for Y(4260)→D* Dmacr or Y(4260)→D* Dmacr *.

  4. D and D Knowledge Management Information Tool - 2012 - 12106

    Energy Technology Data Exchange (ETDEWEB)

    Upadhyay, H.; Lagos, L.; Quintero, W.; Shoffner, P. [Applied Research Center, Florida International University, Miami. FL 33174 (United States); DeGregory, J. [Office of D and D and Facility Engineering, Environmental Management, Department of Energy (United States)

    2012-07-01

    Deactivation and decommissioning (D and D) work is a high priority activity across the Department of Energy (DOE) complex. Subject matter specialists (SMS) associated with the different ALARA (As-Low-As-Reasonably-Achievable) Centers, DOE sites, Energy Facility Contractors Group (EFCOG) and the D and D community have gained extensive knowledge and experience over the years in the cleanup of the legacy waste from the Manhattan Project. To prevent the D and D knowledge and expertise from being lost over time from the evolving and aging workforce, DOE and the Applied Research Center (ARC) at Florida International University (FIU) proposed to capture and maintain this valuable information in a universally available and easily usable system. D and D KM-IT provides single point access to all D and D related activities through its knowledge base. It is a community driven system. D and D KM-IT makes D and D knowledge available to the people who need it at the time they need it and in a readily usable format. It uses the World Wide Web as the primary source for content in addition to information collected from subject matter specialists and the D and D community. It brings information in real time through web based custom search processes and its dynamic knowledge repository. Future developments include developing a document library, providing D and D information access on mobile devices for the Technology module and Hotline, and coordinating multiple subject matter specialists to support the Hotline. The goal is to deploy a high-end sophisticated and secured system to serve as a single large knowledge base for all the D and D activities. The system consolidates a large amount of information available on the web and presents it to users in the simplest way possible. (authors)

  5. D and D Knowledge Management Information Tool - 2012 - 12106

    International Nuclear Information System (INIS)

    Deactivation and decommissioning (D and D) work is a high priority activity across the Department of Energy (DOE) complex. Subject matter specialists (SMS) associated with the different ALARA (As-Low-As-Reasonably-Achievable) Centers, DOE sites, Energy Facility Contractors Group (EFCOG) and the D and D community have gained extensive knowledge and experience over the years in the cleanup of the legacy waste from the Manhattan Project. To prevent the D and D knowledge and expertise from being lost over time from the evolving and aging workforce, DOE and the Applied Research Center (ARC) at Florida International University (FIU) proposed to capture and maintain this valuable information in a universally available and easily usable system. D and D KM-IT provides single point access to all D and D related activities through its knowledge base. It is a community driven system. D and D KM-IT makes D and D knowledge available to the people who need it at the time they need it and in a readily usable format. It uses the World Wide Web as the primary source for content in addition to information collected from subject matter specialists and the D and D community. It brings information in real time through web based custom search processes and its dynamic knowledge repository. Future developments include developing a document library, providing D and D information access on mobile devices for the Technology module and Hotline, and coordinating multiple subject matter specialists to support the Hotline. The goal is to deploy a high-end sophisticated and secured system to serve as a single large knowledge base for all the D and D activities. The system consolidates a large amount of information available on the web and presents it to users in the simplest way possible. (authors)

  6. Drug: D01768 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available oxil (TN) C17H28N2O3. HCl 344.1867 344.8768 D01768.gif Anesthetic [topical] Therapeutic category: 1313 ATC c...ANTIHISTAMINES, ANESTHETICS, ETC. D04AB Anesthetics for topical use D04AB03 Oxybuprocaine D01768 Oxybuprocai

  7. Drug: D00739 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available ) C17H27NO3. HCl 329.1758 329.8621 D00739.gif Anesthetic [topical] ATC code: C05AD07 D04AB07 Anatomical Ther...HISTAMINES, ANESTHETICS, ETC. D04A ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. D04AB Anesthetics for topic

  8. Drug: D00108 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available ound Iodine glycerin [DR:D04412], Dental iodine glycerin [DR:D04880], Iodine tincture [DR:D04723] Therapeuti...0108 Iodine (JP16/USP) 27 Dental preparations 279 Miscellaneous 2790 Miscellaneous D00108 Iodine (JP16/USP)

  9. Drug: D08582 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D08582 Drug Thiamphenicol glycinate acetylcysteinate; Fluimucil antibiotic (TN) C19...CTERIALS FOR SYSTEMIC USE J01B AMPHENICOLS J01BA Amphenicols J01BA02 Thiamphenicol D08582 Thiamphenicol glycinate acetylcystein...02] D08582 Thiamphenicol glycinate acetylcysteinate CAS: 75639-30-4 PubChem: 96025266 LigandBox: D08582 NIKK

  10. Drug: D03172 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D03172 Drug Bucrylate (USAN); Bucrilate (INN) C8H11NO2 153.079 153.1784 D03172.gif Surgical aid [tissue adhe...sive] CAS: 1069-55-2 PubChem: 17397326 LigandBox: D03172 NIKKAJI: J7.235D ATOM 11 1

  11. Drug: D07585 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D07585 Mixture, Drug Isopropylantipyrine - ergotamine tartrate - anhydrous caffeine... mixt; Cleamine A (TN) Isopropylantipyrine [DR:D01380], Ergotamine tartrate [DR:D00679], Anhydrous caffeine ...ers D07585 Isopropylantipyrine - ergotamine tartrate - anhydrous caffeine mixt PubChem: 96024447 ...

  12. Vitamin D and bone health

    International Nuclear Information System (INIS)

    Vitamin D plays an essential role in maintaining a healthy mineralized skeleton for most land vertebrates including humans. Sunlight causes the photoproduction of vitamin D3 in the skin. Once formed, vitamin D3 is metabolized sequentially in the liver and kidney to 1,25-dihydroxyvitamin D. The major biological function of 1,25-dihydroxyvitamin D is to keep the serum calcium and phosphorus concentrations within the normal range to maintain essential cellular functions and to promote mineralization of the skeleton. Most foods do not contain any vitamin D. Foods fortified with vitamin D have a variable amount present and cannot be depended on as a sole source of vitamin D nutrition. Exposure to sunlight provides most humans with their vitamin D requirement. Aging, sunscreen use and the change in the zenith angle of the sun can dramatically affect the cutaneous production of vitamin D3. Vitamin D insufficiency and vitamin D deficiency is now being recognized as a major cause of metabolic bone disease in the elderly. Vitamin D deficiency not only causes osteomalacia but can exacerbate osteoporosis. It is generally accepted that an increase in calcium intake to 1000-1500 mg/d along with an adequate source of vitamin D of at least 400 IU/d is important for maintaining good bone health

  13. Drug: D00008 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available A01 STOMATOLOGICAL PREPARATIONS A01A STOMATOLOGICAL PREPARATIONS A01AB Antiinfectives and antiseptics for lo...ide (USP) D DERMATOLOGICALS D08 ANTISEPTICS AND DISINFECTANTS D08A ANTISEPTICS AND DISINFECTANTS D08AX Other antiseptic

  14. Drug: D06935 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D06935 Formula, Drug Kyukikyogaito Japanese angelica root [DR:D06768], Peony root [...itional Chinese medicines D06935 Kyukikyogaito Traditional Chinese Medicine in Japan [BR:br08304] Formulas F...ormulas for blood Formulas for replenishing blood D06935 Kyukikyogaito PubChem: 51091277 ...

  15. Drug: D00407 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available mical Therapeutic Chemical (ATC) classification [BR:br08303] D DERMATOLOGICALS D07 CORTICOSTEROIDS..., DERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AA Corticosteroids, weak (grou...TIONS, EXCL. SEX HORMONES AND INSULINS H02 CORTICOSTEROIDS FOR SYSTEMIC USE H02A CORTICOSTEROIDS FOR SYSTEMI

  16. Drug: D07053 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D07053 Formula, Drug Ryutanshakanto Japanese angelica root [DR:D06768], Rehmannia r... medicines D07053 Ryutanshakanto Traditional Chinese Medicine in Japan [BR:br0830...4] Formulas Formulas for clearing heat Formulas for clearing heat D07053 Ryutanshakanto PubChem: 51091395 ...

  17. Drug: D07742 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D07742 Mixture, Drug Ethyl aminobenzoate - lidocaine - bismuth subgallate mixt; Hel...mitin S (TN) Ethyl aminobenzoate [DR:D00552], Lidocaine [DR:D00358], Bismuth subgallate [DR:D01398] Therapeu...742 Ethyl aminobenzoate - lidocaine - bismuth subgallate mixt PubChem: 96024465 ...

  18. Drug: D04692 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D04692 Mixture, Drug Diflucortolone valerate - Lidocaine mixt; Neriproct (TN) Diflu...cortolone valerate [DR:D01764], Lidocaine [DR:D00358] Therapeutic category: 2559 Therapeutic category of dru...hoidal preparations 2559 Others D04692 Diflucortolone valerate - Lidocaine mixt PubChem: 17398140 ...

  19. Drug: D10261 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D10261 Mixture, Drug Metformin hydrochloride - sitagliptin phosphate mixt; Janumet (TN) Metformin hydr...ochloride [DR:D00944], Sitagliptin phosphate hydrate [DR:D06645] Antidiabetic [DS:H00409]...SULINS A10BD Combinations of oral blood glucose lowering drugs A10BD07 Metformin and sitagliptin D10261 Metformin hydrochloride - sitagliptin phosphate mixt PubChem: 163312292 ...

  20. Drug: D08754 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D08754 Mixture, Drug L-Arginine - L-arginine hydrochloride mixt; Argi-U (TN) L-Argi...nine [DR:D02982], L-Arginine hydrochloride [DR:D01126] Therapeutic category: 3999 Therapeutic category of dr...us 3999 Others D08754 L-Arginine - L-arginine hydrochloride mixt PubChem: 96025437 ...

  1. Drug: D08749 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D08749 Mixture, Drug Hydroxocobalamin - isotonic sodium chloride solution mixt Hydr...oxocobalamin [DR:D01027], Isotonic sodium chloride solution [DR:D05352] Therapeutic category: 3929 Therapeutic category of dr...m 392 Antidotes 3929 Others D08749 Hydroxocobalamin - isotonic sodium chloride solution mixt PubChem: 96025432 ...

  2. Drug: D05165 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available tozoal [Histomonas, for poultry] CAS: 5579-89-5 PubChem: 47206889 LigandBox: D05165 NIKKAJI: J8.000D ATOM 16...D05165 Drug Nifursemizone (USAN/INN) C8H10N4O4 226.0702 226.1894 D05165.gif Antipro

  3. Drug: D00024 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D00024 Drug Sulfur (JP16); Sulfur, precipitated (USP); Sulfur, sublimed (USP); Bens...Epidermides 265 Antiparasitic dermatosis agents 2659 Others D00024 Sulfur (JP16); Sulfur..., precipitated (USP); Sulfur, sublimed (USP) Anatomical Therapeutic Chemical (ATC) classification [BR...parations containing sulfur D10AB02 Sulfur D00024 Sulfur (JP16); Sulfur, precipitated (USP); Sulfur

  4. Drug: D06982 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D06982 Formula, Drug Jumihaidokuto Bupleurum root [DR:D06727], Platycodon root [DR:... medicines 520 Traditional Chinese medicines 5200 Traditional Chinese medicines D06982 Jumihaidokuto Traditi...onal Chinese Medicine in Japan [BR:br08304] Formulas Formulas for pus discharge Formulas for pus discharge D06982 Jumihaidokuto PubChem: 51091324 ...

  5. Drug: D04750 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D04750 Drug Lithium hydroxide (USP) LiHO. H2O 42.0293 41.9636 D04750.gif Antimanic ...CHOLEPTICS N05A ANTIPSYCHOTICS N05AN Lithium N05AN01 Lithium D04750 Lithium hydroxide (USP) USP drug classif...ication [BR:br08302] Bipolar Agents Mood Stabilizers Lithium D04750 Lithium hydroxide

  6. Drug: D01772 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D01772 Drug Ether (JP16/USP); Diethyl ether C4H10O 74.0732 74.1216 D01772.gif Anest... N01AA01 Diethyl ether D01772 Ether (JP16/USP) CAS: 60-29-7 PubChem: 7848835 PDB-CCD: ETZ LigandBox: D0177

  7. Drug: D01728 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available ponent: Calcium sulfate [DR:D09201] Therapeutic category of drugs in Japan [BR:br08301] 5 Crude drugs... and Chinese medicine formulations 51 Crude drugs 510 Crude drugs 5100 Crude drugs D0172... for clearing heat D01728 Gypsum; Calcium sulfate; Gypsum fibrosum Crude drugs [BR:br08305] Others Minerals D01728 Gypsum PubChem: 7848791 ...

  8. Vitamin D and African Americans

    Science.gov (United States)

    Vitamin D insufficiency is more prevalent among African Americans than other Americans and, in North America, most young, healthy blacks do not achieve optimal 25-hydroxyvitamin D [25(OH)D] concentrations at any time of the year. This is primarily due to the fact that pigmentation reduces vitamin D...

  9. Drug: D06780 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D06780 Crude, Drug Atractylodes rhizome (JP16); Powdered atractylodes rhizome (JP16... drugs 510 Crude drugs 5100 Crude drugs D06780 Atractylodes rhizome (JP16); Powder...pness Diuretic drugs D06780 *Atractylodes rhizome; Powdered atractylodes rhizome; Atractyloides rhizoma Drug...s for resolving dampness D06780 *Atractylodes rhizome; Powdered atractylodes rhizome; Atractyloides rhizoma

  10. Drug: D06951 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D06951 Formula, Drug Keishakuchimoto Cinnamon bark [DR:D06712], Anemarrhena rhizome...tional Chinese medicines 5200 Traditional Chinese medicines D06951 Keishakuchimoto Traditional Chinese Medic...ine in Japan [BR:br08304] Formulas Formulas for dampness Antirheumatic formulas D06951 Keishakuchimoto PubChem: 51091293 ...

  11. Drug: D02261 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available Quinine hydrochloride (TN) C20H24N2O2. 2H2O. HCl 396.1816 396.9083 D02261.gif Antiprotozoal, Antimalarial [D... and parasites 64 Parasitics (systemic) 641 Antiprotozoans 6415 Quinines D02261 Q...ation [BR:br08302] Antiparasitics Antiprotozoals Quinine D02261 Quinine hydrochloride hydrate (JP16) Antiinf

  12. Drug: D03406 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D03406 Drug Cariporide mesylate (USAN) C12H17N3O3S. CH4SO3 379.0872 379.4523 D03406...5742] [TC:2.A.36.1.13] Cariporide D03406 Cariporide mesylate (USAN) CAS: 159138-81-5 PubChem: 17397546 LigandBox: D03406

  13. Drug: D08406 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D08406 Drug Pramiverine (INN); Sistalgina (TN) C21H27N 293.2144 293.4458 D08406.gif... Antispasmodic CAS: 14334-40-8 PubChem: 96025092 LigandBox: D08406 NIKKAJI: J8.496D ATOM 22 1 C8x C 13.7200

  14. Drug: D09367 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09367 Drug Pozanicline (USAN); ABT-089 C11H16N2O 192.1263 192.2575 D09367.gif Atte...137 1141] [KO:K04806 K04813] Pozanicline D09367 Pozanicline (USAN) CAS: 161417-03-4 PubChem: 96026047 LigandBox: D09367

  15. Drug: D07756 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D07756 Drug Cyamemazine tartrate; Tercian (TN) C19H21N3S. C4H6O6 473.1621 473.542 D0775...e-chain N05AA06 Cyamemazine D07756 Cyamemazine tartrate CAS: 93841-82-8 PubChem: 51092048 LigandBox: D0775

  16. Drug: D07752 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D07752 Drug Croconazole (INN) C18H15ClN2O 310.0873 310.7775 D07752.gif Antifungal; ...7] Imidazoles Croconazole D07752 Croconazole (INN) CAS: 77175-51-0 PubChem: 51092044 LigandBox: D07752 NIKKA

  17. Drug: D09106 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09106 Formula, Drug Satotsuko Bitumen, , Lard [DR:D05301], Sesame oil [DR:D03314] ...Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formulas for external use Formulas for external use D09106 Satotsuko PubChem: 96025786 ...

  18. Drug: D07055 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D07055 Formula, Drug Ryokyojutsukanto Poria sclerotium [DR:D06783], Atractylodes rh...hinese medicines 5200 Traditional Chinese medicines D07055 Ryokyojutsukanto Traditional Chinese Medicine in Japan [BR:br08304] Formul...as Formulas for warming the interior Formulas for warming the interior D07055 *Ryokyojutsukanto Formula

  19. Drug: D09074 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09074 Formula, Drug Byakkokakeishito Gypsum [DR:D01728], Anemarrhena rhizome [DR:D...icine in Japan [BR:br08304] Formulas Formulas for clearing heat Formulas for clearing heat D09074 Byakkokakeishito PubChem: 96025755 ...

  20. Drug: D09117 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09117 Formula, Drug Shoyosan Japanese angelica root [DR:D06768], Peony root [DR:D0...raditional Chinese Medicine in Japan [BR:br08304] Formulas Formulas for Qi Sedative formulas D09117 Shoyosan PubChem: 96025797 ...

  1. Drug: D09046 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09046 Formula, Drug Hokikenchuto Ginseng [DR:D06772], (Atractylodes lancea rhizome...R:D06775] Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formulas for Qi Formulas for replenishing Qi D09046 Hokikenchuto PubChem: 96025727 ...

  2. Drug: D09060 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09060 Formula, Drug Kamiheiisan (Atractylodes lancea rhizome [DR:D06752] | Atracty...10], Crataegi fructus [DR:D06904] Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formula...s for dampness Formulas for resolving dampness D09060 Kamiheiisan PubChem: 96025741 ...

  3. Drug: D09057 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09057 Formula, Drug Kamiuntanto Pinellia tuber [DR:D06778], Poria sclerotium [DR:D... Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formulas for Qi Formulas for regulating Qi D09057 Kamiuntanto PubChem: 96025738 ...

  4. Drug: D09104 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09104 Formula, Drug Gomotsugedokusan (Cnidium rhizome [DR:D06748] | Chinese cnidiu...onepeta spike [DR:D06711] Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formulas for blood Formulas for removing blood stasis D09104 Gomotsugedokusan PubChem: 96025784 ...

  5. Drug: D09043 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09043 Formula, Drug Yohakusan Myrica [DR:D09185], Phellodendron bark [DR:D06689], ...Sichuan-pepper [ED:E00295] Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formulas for external use Formulas for external use D09043 Yohakusan PubChem: 96025725 ...

  6. Drug: D09042 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09042 Formula, Drug Untanto Pinellia tuber [DR:D06778], Poria sclerotium [DR:D0678...tional Chinese Medicine in Japan [BR:br08304] Formulas Formulas for Qi Formulas for regulating Qi D09042 Untanto PubChem: 96025724 ...

  7. Drug: D09083 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09083 Formula, Drug Chokoshiteito Persimmon calyx [DR:D07154], Cinnamon bark [DR:D...Boswellia gum substance [ED:E00343] Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formulas for Qi Formulas for regulating Qi D09083 Chokoshiteito PubChem: 96025764 ...

  8. Drug: D09044 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09044 Formula, Drug Hohaito Ophiopogon tuber [DR:D06775], Schisandra fruit [DR:D06...ssilago farfara flower bud [ED:E00345], Ginger [DR:D06744] Traditional Chinese Medicine in Japan [BR:br08304] Formulas Formula

  9. Drug: D10252 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available xt; Allegra-d (TN) Fexofenadine hydrochloride [DR:D00671], Pseudoephedrine hydrochloride [DR:D00485] Therape...E R01BA Sympathomimetics R01BA52 Pseudoephedrine, combinations D10252 Fexofenadine hydrochloride - pseudoephedorine hydrochloride mixt PubChem: 163312283 ...

  10. Drug: D04810 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D04810 Drug Potash soap (JP16); Potash soap (TN) Therapeutic category: 2359 2662 26...an agents 235 Purgatives, clysters 2359 Others D04810 Potash soap (JP16) 26 Epidermides 266 Emollients 2662 ...Alkaline agents D04810 Potash soap (JP16) 269 Miscellaneous 2699 Others D04810 Potash soap (JP16) PubChem: 17398179 ...

  11. Drug: D04412 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D04412 Mixture, Drug Compound iodine glycerin (JP16); Lugol (TN) Iodine [DR:D00108]...s 2399 Others D04412 Compound iodine glycerin (JP16) 27 Dental preparations 279 M...iscellaneous 2790 Miscellaneous D04412 Compound iodine glycerin (JP16) PubChem: 17398098 ...

  12. Drug: D00036 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D00036 Drug Nicotinamide (JP16/INN); Niacinamide (USP) C6H6N2O 122.048 122.1246 D00... 3132 Nicotinic acids D00036 Nicotinamide (JP16/INN); Niacinamide (USP) Anatomica... OTHER PLAIN VITAMIN PREPARATIONS A11HA Other plain vitamin preparations A11HA01 Nicotinamide D00036 Nicotinamide (JP16/INN); Niacin

  13. Drug: D10284 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D10284 Mixture, Drug Olmesartan medoxomil - hydrochlorothiazide mixt; Benicar hct (...TN) Olmesartan medoxomil [DR:D01204], Hydrochlorothiazide [DR:D00340] Antihypertensive ATC code: C09DA08 Ana...Angiotensin II antagonists and diuretics C09DA08 Olmesartan medoxomil and diuretics D10284 Olmesartan medoxomil - hydrochlorothiazide mixt PubChem: 163312315 ...

  14. Drug: D10289 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D10289 Mixture, Drug Aliskiren hemifumarate - hydrochlorothiazide mixt; Tekturna hc...t (TN) Aliskiren fumarate [DR:D06412], Hydrochlorothiazide [DR:D00340] Treatment of hypertension ATC code: C...OTENSIN SYSTEM C09XA Renin-inhibitors C09XA52 Aliskiren and hydrochlorothiazide D10289 Aliskiren hemifumarate - hydrochlorothiazide mixt PubChem: 163312320 ...

  15. Drug: D10275 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D10275 Mixture, Drug Bisoprolol fumarate - hydrochlorothiazide mixt; Ziac (TN) Biso...prolol fumarate [DR:D00634], Hydrochlorothiazide [DR:D00340] Antihypertensive ATC code: C07BB07 Anatomical T...azides C07BB07 Bisoprolol and thiazides D10275 Bisoprolol fumarate - hydrochlorothiazide mixt PubChem: 163312306 ...

  16. Drug: D10271 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D10271 Mixture, Drug Amiloride hydrochloride - hydrochlorothiazide mixt; Amiloride ...hydrochloride and hydrochlorothiazide (TN) Amiloride hydrochloride [DR:D00649], Hydrochlorothiazide [DR:D003... COMBINATION C03EA Low-ceiling diuretics and potassium-sparing agents C03EA01 Hydrochlorothiazide and potass...ium-sparing agents D10271 Amiloride hydrochloride - hydrochlorothiazide mixt PubChem: 163312302 ...

  17. Drug: D10283 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D10283 Mixture, Drug Eprosartan mesylate - hydrochlorothiazide mixt; Teveten htc (T...N) Eprosartan mesylate [DR:D02082], Hydrochlorothiazide [DR:D00340] Antihypertensive ATC code: C09DA02 Anato...giotensin II antagonists and diuretics C09DA02 Eprosartan and diuretics D10283 Eprosartan mesylate - hydrochlorothiazide mixt PubChem: 163312314 ...

  18. Drug: D10276 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D10276 Mixture, Drug Captopril - hydrochlorothiazide mixt; Capozide (TN) Captopril [DR:D00251], Hydrochlorot...Captopril and diuretics D10276 Captopril - hydrochlorothiazide mixt PubChem: 163312307 ... ...hiazide [DR:D00340] Antihypertensive ATC code: C09BA01 Anatomical Therapeutic Chemi

  19. Drug: D10288 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D10288 Mixture, Drug Olmesartan medoxomil - amlodipine besylate - hydrochlorothiazide... mixt; Tribenzor (TN) Olmesartan medoxomil [DR:D01204], Amlodipine besilate [DR:D00615], Hydrochlorothiazide... C09DX03 Olmesartan medoxomil, amlodipine and hydrochlorothiazide D10288 Olmesartan medoxomil - amlodipine besylate - hydrochlorothiazide mixt PubChem: 163312319 ...

  20. Drug: D08775 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D08775 Mixture, Drug Abacavir sulfate - lamivudine mixt; Epzicom (TN) Abacavir sulf...emotherapeutics 625 Antivirals 6250 Antivirals D08775 Abacavir sulfate - lamivudi...ns, combinations J05AR02 Lamivudine and abacavir D08775 Abacavir sulfate - lamivu... Transcriptase Inhibitors (NRTI)v Abacavir and Lamivudine D08775 Abacavir sulfate - lamivudine mixt PubChem: 96025458 ...

  1. Drug: D06416 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D06416 Mixture, Drug Cresol solution (JP16) Saponated cresol solution [DR:D06417], ...Water [DR:D00001] Cresol solution is included 1.25-1.60 volume percent Cresol [DR:D01960] PubChem: 47208072 ...

  2. Drug: D10256 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D10256 Mixture, Drug Albuterol sulfate - ipratropium bromide mixt; Combivent (TN) S...albutamol sulfate [DR:D00683], Ipratropium bromide hydrate [DR:D02212] Treatment of COPD (Chronic obstructiv...ALANTS R03AL Adrenergics in combination with anticholinergics R03AL02 Salbutamol and ipratropium bromide D10256 Albuterol sulfate - ipratropium bromide mixt PubChem: 163312287 ...

  3. Drug: D07084 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D07084 Drug Pipenzolate bromide (INN) C22H28NO3. Br 433.1253 434.3666 D07084.gif AT...nzolate D07084 Pipenzolate bromide (INN) CAS: 125-51-9 PubChem: 51091426 LigandBox: D07084 NIKKAJI: J300.499

  4. Drug: D05730 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D05730 Drug Rimiterol hydrobromide (USAN) C12H17NO3. HBr 303.047 304.1802 D05730.gi...terol D05730 Rimiterol hydrobromide (USAN) Target-based classification of drugs [...K04142] Rimiterol [ATC:R03AC05] D05730 Rimiterol hydrobromide (USAN) CAS: 31842-61-2 PubChem: 47207391 Ligan

  5. Drug: D08135 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D08135 Drug Lithium bromide; Lithium Microsol (TN) LiBr 85.9343 86.845 D08135.gif A...SYSTEM N05 PSYCHOLEPTICS N05A ANTIPSYCHOTICS N05AN Lithium N05AN01 Lithium D08135 Lithium bromide USP drug c...lassification [BR:br08302] Bipolar Agents Mood Stabilizers Lithium D08135 Lithium bromide

  6. Drug: D10208 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D10208 Mixture, Drug Dextromethorphan hydrobromide and quinidine sulfate; Nuedexta ...(TN) Dextromethorphan hydrobromide hydrate [DR:D00848], Quinidine sulfate hydrate [DR:D02272] ATC code: N07X...ons D10208 Dextromethorphan hydrobromide and quinidine sulfate USP drug classific...0208 Dextromethorphan hydrobromide and quinidine sulfate PubChem: 163312239 ...

  7. Drug: D08769 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D08769 Mixture, Drug Diphenhydramine hydrochloride - calcium bromide mixt; Rescalmi...n (TN) Diphenhydramine hydrochloride [DR:D00669], Calcium bromide [DR:D01723] Therapeutic category: 4419 The... Antihistamines 4419 Others D08769 Diphenhydramine hydrochloride - calcium bromide mixt PubChem: 96025452 ...

  8. Drug: D10181 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D10181 Drug Umeclidinium bromide (JAN/USAN) C29H34NO2. Br 507.1773 508.4898 D10181....K04133] Umeclidinium D10181 Umeclidinium bromide (USAN) CAS: 869113-09-7 PubChem: 135626899 LigandBox: D1018

  9. Drug: D07081 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D07081 Drug Penthienate bromide (NF XIII) C18H30NO3S. Br 419.113 420.4047 D07081.gi...Penthienate D07081 Penthienate bromide (NF XIII) CAS: 60-44-6 PubChem: 51091423 LigandBox: D07081 NIKKAJI: J

  10. Drug: D10134 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D10134 Drug Lumacaftor (USAN) C24H18F2N2O5 452.1184 452.4069 D10134.gif Treatment o...subfamily CFTR [HSA:1080] [KO:K05031] Lumacaftor D10134 Lumacaftor (USAN) CAS: 936727-05-8 PubChem: 135626852 LigandBox: D101

  11. Drug: D04406 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D04406 Mixture, Drug Dioctyl sodium sulfosuccinate - casanthranol mixt; Vemas S (TN...) Dioctyl sodium sulfosuccinate [DR:D00305], Casanthranol [DR:D03417] Therapeutic category: 2359 Therapeutic...Purgatives, clysters 2359 Others D04406 Dioctyl sodium sulfosuccinate - casanthranol mixt PubChem: 17398095 ...

  12. Drug: D02775 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available 5.gif Treatment of the symptoms of Parkinson's disease [dopamine D1 receptor agonist] dopamine D1-receptor a...D02775 Drug Adrogolide hydrochloride (USAN) C22H25NO4S. HCl 435.1271 435.9641 D0277

  13. Drug: D04364 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D04364 Mixture, Drug Dicyclomine hydrochloride - aluminium hydroxide, dried - magne...sium oxide mixt; Kolantyl (TN) Dicyclomine hydrochloride [DR:D00717], Aluminum hydroxide, dried [DR:D02416],...gents 2329 Others D04364 Dicyclomine hydrochloride - aluminium hydroxide, dried - magnesium oxide mixt PubChem: 17398075 ...

  14. Drug: D07432 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D07432 Mixture, Drug Streptoduocin (BAN) Dihydrostreptomycin sulfate [DR:D02512], S...IALS J01GA Streptomycins J01GA02 Streptoduocin D07432 Streptoduocin (BAN) Antiinf...or [KO:K01977] Aminoglycosides Streptoduocin [ATC:J01GA02] D07432 Streptoduocin (BAN) PubChem: 51091764 ...

  15. Drug: D04362 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D04362 Mixture, Drug Berberine chloride - geranium herb extract mixt; Phelloberin A... (TN) Berberine chloride [DR:D01250], Geranium herb extract [DR:D04360] Therapeutic category: 2319 Therapeut...1 Antidiarrheals, intestinal regulators 2319 others D04362 Berberine chloride - geranium herb extract mixt PubChem: 17398073 ...

  16. Drug: D08698 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D08698 Mixture, Drug Platycodon fluidextract - plantago herb extract - peony root extract... mixt; Opisezol A (TN) Platycodon fluidextract [DR:D06812], Plantago herb extract [DR:D04333], Peony root extract...expectorants 2249 Others D08698 Platycodon fluidextract - plantago herb extract - peony root extract mixt PubChem: 96025381 ...

  17. Drug: D06802 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D06802 Formula, Drug Ryokeijutsukanto extract (JP16); Ryokeijutsukanto Poria sclero...Chinese medicines 520 Traditional Chinese medicines 5200 Traditional Chinese medicines D06802 Ryokeijutsukanto extract...mulas for Qi Sedative formulas D06802 Ryokeijutsukanto extract; Ryokeijutsukanto Formulas for dampness Diure...tic formulas D06802 *Ryokeijutsukanto extract; Ryokeijutsukanto PubChem: 47208453 ...

  18. Drug: D07630 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D07630 Drug An extract from inflammatory rabbit skin inoculated by vaccinia virus; ...d analgesics, anti-inflammatory agents 1149 Others D07630 An extract from inflamm...timulation therapy agents 4420 Stimulation therapy agents D07630 An extract from inflammatory rabbit skin inoculated by vaccinia virus PubChem: 96024452 ...

  19. Drug: D04709 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D04709 Mixture, Drug Scopolia extract and tannic acid suppositories (JP16); Scopolia extract... and tannic acid (TN) Scopolia extract [DR:D04062], Tannic acid [DR:D01959] Therapeutic category: 2...nd anal organ agents 255 Hemorrhoidal preparations 2559 Others D04709 Scopolia extract and tannic acid suppositories (JP16) PubChem: 17398146 ...

  20. Drug: D04377 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D04377 Mixture, Drug Magnesium aluminometasilicate - licorice extract mixt; Neo umo...r (TN) Magnesium aluminometasilicate [DR:D03242], Crude glycyrrhiza extract [DR:D06811] Therapeutic category... organ agents 232 Peptic ulcer agents 2329 Others D04377 Magnesium aluminometasilicate - licorice extract mixt PubChem: 17398079 ...

  1. Drug: D06873 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D06873 Crude, Drug Nux vomica extract (JP16); Nux vomica extract powder (JP16); Strychnos extract...d digestives 2333 Bitter agents D06873 Nux vomica extract (JP16); Nux vomica extract powder (JP16) Crude dru...gs [BR:br08305] Dicot plants: asterids Loganiaceae (logania family) D06873 Nux vomica extract PubChem: 47208523 ...

  2. Drug: D04800 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D04800 Mixture, Drug Heparinoid - adrenal extract - salicylic acid mixt; Amel S (TN...) Heparinoid [DR:D04799], Adrenal extract, Salicylic acid [DR:D00097] Therapeutic category: 2649 Therapeutic... anti-itchings, astringents, anti-inflammatory agents 2649 Others D04800 Heparinoid - adrenal extract - salicylic acid mixt PubChem: 17398169 ...

  3. Drug: D04379 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D04379 Mixture, Drug Propantheline bromide - sodium copper chlorophyllin - magnesium silica...te mixt; Methaphyllin (TN) Propantheline bromide [DR:D00481], Sodium copper chlorophyllin [DR:D06465], Magnesium silica...cer agents 2329 Others D04379 Propantheline bromide - sodium copper chlorophyllin - magnesium silicate mixt PubChem: 17398080 ...

  4. Drug: D10207 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D10207 Mixture, Drug Chlordiazepoxide and amitriptyline hydrochloride; Chlordiazepo...xide and amitriptyline hcl (TN) Chlordiazepoxide [DR:D00267], Amitriptyline hydrochloride [DR:D00809] Antidepressant Genomic biomarker: CYP2D6 [HSA:1565] PubChem: 163312238 ...

  5. Drug: D03068 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D03068 Drug Belimumab (genetical recombination) (JAN); Belimumab (USAN); Benlysta (...nts L04AA26 Belimumab D03068 Belimumab (genetical recombination) (JAN); Belimumab... (USAN) USP drug classification [BR:br08302] Immunological Agents Immunomodulators Belimumab D03068 Belimumab (genetica...nes TNF family BAFF [HSA:10673] [KO:K05476] Belimumab [ATC:L04AA26] D03068 Belimumab (genetica

  6. Drug: D00172 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D00172 Drug Eptacog alfa (activated) (genetical recombination) (JAN); Eptacog alfa ...a preparations D00172 Eptacog alfa (activated) (genetical recombination) (JAN); Eptacog alfa (INN) Anatomica...oagulation factor VII D00172 Eptacog alfa (activated) (genetical recombination) (JAN); Eptacog alfa (INN) B0...2BD08 Eptacog alfa (activated) D00172 Eptacog alfa (activated) (genetical recombi

  7. Drug: D00196 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D00196 Drug Physostigmine (USP); Eserine (TN) C15H21N3O2 275.1634 275.3461 D00196.g... D00196 Physostigmine (USP) CAS: 57-47-6 PubChem: 7847264 DrugBank: DB00981 LigandBox: D00196 NIKKAJI: J4.57

  8. Drug: D05074 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D05074 Drug Monoethanolamine (NF) C2H7NO 61.0528 61.0831 D05074.gif Pharmaceutic ai...d [surfactant] Same as: C00189 CAS: 141-43-5 PubChem: 47206801 DrugBank: DB03994 PDB-CCD: ETA LigandBox: D05

  9. Drug: D07717 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available L PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AB Corticosteroids, moderately potent (group II) D07AB01 Clobe...tasone D07717 Clobetasone (INN) S SENSORY ORGANS S01 OPHTHALMOLOGICALS S01B ANTIINFLAMMATORY AGENTS S01BA Corticosteroids

  10. Drug: D02204 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D02204 Drug Hexamethonium bromide (JAN/INN); Hexamethonium bromide (TN) C12H30N2. 2Br 360.0776 362.188 D0220...1139 55584 57053 1141 1142 1143] Hexamethonium D02204 Hexamethonium bromide (JAN/INN) CAS: 55-97-0 PubChem: 7849264 LigandBox: D0220

  11. Drug: D05352 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available 515], Water [DR:D00001] Therapeutic category: 3311 0.9% Sodium chloride [DR:D02056] solution Therapeutic cat...JP16) USP drug classification [BR:br08302] Therapeutic Nutrients/Minerals/Electrolytes Electrolyte/Mineral R...D05352 Mixture, Drug Isotonic sodium chloride solution (JP16) Nitroglycerin [DR:D00

  12. Drug: D03841 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available rapeutic category: 1116 ATC code: N01AX63 Therapeutic category of drugs in Japan [B...11 General anesthetics 1116 Nitrous oxides D03841 Nitrous oxide - oxygen Anatomical Therapeutic...D03841 Mixture, Drug Nitrous oxide - oxygen; Anesoxyn (TN) Nitrous oxide [DR:D00102], Oxygen [DR:D00003] The

  13. Drug: D09595 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D09595 Mixture, Drug Budesonide - formoterol fumarate dihydrate mixt; Symbicort (TN...us 2290 Miscellaneous D09595 Budesonide - formoterol fumarate dihydrate mixt Anatomical Therapeutic Chemical...drugs, excl. anticholinergics R03AK07 Formoterol and budesonide D09595 Budesonide - formoterol fumarate dihy... Other Budesonide/Formoterol fumarate D09595 Budesonide - formoterol fumarate dihydrate mixt PubChem: 124490335 ...

  14. Drug: D07463 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D07463 Drug Arformoterol (INN) C19H24N2O4 344.1736 344.4049 D07463.gif Bronchodilat...espiratory Tract/Pulmonary Agents Bronchodilators, Sympathomimetic Arformoterol D07463 Arformoterol (INN) Ta...psin family Adrenaline beta2-adrenergic receptor [HSA:154] [KO:K04142] Arformoterol D07463 Arformoterol (INN

  15. Drug: D10264 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available of oral blood glucose lowering drugs A10BD11 Metformin and linagliptin D10264 Linagliptin - metformin hydrochloride mixt PubChem: 163312295 ... ...formin hydrochloride [DR:D00944] Antidiabetic [DS:H00409] ATC code: A10BD11 Anatomi...D10264 Mixture, Drug Linagliptin - metformin hydrochloride mixt; Jentaduet (TN) Linagliptin [DR:D09566], Met

  16. Drug: D01277 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D01277 Drug Droxidopa (JP16/INN); Dops (TN) C9H11NO5 213.0637 213.1873 D01277.gif Antiparkins...onian [DS:H00057] Therapeutic category: 1169 precursor of Norepinephrine [DR:D00076] map07057 Antiparkins...d sensory organs 11 Agents affecting central nervous system 116 Antiparkinsonian

  17. Drug: D07906 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D07906 Drug Ergotamine (INN) C33H35N5O5 581.2638 581.6615 D07906.gif Claviceps purp...B Ergot alkaloids G02AB02 Ergot alkaloids D07906 Ergotamine (INN) N NERVOUS SYSTE...M N02 ANALGESICS N02C ANTIMIGRAINE PREPARATIONS N02CA Ergot alkaloids N02CA02 Ergotamine D07906 Ergotamine (...INN) USP drug classification [BR:br08302] Antimigraine Agents Ergot Alkaloids Ergotamine D07906 Ergotamine (...lkaloids [ATC:G02AB02] D07906 Ergotamine (INN) Ergotamine [ATC:N02CA02] D07906 Ergotamine (INN) Dopamine dop

  18. Drug: D07799 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available (ATC) classification [BR:br08303] A ALIMENTARY TRACT AND METABOLISM A01 STOMATOLOGICAL PREPARATION...S A01A STOMATOLOGICAL PREPARATIONS A01AC Corticosteroids for local oral treatment A01AC02 ...05AA09 Dexamethasone D07799 Dexamethasone 21-tebutate D DERMATOLOGICALS D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATION...PARATIONS D10A ANTI-ACNE PREPARATIONS FOR TOPICAL USE D10AA Corticosteroids, combin...ations for treatment of acne D10AA03 Dexamethasone D07799 Dexamethasone 21-tebutate H SYSTEMIC HORMONAL PREPARATION

  19. Drug: D07797 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available lassification [BR:br08303] A ALIMENTARY TRACT AND METABOLISM A01 STOMATOLOGICAL PREPARATION...S A01A STOMATOLOGICAL PREPARATIONS A01AC Corticosteroids for local oral treatment A01AC02 Dexameth... Dexamethasone D07797 Dexamethasone isonicotinate D DERMATOLOGICALS D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATION...PARATIONS D10A ANTI-ACNE PREPARATIONS FOR TOPICAL USE D10AA Corticosteroids, combin...ations for treatment of acne D10AA03 Dexamethasone D07797 Dexamethasone isonicotinate H SYSTEMIC HORMONAL PREPARATION

  20. Drug: D00230 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D00230 Mixture, Drug Amoxicillin - potassium clavulanate combination; Amoxicillin - clavulanate... potassium mixt C16H19N3O5S. C8H8NO5. K 602.1085 602.6553 D00230.gif Amoxicillin [DR:D07452], Potassium clavulanate...cl. beta-lactamase inhibitors J01CR02 Amoxicillin and enzyme inhibitor D00230 Amoxicillin - potassium clavulanate...acterials J01RA01 Penicillins, combinations with other antibacterials D00230 Amoxicillin - potassium clavulanate...d Clavulanate Potassium D00230 Amoxicillin - potassium clavulanate combination CA

  1. Drug: D01708 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D01708 Drug Fluticasone propionate (JAN/USAN); Cutivate (TN); Flonase (TN); Flovent...and nasal agents 1329 Others D01708 Fluticasone propionate (JAN/USAN) 2 Agents af...fecting individual organs 22 Respiratory organ agents 229 Miscellaneous 2290 Miscellaneous D01708 Fluticason...C Corticosteroids, potent (group III) D07AC17 Fluticasone D01708 Fluticasone propionate (JAN/USAN) R RESPIRA...ticosteroids R01AD08 Fluticasone D01708 Fluticasone propionate (JAN/USAN) R03 DRUGS FOR OBSTRUCTIVE AIRWAY D

  2. Drug: D01730 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D01730 Drug Silver nitrate (JP16/USP); Silver nitrate (TN) Ag. NO3 168.8929 169.873...ing sensory organs 131 Ophthalmic agents 1319 Others D01730 Silver nitrate (JP16/...USP) 2 Agents affecting individual organs 26 Epidermides 266 Emollients 2663 Metallic agents D01730 Silver n...TISEPTICS AND DISINFECTANTS D08A ANTISEPTICS AND DISINFECTANTS D08AL Silver compounds D08AL01 Silver... nitrate D01730 Silver nitrate (JP16/USP) S SENSORY ORGANS S01 OPHTHALMOLOGICALS S01A ANT

  3. Drug: D08432 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D08432 Drug Promethazine maleate; Romergan (TN) C17H20N2S. C4H4O4 400.1457 400.4913...L. ANTIHISTAMINES, ANESTHETICS, ETC. D04AA Antihistamines for topical use D04AA10 Promethazine D08432 Promet... R06AD Phenothiazine derivatives R06AD02 Promethazine D08432 Promethazine maleate... USP drug classification [BR:br08302] Antiemetics Antiemetics, Other Promethazine D08432 Promethazine maleat...e Respiratory Tract/Pulmonary Agents Antihistamines Promethazine D08432 Promethazine maleate Target-based cl

  4. Drug: D07979 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D07979 Drug Flupirtine D-gluconate; Katadolon (TN) C15H17FN4O2. C6H12O7 500.1919 50...esics and antipyretics N02BG07 Flupirtine D07979 Flupirtine D-gluconate Target-ba..., NMDA N-methyl-D-aspartate receptor [HSA:2902 2903 2904 2905 2906] [KO:K05208 K05209 K05210 K05211 K05212] Flupirtine... [ATC:N02BG07] D07979 Flupirtine D-gluconate CAS: 105507-11-7 PubChem:

  5. Drug: D00222 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D00222 Drug Aciclovir (JP16/INN); Acyclovir (USP); Sitavig (TN); Zovirax (TN) C8H11...Ophthalmic agents 1319 Others D00222 Aciclovir (JP16/INN); Acyclovir (USP) 6 Agents against pathologic organ...isms and parasites 62 Chemotherapeutics 625 Antivirals 6250 Antivirals D00222 Aciclo...SE D06BB Antivirals D06BB03 Aciclovir D00222 Aciclovir (JP16/INN); Acyclovir (USP...eosides and nucleotides excl. reverse transcriptase inhibitors J05AB01 Aciclovir D00222 Aciclovir (JP16/INN)

  6. Drug: D02124 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D02124 Drug Penciclovir sodium (USAN); Denavir (TN) C10H14N5O3. Na 275.0994 275.239...LOGICAL USE D06B CHEMOTHERAPEUTICS FOR TOPICAL USE D06BB Antivirals D06BB06 Penciclovir D02124 Penciclovir s... J05AB Nucleosides and nucleotides excl. reverse transcriptase inhibitors J05AB13 Penciclo...vir D02124 Penciclovir sodium (USAN) USP drug classification [BR:br08302] Antivirals Antiherpetic Agents Penciclo...vir D02124 Penciclovir sodium (USAN) Antiinfectives [BR:br08307] Antivirals Anti-HSV agent DNA

  7. Drug: D08664 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D08664 Drug Valaciclovir (INN); Valacyclovir; Valtrex (TN) C13H20N6O4 324.1546 324....3357 D08664.gif Antiviral [DS:H00365] ATC code: J05AB11 prodrug, active substance: Aciclovir [DR:D00222] DNA...xcl. reverse transcriptase inhibitors J05AB11 Valaciclovir D08664 Valaciclovir (INN) USP drug classification... [BR:br08302] Antivirals Antiherpetic Agents Valacyclovir D08664 Valaciclovir (IN...ir [ATC:J05AB11] D08664 Valaciclovir (INN) CAS: 124832-26-4 PubChem: 96025347 DrugBank: DB00577 LigandBox: D

  8. Drug: D05407 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D05407 Drug Penciclovir (USAN/INN); Denavir (TN) C10H15N5O3 253.1175 253.2578 D0540...TICS FOR TOPICAL USE D06BB Antivirals D06BB06 Penciclovir D05407 Penciclovir (USAN/INN) J ANTIINFECTIVES FOR...s excl. reverse transcriptase inhibitors J05AB13 Penciclovir D05407 Penciclovir (...USAN/INN) USP drug classification [BR:br08302] Antivirals Antiherpetic Agents Penciclovir D05407 Penciclovir... (USAN/INN) Antiinfectives [BR:br08307] Antivirals Anti-HSV agent DNA polymerase inhibitor Purine analogue Penciclo

  9. Drug: D01921 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available D01921 Mixture, Drug Estradiol - testosterone mixt; Bothermon (TN) C19H28O2. C18H24... Hormones 248 Mixed hormone preparations 2481 Androgens and estrogens D01921 Estr... HORMONES IN COMBINATION G03EA Androgens and estrogens G03EA02 Testosterone and estrogen D01921... Estradiol - testosterone mixt CAS: 8055-33-2 PubChem: 7848983 LigandBox: D01921 ATOM 41 1 C1y...O2 560.3866 560.8064 D01921.gif Estradiol [DR:D00105], Testosterone [DR:D00075] Therapeutic category: 2481 A

  10. Drug: D00165 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available 07E INTESTINAL ANTIINFLAMMATORY AGENTS A07EA Corticosteroids acting locally A07EA02 Hydrocortisone D00165 Hy...ORRHOIDS AND ANAL FISSURES FOR TOPICAL USE C05AA Corticosteroids C05AA01 Hydrocor...ATIONS D07A CORTICOSTEROIDS, PLAIN D07AA Corticosteroids, weak (group I) D07AA02 Hydrocortisone D00165 Hydro...cortisone acetate (JP16/USP) D07X CORTICOSTEROIDS, OTHER COMBINATIONS D07XA Corticosteroids...165 Hydrocortisone acetate (JP16/USP) S SENSORY ORGANS S01 OPHTHALMOLOGICALS S01B ANTIINFLAMMATORY AGENTS S01BA Corticosteroids

  11. Drug: D01637 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available LAMMATORY AGENTS A07EA Corticosteroids acting locally A07EA04 Betamethasone D0163...T OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE C05AA Corticosteroids C05AA05 Betamethasone D01637 Betame...ICOSTEROIDS, PLAIN D07AC Corticosteroids, potent (group III) D07AC01 Betamethason...e D01637 Betamethasone dipropionate (JP16/USP) D07X CORTICOSTEROIDS, OTHER COMBINATIONS D07XC Corticosteroids...R NASAL PREPARATIONS FOR TOPICAL USE R01AD Corticosteroids R01AD06 Betamethasone

  12. Drug: D08412 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available GENTS A07E INTESTINAL ANTIINFLAMMATORY AGENTS A07EA Corticosteroids acting locall...FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE C05AA Corticosteroids C05AA04 Prednisolone D0...PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AA Corticosteroids, weak (group I) D07AA03 Prednisolone D08412 P...rednisolone pivalate D07X CORTICOSTEROIDS, OTHER COMBINATIONS D07XA Corticosteroids, weak, other combination...NASAL PREPARATIONS R01A DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE R01AD Corticosteroids R01

  13. Drug: D07073 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available MATOLOGICAL PREPARATIONS A01AC Corticosteroids for local oral treatment A01AC02 D...TS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE C05AA Corticosteroids C05AA09 Dexamethason...NS D07A CORTICOSTEROIDS, PLAIN D07AB Corticosteroids, moderately potent (group II...) D07AB19 Dexamethasone D07073 Dexamethasone cipecilate (JAN/INN) D07X CORTICOSTEROIDS, OTHER COMBINATIONS D07XB Corticosteroids... R01A DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE R01AD Corticosteroids R01AD03 Dexamethasone

  14. Drug: D01998 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available S, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS A07E INTESTINAL ANTIINFLAMMATORY AGENTS A07EA Corticosteroids... D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AA Corticosteroids, weak (g...EROIDS, OTHER COMBINATIONS D07XA Corticosteroids, weak, other combinations D07XA02 Prednisolone D01998 Predn...S R01A DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE R01AD Corticosteroids R01AD02 Prednisolone...B ANTIINFLAMMATORY AGENTS S01BA Corticosteroids, plain S01BA04 Prednisolone D01998 Prednisolone farnesylate

  15. Drug: D00472 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available OVASCULAR SYSTEM C05 VASOPROTECTIVES C05A AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE C05AA Corticosteroids... D DERMATOLOGICALS D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AA Corticosteroids...R COMBINATIONS D07XA Corticosteroids, weak, other combinations D07XA02 Prednisolo...EPARATIONS R01A DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE R01AD Corticosteroids R01AD02 Pre...dnisolone D00472 Prednisolone (JP16/USP/INN) S SENSORY ORGANS S01 OPHTHALMOLOGICALS S01B ANTIINFLAMMATORY AGENTS S01BA Corticosteroid

  16. Drug: D08415 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available VE AGENTS A07E INTESTINAL ANTIINFLAMMATORY AGENTS A07EA Corticosteroids acting lo...05A AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE C05AA Corticosteroids C05AA04 Pred...S, DERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AA Corticosteroids, weak (group I) D07AA03 Pre...dnisolone D08415 Prednisolone steaglate (BAN) D07X CORTICOSTEROIDS, OTHER COMBINATIONS D07XA Corticosteroids...R TOPICAL USE R01AD Corticosteroids R01AD02 Prednisolone D08415 Prednisolone stea

  17. Drug: D09796 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available STOMATOLOGICAL PREPARATIONS A01AC Corticosteroids for local oral treatment A01AC03 Hydrocortisone D09796 Hy...NFECTIVE AGENTS A07E INTESTINAL ANTIINFLAMMATORY AGENTS A07EA Corticosteroids acting locally A07EA02 Hydroco...ATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE C05AA Corticosteroids C05...AL PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AA Corticosteroids, weak (group I) D07AA02 Hydrocortisone D09...796 Hydrocortisone caproate (JAN) D07X CORTICOSTEROIDS, OTHER COMBINATIONS D07XA Corticosteroids, weak, othe

  18. Drug: D01619 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available :br08303] A ALIMENTARY TRACT AND METABOLISM A01 STOMATOLOGICAL PREPARATIONS A01A STOMATOLOGICAL PREPARATIONS A01AC Corticosteroids...TESTINAL ANTIINFLAMMATORY AGENTS A07EA Corticosteroids acting locally A07EA02 Hydrocortisone D01619 Hydrocor...IDS AND ANAL FISSURES FOR TOPICAL USE C05AA Corticosteroids C05AA01 Hydrocortison...NS D07A CORTICOSTEROIDS, PLAIN D07AA Corticosteroids, weak (group I) D07AA02 Hydrocortisone D01619 Hydrocort...isone butyrate (JP16/USP) D07AB Corticosteroids, moderately potent (group II) D07

  19. Drug: D00975 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available STOMATOLOGICAL PREPARATIONS A01A STOMATOLOGICAL PREPARATIONS A01AC Corticosteroids for local oral treatment...SCULAR SYSTEM C05 VASOPROTECTIVES C05A AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE C05AA Corticosteroids...LS D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AB Corticosteroids...te (JAN/USP) D07X CORTICOSTEROIDS, OTHER COMBINATIONS D07XB Corticosteroids, moderately potent, other combin...ANTI-ACNE PREPARATIONS D10A ANTI-ACNE PREPARATIONS FOR TOPICAL USE D10AA Corticosteroids, combinations for t

  20. Drug: D04467 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available PREPARATIONS A01AC Corticosteroids for local oral treatment A01AC03 Hydrocortiso...GENTS A07E INTESTINAL ANTIINFLAMMATORY AGENTS A07EA Corticosteroids acting locally A07EA02 Hydrocortisone D0...ES C05A AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE C05AA Corticosteroids C05AA01 ...AL PREPARATIONS D07A CORTICOSTEROIDS, PLAIN D07AA Corticosteroids, weak (group I) D07AA02 Hydrocortisone D04...467 Hydrocortisone hemisuccinate (USP) D07X CORTICOSTEROIDS, OTHER COMBINATIONS D07XA Corticosteroids